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ABSTRACT 
 
Among the enzymes dependent on a thiol nucleophile (cysteine) at their active sites, the largest 
and best studied is the papain superfamily, which encompasses parasite enzymes (falcipain, cruzain 
and rhodesain) and mammalian enzymes (e.g. cathepsins and calpains). The first group is crucial in the 
metabolism and reproductive function of Plasmodium falciparum and Trypanosoma spp., while 
elevated levels of the second group of enzymes are evident in pathological processes, such as muscular 
dystrophy, osteoporosis, chronic inflammatory diseases and cancer. Therefore, papain-like cysteine 
proteases represent major therapeutic targets for protease inhibitor development. This work focused on 
the evaluation of the vinyl sultam and 1,4-naphthoquinone scaffolds as potential building blocks for 
the design of novel irreversible inactivators for these enzymes. 
Five dipeptide vinyl sultams were synthesised through an initial Horner-Wadsworth-Emmons 
reaction between N-Boc-S-phenylalaninal and sultam phosphonates, followed by the attachment of the 
E- and Z- intermediates to N-protected amino acids, under standard peptide coupling conditions. These 
compounds were found to be inactive against papain at concentrations up to 50 µM and weakly active 
toward recombinant falcipain-2 (IC50 between 13.7 and 48.4 µM) and Plasmodium falciparum W2 
(IC50 > 7.8 µM). Docking studies suggested that two different binding modes of vinyl sultams to 
cysteine proteases are available, neither of which is favourable for the conjugate addition of Cys25 to 
the vinyl sultam system. 
A series of 1,4-naphthoquinone derivatives was prepared by reaction of methylamine, amino acid 
ethyl esters and EtOH with commercial 1,4-naphthoquinones. These compounds were found to be 
irreversible inhibitors of papain and bovine spleen cathepsin B, with second-order rate constants, k2, 
ranging from 0.67 to 35.4 M−1 s−1 for papain, and from 0.54 to 8.03 M−1 s−1 for cathepsin B. Some 
compounds displayed saturation inhibition kinetics with respect to inhibitor concentration, with KI 
values between 9.57 and 266 µM for papain, and between 14.0 and 797 µM for cathepsin B. The 
chemical reactivity of the compounds toward cysteine as a model thiol is dependent on the 
naphthoquinone LUMO energy, whereas papain inactivation is not. 
The 1,4-naphthoquinone derivatives were unable to inhibit recombinant falcipain-2 and 
Plasmodium falciparum W2 at concentrations up to 10 µM, and were also inactive against the serine 
protease, porcine pancreatic elastase. 
 
KEYWORDS 
Vinyl sultams, Naphthoquinones, Irreversible Inhibitors, Cysteine Protease Inhibitors, Thiols, 
Reactivity. 
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RESUMO 
 
A superfamília a que pertence o enzima papaína é o maior grupo de proteases de cisteína e também o 
mais estudado. Entre os seus membros, incluem-se alguns dos enzimas presentes nos parasitas (falcipaína, 
cruzaína e rodesaína) e nos mamíferos (e.g. catepsinas e calpaínas). O primeiro grupo é crucial no 
metabolismo e na reprodução do Plasmodium falciparum e Trypanosoma spp. Relativamente às 
catepsinas e às calpaínas, o seu aumento está associado a patologias como a distrofia muscular, a 
osteoporose, as doenças inflamatórias crónicas e o cancro. Desta forma, a inactivação destas proteases é 
uma estratégia viável em terapêutica, através do desenvolvimento de inibidores apropriados. O trabalho 
aqui apresentado teve como objectivo a avaliação de um grupo de sultamas vinílicas e de 1,4-
naftoquinonas como potenciais inibidores irreversíveis destes enzimas. 
Foram preparadas cinco sultamas vinílicas, cuja estrutura inclui um segmento dipeptídico. A sua 
síntese envolveu duas etapas principais: (i) a síntese de sultamas vinílicas intermediárias E- e Z- com um 
só aminoácido, através da reacção de Horner-Wadsworth-Emmons entre o N-Boc-S-fenilalaninal e os 
diversos fosfonatos das sultamas e (ii) a reacção dessas sultamas com aminoácidos N-protegidos, em 
condições usadas habitualmente em síntese peptídica. Estes compostos não inibiram a papaína quando 
testados até uma concentração máxima de 50 µM e mostraram uma fraca acção antimalárica, através do 
estudo do seu efeito inibitório na actividade da falcipaína-2 recombinante (valores de CI50 compreendidos 
entre 13,7 e 48,4 µM) e no crescimento do Plasmodium falciparum W2 (CI50 > 7,8 µM). Estudos de 
docking apresentaram dois modelos possíveis para a interacção entre as sultamas vinílicas e as proteases 
de cisteína, ambos desfavoráveis ao ataque da Cys25 aos compostos. 
Os derivados da 1,4-naftoquinona foram preparados através da reacção de diversas 1,4-naftoquinonas 
comerciais com a metilamina, ésteres etílicos dos aminoácidos e com o etanol. Este grupo de compostos 
inibiu a papaína e a catepsina B bovina, de forma irreversível, com constantes cinéticas de segunda 
ordem, k2, compreendidas entre 0,67 e 35,4 M−1 s−1 para a papaína, e entre 0,54 e 8,03 M−1 s−1 para a 
catepsina B. Alguns compostos exibiram uma cinética de saturação relativamente à concentração do 
inibidor, com valores de KI entre 9,57 e 266 µM para a papaína e entre 14,0 e 797 µM para a catepsina B. 
Estudou-se a reactividade química de algumas 1,4-naftoquinonas na presença do aminoácido cisteína e 
verificou-se que este parâmetro é dependente da energia da LUMO da naftoquinona, enquanto a 
actividade como inibidores da papaína é independente. As 1,4-naftoquinonas não inibiram a falcipaína-2 
recombinante nem o crescimento do Plasmodium falciparum W2 quando testadas até uma concentração 
máxima de 10 µM. Foram também inactivas contra uma protease de serina, a elastase porcina pancreática. 
 
PALAVRAS CHAVE 
Sultamas Vinílicas, Naftoquinonas, Inibidores Irreversíveis, Inibidores das Proteases de Cisteína, Tióis, 
Reactividade. 
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ABBREVIATIONS AND SYMBOLOGY 
 
Amino acids are written in the three-letter code. Other abbreviations are: 
 
abs absolute 
Ac acetyl 
Anal. Calcd. Analysis Calculated 
Ar aromatic group 
AU Absorbance Units 
Boc tert-Butoxycarbonyl 
BOP (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate  
b.p. boiling point 
br broad 
brd broad doublet 
brdd broad double doublet 
brq broad quartet 
brs broad singlet 
brt broad triplet 
n-BuLi n-butyllithium 
Bz benzyl 
Cbz benzyloxycarbonyl 
CDCl3 deuterated chloroform 
CD3CN deuterated acetonitrile 
13C NMR carbon-13 Nuclear Magnetic Resonance 
CNS Central Nervous System 
conc. concentrated 
d doublet 
DCC N,N′-dicyclohexylcarbodiimide 
DCM dichloromethane 
dd double doublet 
ddd doublet of doublet of doublets 
dddd doublet of doublet of doublet of doublets 
DEPT Distortionless Enhancement by Polarization Transfer 
DIBAL diisobutylaluminum hydride 
DMSO dimethyl sulfoxide 
d6-DMSO deuterated dimethyl sulfoxide 
D2O deuterium oxide 
dt triple doublet 
DTT DL-dithiothreitol  
EDTA ethylenediaminetetraacetic acid 
ESI-MS Electrospray Ionization Mass Spectrometry 
Et ethyl 
EtOAc ethyl acetate 
EtOH ethanol 
GC-MS Gas Chromatography - Mass Spectrometry 
GSH glutathione 
1H-1H COSY Proton-Proton COrrelation SpectroscopY  
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HMBC Heteronuclear Multiple Bond Correlation 
HMQC Heteronuclear Multiple Quantum Correlation 
1H NMR Proton Nuclear Magnetic Resonance 
HOBt 1-hydroxybenzotriazole 
Hph homophenylalanine 
HPLC High Performance Liquid Chromatography 
HR-ESI-MS High Resolution Electrospray Ionization Mass Spectrometry 
HTyr homotyrosine 
i-Am iso-amylamine 
IC50 the concentration of a drug that is required for 50% of its maximal inhibitory effect 
iPr isopropyl 
IR infrared 
J proton-proton coupling constant 
1J one-bond coupling constant 
2J geminal coupling constant 
3J vicinal coupling constant 
JHP one-bond coupling constant for proton-phosphorus (31P) 
JCP one-bond coupling constant for proton-carbon (13C)  
2JCH geminal coupling constant for proton-carbon (13C) 
Jortho ortho coupling constant 
LDA Lithium DiisopropylAmide 
lit. literature 
LUMO Lowest Unoccupied Molecular Orbital 
m multiplet 
Me methyl 
MeOD deuterated methanol 
MeOH methanol 
mol eq mole equivalent 
m.p. melting point 
Ms mesyl 
Mu 4-morpholinecarbonyl 
m/z mass-to-charge ratio 
NMR Nuclear Magnetic Resonance 
NOE Nuclear Overhauser Effect 
NOESY Nuclear Overhauser Effect SpectroscopY 
n-Pr n-propyl 
Ph phenyl 
q quartet 
qd double quartet 
rel. int. relative intensity 
Rf retardation factor 
rt room temperature 
s singlet 
Suc succinyl 
t triplet 
TBTU N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
td double triplet 
TEA triethylamine 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
 xvii 
TLC Thin Layer Chromatography 
TMEDA N,N,N′,N′-tetramethylethylenediamine  
tt triple triplet 
UV ultraviolet 
w/v weight/volume percentage solution 
Ax absorbance at X nm 
N2 nitrogen atmosphere 
(M+) molecular ion peak (in mass spectrometry) 
νmax maximum wave number 
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1. INTRODUCTION 
 
This chapter has three main purposes. Firstly, it will focus on the emergent role of 
cysteine proteases as attractive therapeutic targets for protease inhibitor development. 
Secondly, it will summarise the development of vinyl sulfones and analogues as a promising 
class of cysteine protease irreversible inhibitors. In connection, the synthetic pathway to these 
compounds is briefly described. Finally, it will focus on the chemical reactivity of the quinone 
scaffold and on its therapeutic usefulness, including the targeting of cysteine residues. 
 
 
1.1 Cysteine proteases 
 
1.1.1 Update 
 
Cysteine proteases are one of the most ubiquitously distributed enzyme classes in nature. 
They have been found in mammals, virus, bacteria, protozoa, plants and fungi.1  
This group of enzymes has been widely studied over the years. Nevertheless, until the past 
decade, they were considered to be of little if any therapeutic interest, because it was thought 
that they were restricted to housekeeping functions, through the non-specific degradation of 
proteins in lysosomes or equivalent cellular compartments.2  However, the recent elucidation 
of their physiological roles has changed this view. At present, cysteine proteases are known to 
regulate key biological processes in humans and their overexpression, in particular, has been 
associated with very diverse pathological manifestations ranging from cardiovascular, 
inflammatory, neurological, respiratory, musculo-skeletal, immunological and CNS disorders 
to cancer.3  On the other hand, they perform critical functions in disease-causing parasites and 
viruses.3,4  
Therefore, there is an increasing interest in the effective inhibition of cysteine proteases 
for therapeutic intervention.2  This situation is manifested in a fair number of recent reviews1-
3,5-8  and major efforts in protease inhibitor discovery, which has been improved by the 
availability of three-dimensional structural information for representative cysteine proteases.  
At present, several inhibitors are already in clinical drug development (Figure 1.1).2  For 
example, compound 1.1 is an available orphan drug for the treatment of patients undergoing 
organ transplantations (phase IIb); 1.2a is being developed for the treatment of Chagas 
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disease (pre-clinical) and 1.3a for the treatment of common cold (phase II/III).2,9  Further, a 
search in a patents database10  revealed more than 50 patents concerning cysteine protease 
inhibitors, for the period between 2002 and 2006. 
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Figure 1.1 IDN-6556 (1.1), CRA-3316 (1.2a) and ruprintrivir (1.3a). 
 
 
1.1.2 Potential therapeutic targets 
 
To date, the cysteine proteases of therapeutic importance have been categorised into three 
groups: papain-like (clan CA), ICE-like (clan CD) and picornain-like (clan PA(C)).8  Table 
1.1 lists the proteases with larger impact at the present time. For cathepsin K, caspases and 
rhinovirus 3C protease, inhibitor development is currently in clinical trials.2  Inhibition of 
cathepsin S and of cruzain is under pre-clinical study.2  
 
Table 1.1 Pathologically relevant cysteine proteases. 
 
Clan Family Protease 
C1 (mammalian) Cathepsins B, K and S 
C1 (parasite) Falcipains, cruzain and rhodesain CA 
C2 (mammalian) Calpains 
CD C14 (mammalian) Caspases  
C3 (viral) Rhinovirus 3C PA(C) 
C30 (viral) SARS-CoV 3CLpro 
 
The largest and best studied is the papain-like group (clan CA), which encompasses 
papain (a plant protease), mammalian (cathepsins and calpains) and parasite (falcipain, 
cruzain and rhodesain) enzymes.8  
Papain has been extensively investigated since the earlier twentieth century and it is a 
good study model for this group of enzymes.8  
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For mammalian proteases, major advances in drug discovery have been accomplished for 
cathepsins, mainly cathepsins K, S and B.2  The first one is the major protease responsible for 
bone resorption and therefore is a novel therapeutic target for diseases characterised by 
excessive bone loss, such as osteoporosis and rheumatoid arthritis.2  Cathepsin S plays a key 
role in processing antigens for presentation to the immune cells system. Thus, its inhibitors 
are being developed for the treatment of inflammation and immune system-related diseases 
(e.g. rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, asthma).2,3  An 
elevated cathepsin B has been associated with the development of cancer. It has been 
demonstrated that this enzyme is involved in the degradation of the extracellular matrix 
allowing the invasive growth of malignant tumours and the formation of metastases. 
However, it is considered that more than 20 years of research did not provide sufficient 
preclinical data to establish the potential of cathepsin B inhibitors in cancer chemotherapy, 
which was demonstrated in in vitro studies.11  In addition, the enzyme has been associated 
with other important pathological processes, e.g. inflammation, neurodegenerative disorders 
and ischemic neuronal death.2,11  
Calpains have a calcium-dependent proteolytic activity. They have been implicated in 
ischaemia/reperfusion injuries (e.g. myocardial infarction), CNS diseases (e.g. Alzheimer’s 
disease) and cataract formation.2,5  Nevertheless, most of their physiological functions are still 
unknown and clinical investigations on the role of its inhibitors as effective drugs have yet to 
be reported.2  
 
Cysteine proteases have proved to be essential in the life cycle of many species of 
parasites (e.g. replication or growth, cell differentiation, signalling, host invasion).3  Cruzipain 
(also known as cruzain) is the enzyme with the highest proteolytic activity in Trypanosoma 
cruzi, which is the causative agent of Chagas disease.3  Trypanosoma brucei rhodesiense 
(sleeping sickness) expresses rhodesain whereas Plasmodium falciparum, the most virulent 
malaria-causing parasite in humans, expresses a family of four papain-like proteases, named 
falcipains 1, 2, 3 and 2’.3,12  Falcipain-2 is the most abundant and best-studied enzyme among 
the falcipains.13  This enzyme and the related falcipain-3 play critical roles in the host 
haemoglobin proteolysis to provide free amino acids required for parasite survival, while 
function of falcipain-1 remains uncertain, although it has been demonstrated that it is not 
essential for normal development during erythrocytic stage.14  Falcipain 2’ has been recently 
described.15  It is very similar in sequence to falcipain-2 and the studies suggest that it may 
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play an identical role. Investigations also suggest the possibility of generate effective 
inhibitors that target all falcipains 2, 3 and 2’.15,16  
The mentioned vector-borne protozoan diseases are some of the major and increasing 
causes of morbidity and mortality in Africa, Asia, Central and South America.3  Due to 
socioeconomic reasons, these infections have received limited attention from pharmaceutical 
companies.3  At present, few drugs are available and the present chemotherapy is decades old 
and is not satisfactory in terms of drug resistance and also due to the toxicity associated to 
long-term treatments.12  In addition, vector resistance to insecticides is other significant 
obstacle.12  In this context, the development of new therapies is urgently required, a situation 
appreciated by the World Health Organization.17  The studies with cysteine protease inhibitors 
have established these enzymes as molecular targets for an alternative to traditional 
antiparasitic chemotherapy.12  
 
A second group of therapeutically relevant mammalian cysteine proteases is the one of 
caspases (clan CD, family C14). Caspase-1 (also known as ICEa) is the most studied and it is 
required for the activation of cytokines, which play essential roles in inflammatory diseases 
(e.g. asthma, rheumathoid arthritis, psoriasis, inflammatory bowel disease).2  Currently, ICE 
inhibitors are in clinical development as anti-inflammatory agents.2  The other caspases (2, 3, 
6, 7, 8, 9, 10 and 14) are involved in cascades that lead to apoptosis, but the exact role of the 
individual caspases is not fully known to date.2  Thus, broad-spectrum caspase inhibitors are 
being developed for the treatment and prevention of situations in which cell death contributes 
to organ damage (e.g. liver diseases, CNS diseases, organ transplantations).2  
 
The third group is the picornain-like cysteine proteases, clan PA(C), which play key roles 
in viral life cycles. They are required to the cleavage of a polyprotein into mature viral 
proteins. Inhibition of this process disables the replication of the virus.5  HRV-3C protease is 
essential for human rhinoviruses, which may well be responsible for more than 50% of 
common cold in adults and children.2  The protease SARS-CoV 3CLpro is equally important to 
SARS coronavirus, identified as the causative agent of the severe acute respiratory syndrome. 
This illness was the first severe and readily transmissible disease of the 21st century (from 
November 2002 to July 2003).18  Due to its rapid transmission (it was reported in 26 
countries) and high mortality rate, SARS is a potential global threat and there is no effective 
drug available for its treatment.2,18  
                                                 
a Interleukin-1β Converting Enzyme. 
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Protease-inhibitor X-ray crystal structures are available from the PDB database9  for the 
majority of the above-mentioned cysteine proteases. Exceptions are found in the calpain and 
caspase families, along with rhodesain and falcipains 1, 3 and 2’. 
During the time course of this thesis, two crystal structures of falcipain-2 in complex to 
iodoacetamide19  and cystatin13  have been reported. This provides an opportunity to the 
rational discovery of effective inhibitors against malaria, which is already being exploited by 
GlaxoSmithKline (Spain).13  It is noteworthy that the three-dimensional structure of falcipain-
2 was compared to those in the PDB database.19,20  Cruzain was identified as the most similar 
structural homologue.19  Thus, it is considered that the inhibitors designed against cruzain, e.g. 
vinyl sulfones (Section 1.2.3), provide starting compounds for the rational design of novel 
antimalarials.19  
 
 
1.1.3 Structural differences 
 
Enzymes of the same family show evidence of their evolutionary relationship by their 
similar tertiary structures, by the order of catalytic residues in their sequences or by common 
sequence motifs around the catalytic residues. Related families are grouped into a clan.7  
Structural differences between clans are important in the design of specific inhibitors. 
 
The picornain-like cysteine proteases, clan PA(C), have no homology to papain (clan CA) 
and caspase families (clan CD). The sequence and fold of clan PA(C) cysteine proteases is 
most similar to the one of the serine protease chymothrypsin and although an active site 
cysteine exist instead of a serine nucleophile, the catalytic mechanism resembles more the one 
of a serine protease than that of a classical cysteine protease (Section 1.1.4).1,5  
The papain-like proteases (clan CA) and caspases (clan CD) are also unrelated. A useful 
difference concerns the primary specificity site.b Caspases show selectivity for substrates with 
an aspartate at the P1 position.7  Papain-like cysteine proteases do not have a well-defined S1 
subsite and the most important element of substrate specificity is the hydrophobic S2 subsite, 
which is highly selective for bulky S-amino acids such as Phe or Leu.1  
 
                                                 
b In describing the binding of substrates and inhibitors to the active site of proteases, it is considered that 
enzymatic binding pockets (subsites) from the scissile peptide bond toward the N-terminus (non-prime side) are 
termed S1, S2, etc. and those toward the C-terminus (prime side) S1’, S2’, etc. The corresponding substrate or 
inhibitor amino acids associated with each subsite are termed P1, P2, etc.6  
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A major challenge in inhibitor design is selectivity within the same family or within the 
same clan. For example, members of the papain clan, i.e. papain superfamily, have similar 
non-primed substrate binding pockets and as mentioned above they share a P2-selectivity for 
hydrophobic residues. Larger differences exist within the prime side.5  
A unique feature of cathepsin B, which distinguishes it from other papain-like proteases, 
is the presence of an 18-residue-long insertion known as the occluding loop. This structure is 
characterised by two adjacent histidine residues (His110 and His111, cathepsin B numbering) 
in the S2’ region, which bind to the C-terminal carboxylic group of the substrate allowing the 
carboxypeptidase activity of this enzyme.2,11  This insight was applied in inhibitor design. 
Thus, the dipeptidyl sequences Ile(or Leu)-Pro-OH were used to interact with the S1’ and S2’ 
subsites. Selective and highly potent inhibitors of cathepsin B were achieved, from which 
CA-074 (Section 1.2.2) is a representative member.2,11  
In addition, the S2 subsite of cathepsin B lacks a residue equivalent to Val157 of papain, 
which means that the S2 pocket is larger.1  Cathepsin B and cruzain also possess an extra Glu 
residue in the mentioned subsite, which explains the dual specificity of both enzymes for 
substrates containing either a hydrophobic (e.g. Phe) or basic residue (e.g. Arg) at the P2 
position.21  
Thus, by exploiting the prime side and the subtle differences at the P2 pocket it should be 
possible to selectively inhibit individual papain-like proteases.5  
On the other hand, this similarity is regarded as an opportunity to target several disease-
related enzymes, when broad-spectrum drugs might be an advantage, e.g. antiprotozoal 
agents.22  
 
 
1.1.4 Catalytic mechanism 
 
The catalytic mechanism herein described is the one of a classical cysteine protease, 
which means a papain-like (Scheme 1.1). 
The activity of these enzymes depends on the nucleophilicity of the cysteine thiolate 
group which, after the formation of the non-covalent Michaelis complex (Scheme 1.1a), 
attacks the carbonyl carbon of the scissile amide bond leading to a tetrahedral intermediate 
(Scheme 1.1b). This situation is favoured by the stabilization of the produced tetrahedral 
intermediate anion through hydrogen bonding to the side chain of Gln19 and to the amide 
group of Cys25, which are commonly referred to as the oxyanion hole. In the next step 
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(Scheme 1.1b), the imidazolium ion protonates the nitrogen of a leaving amine to form an 
acyl-enzyme. Subsequently (Scheme 1.1c), the imidazole nitrogen polarizes a water molecule 
which attacks the acyl-enzyme and a second tetrahedral intermediate is produced (Scheme 
1.1d). Finally, the acid is released and the free enzyme is regenerated.1,4,7  
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Scheme 1.1 Currently accepted catalytic mechanism for papain-like cysteine proteases. Amino acid 
residues are in papain numbering. Hydrogen bonds are in grey. 
 
 
 
The main feature in the active site of papain-like cysteine proteases is the close proximity 
of the residues Cys25 and His159, which are spatially orientated to form a catalytic ion pair 
(Figure 1.2). The histidine imidazole group polarizes the cysteine thiol, allowing 
deprotonation even at physiological conditions.4  Therefore, the reactive specie is a thiolate 
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anion, which explains the unusually high reactivity of cysteine proteases in comparison with 
simple thiols. In fact, the thiol moiety of cysteine proteases has a pKa of 2.5, in contrast with 
the pKa of free cysteine thiol, which is 8.3.2  
It has been proposed that the thiolate/imidazolium ion pair is significantly stabilised by 
the residues Asp158, Trp177 and Asn175. The latter amino acid form with Cys25 and His159 
the referred “catalytic triad of the papain superfamily” and it may be also responsible to direct 
the histidine imidazole’s position through the different steps of the catalytic mechanism.23,24  
However, the exact role of these residues, i.e. Asp158, Trp177 and Asn175, remains under 
discussion.25  
 
 
 
Cys25
Gln19
Trp177
Asp158
His159
Asn175
 
 
Figure 1.2 Active-site of papain. Cys25 and His159 are in green. The sulphur atom of Cys25 is highlighted in 
red. Asn175 is in blue. Gln19, Asp158 and Trp177 are in magenta. This figure was prepared from 1PPN20  using 
Pymol software.26  
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1.2 Inhibitors of cysteine proteases 
 
1.2.1 Irreversible versus reversible action 
 
In general, the ideal protease inhibitor would be highly selective for its target enzyme and 
it would bind with such high affinity that the dissociation, although possible, would be very 
slow (tight binding).1,27  
To achieve a tight binding interaction, efforts have been directed to inhibitors with an 
electrophilic moiety capable of forming a reversible covalent bond.4  For cysteine proteases, 
this goal has been pursued through the design of inhibitors employing aldehyde and ketone 
“warheads”.4  This strategy was based on the mechanism of the catalytic process. Thus, 
bearing in mind that the transition state involves a tetrahedral intermediate (Scheme 1.1b), it 
was rationalised that aldehydes/ketones would react with the enzyme with production of an 
analogous product, i.e. a tetrahedral hemithioacetal/hemithiocetal.1  However, because 
cysteine and serine proteases have a similar proteolytic mechanism, the incorporation of these 
functional groups (aldehyde in particular) afforded inhibitors for both classes of enzymes, 
with concomitant pharmacological problems.1,4  Furthermore, aldehydes are easily oxidized to 
the corresponding carboxylic acids and are prone to racemisation, displaying poor 
bioavailability.4  
On the other hand, a great number of compounds capable of react irreversibly with the 
active site cysteine have been reported.7  These inhibitors usually possess a peptide segment 
corresponding to the sequence of a good substrate, which is important in the formation and 
stability of the non-covalent enzyme-inhibitor complex. This moiety is attached to an 
intrinsically reactive functional group (e.g. fluoromethyl ketones, epoxides, Michael 
acceptors), whose electrophilicity determines the rate of the inhibition irreversible step.1  
Because the active site cysteine has a greater nucleophilicity compared to the serine group, 
these inhibitors are generally quite selective for cysteine versus serine proteases.1  
However, the therapeutical usefulness of irreversible inhibitors is always subject of 
discussion. A major concern is their potential for developing immunological disorders in 
vivo.7,8  This biological response might occur when the proteases are cleaved to fragments 
which are presented to the immune system cells. Reversible inhibitors will dissociate from the 
protease as the recognition sites of the protein are destroyed, but the irreversible ones may 
remain attached leading to covalently derivatized peptides, which may be recognised as 
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foreign.8  While theoretically a problem, evidence exists that this issue is probably less 
important in acute conditions (i.e. infectious diseases) than it would be in chronic diseases 
(e.g. cancer, osteoporosis), where therapy might have to be continuously administered for 
years.7,8  A strong argument in support of this view is the application of β-lactam antibiotics 
which although irreversible are among the most successful antimicrobials available.8  
Therefore, irreversible inhibitors have been exploited for short-term therapies, e.g. 
bacterial, viral and parasite infections.7,8  In this connection, it should be noted that the three 
mentioned inhibitors in clinical development (Figure 1.1) act in an irreversible manner.  
Another concern that has severely limited the applicability of protease irreversible 
inhibitors, under biological conditions, is their capacity to react in an unspecific manner with 
many nucleophiles en route to the intended target.4  
Vinyl sulfones and their analogues are a promising class among cysteine protease 
irreversible inhibitors. These compounds were found to be highly potent, selective over serine 
proteases and effectively inert in the absence of an enzyme’s catalytic machinery. The latter 
means that they do not react significantly with irrelevant nucleophiles, such as low molecular 
weight thiols.1,5,7  The design of this group of inhibitors has followed the discovery of another 
interesting class, the epoxysuccinyl derivatives.1,5,7  Both are briefly described in the 
following sections. 
 
 
1.2.2 Epoxysuccinyl derivatives 
 
The first epoxysuccinyl peptide discovered was E-64 1.4a (Table 1.2), isolated from 
culture extract of Aspergillus japonicus in 1978.1  Once recognised its potent and irreversible 
inhibitory action against papain and a large number of other cysteine proteases (Table 1.2), a 
new generation of epoxysuccinyl derivatives has been designed and synthesised.7  
In addition to their potency as cysteine protease inhibitors, these compounds showed little 
or no activity against serine, metallo and aspartic proteases.2  They also revealed specificity 
for papain superfamily proteases, i.e. the clan CA. Neither the caspase family enzymes (clan 
CD) nor viral clan PA enzymes are inhibited.5  Another advantage is their stability under 
physiological conditions toward simple thiols.1,7  Prominent examples of this class are the 
mentioned natural lead E-64 1.4a and its synthetic analogues E-64c 1.4b, E-64d 1.4c, CA-030 
1.4d, CA-074 1.4e and CA-074Me 1.4f (Table 1.2).2,7  
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Table 1.2 (a) Second-order rate constants for inactivation of cysteine proteases by epoxysuccinyl 
derivatives; (b) IC50 values of epoxysuccinyl derivatives for cysteine proteases. 
 
AA1
O
OO
R2
R1
 
a 
 
Inhibitor R1 AA1 R2 k2 (M−1 s−1)a 
    Papain CatBb CatLc Cruzain 
1.4a, E-64 HO Leu Agmd 638000 89400 96300  
1.4b, E-64c HO Leu NH(CH2)2CH(CH3)2 357000 298000 206000  
1.4c, E-64d EtO Leu NH(CH2)2CH(CH3)2     
1.4h BzONH D-HTyr NH(CH2)2CH(CH3)2 1450   441600 
1.4i BzONH D-Hph Ph    179700 
a These values are from a most cited review.7  They are herein presented to illustrate the potency of E-64 derivatives. However, it is noteworthy that the 
values may be different in other papers, according to the employed conditions. b Cathepsin B; c Cathepsin L, d Agmatine. 
 
b 
 
Inhibitor R1 AA1 AA2 R2 IC50 (nM)a 
     Papain CatB CatL 
1.4d, CA-030 EtO Ile Pro OH 16000 2.3 32000 
1.4e, CA-074 n-Pr-NH Ile Pro OH 57400 2.2 172000 
1.4f, CA-074Me n-Pr-NH Ile Pro OMe    
1.4g, CA-028 HO Ile Pro OH  30.4 530 
a These values are from a most cited review.1  They are herein presented to illustrate the potency and selectivity of compound CA-074 and of its analogues. 
However, it is noteworthy that the values may be different in other papers, according to the employed conditions. 
 
 
Since its discovery, E-64 has been used as an active site tritrant and a diagnostic tool for 
the identification of cysteine proteases.7  Its derivatives have been labelled with biotin, 
radiolabeled iodine and fluorescent dyes, such as rhodamine B, to be used as affinity labels in 
studies of the biological function and histochemical mapping of cysteine proteases.7  
The replacement of the guanidine function of E-64 by an uncharged substituent was 
expected to improve cell permeability.1  The resultant compound, E-64c, maintained the 
inhibitory activity and showed to be effective in animal models of muscular dystrophy when it 
was administered by subcutaneous and intraperitoneally injection.7  Unfortunately, it was 
inactive when given orally due to poor absorption in the gastrointestinal tract.7   
Thus, esterification of the acid group at C-3 led to the prodrug E-64d (also known as 
aloxistatin and loxistatin).1  The ester moiety of this compound is hydrolysed during 
permeation through the intestinal membrane, giving E-64c.7   
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E-64d was tested in clinical trials in Japan for the treatment of muscular dystrophy, but the 
development was stopped in 1992 in phase III due to its low efficacy and toxicity, such as 
hepatic injury and teratogenic effects on rat embryogenesis.1,7  This inhibitor in the form of 
eyes drops has also been shown to be effective in the prevention and treatment of cataracts 
probably by inhibition of calpain.1  
Compounds CA-030 and CA-074 are part of a group developed to selectively target 
cathepsin B.7,11  As mentioned earlier (Section 1.1.3), the Ile(or Leu)-Pro-OH sequence is 
complementary to the unique prime site of this enzyme. This dipeptide was therefore attached 
to the epoxide ring, along with different amide and ester substituents at C-2 position.11  While 
CA-074 is specific for cathepsin B within living cells, the derivative CA-030 is not, because 
the ethyl ester of the epoxysuccinyl moiety is hydrolysed by esterases to produce the non-
specific inhibitor CA-028 (1.4g, Table 1.2b).7  
The derivative CA-074Me is a prodrug of CA-074, which requires intracellular 
deesterification for activity.2  It is membrane-permeable, but is a comparatively weak and 
non-selective inhibitor for cathepsins.2  
This class of inhibitors has also provided avenues to targeting parasitic cysteine proteases, 
particularly cruzain.22  Although potent (1.4h and 1.4i, Table 1.2a), most of the compounds 
show little or no activity in vitro when tested against Trypanosoma cruzi infected-cells.7  
Epoxysuccinyl derivatives inhibit cysteine proteases by alkylating the active site cysteine, 
which results in the opening of the epoxide ring (Scheme 1.2).7  The nucleophilic attack 
occurs at either C-2 or C-3 positions depending on the orientation of the inhibitor in the active 
site.7  
A great number of X-ray structures of these inhibitors complexed to cysteine proteases 
have been reported, explaining in detail the binding modes (Scheme 1.3) as well as answering 
the question which carbon is attacked.5,20  Thus, binding in the S subsites (e.g. E-64, E-64d) 
leads to C-2 attack, whereas binding in the S’ subsites leads to C-3 attack.7  The latter is 
associated with cathepsin B, i.e. CA-074 and analogues.7  Interestingly, the peptide chain 
direction of E-64 is reversed to that of a substrate.7  
Once the epoxide ring was discovered to be the reactive group essential for inhibition, it 
was replaced by a Michael system, which may also undergo nucleophilic attack.1  These 
investigations generated a new class of inhibitors, which is described in the following section. 
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Scheme 1.2 Mechanism of inhibition of cysteine proteases by epoxysuccinyl derivatives. Hydrogen bonds 
are in grey. 
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Scheme 1.3 Schematic representation of the binding modes of epoxysuccinyl derivatives. The arrow 
indicates the carbon atom that is attacked by Cys25. Hydrogen bonds are in grey. 
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1.2.3 Vinyl sulfones and analogues 
 
1.2.3.1 As inhibitors of cysteine proteases 
 
In the middle 1980’s, Hanzlik et al. designed a series of dipeptidyl derived Michael 
acceptors and demonstrated their inhibitory activity toward papain (second-order rate 
constants ranging from 0.05 to 26.1 M−1 s−1).28-30  The most reactive derivatives were the 
unsaturated ester 1.3b and the simple vinyl sulfone 1.2b (Figure 1.3).30  
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Figure 1.3 Hanzlik et al. lead compounds for inhibition of papain. 
 
In connection with efforts to develop selective inhibitors of cysteine proteases, Palmer et 
al.31  became interested in the vinyl sulfone scaffold for two reasons. Firstly, this functionality 
appeared as sufficiently chemical stable.31  Secondly, it was reasoned and validated by 
molecular modelling studies that the sulfonyl unit would be capable of hydrogen-bond 
formation with the enzymatic residues Gln19 and His159 (Scheme 1.4). This recognition 
process would serve to direct the vinyl sulfone in the active site in proximity to the sulphur 
atom of Cys25, leading to Michael addition chemistry.31,32  
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Scheme 1.4 Mechanism of inhibition of cysteine proteases by vinyl sulfones. Hydrogen bonds are in grey. 
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With this background, Palmer et al.31  developed dipeptidyl vinyl sulfones as a new class 
of irreversible inhibitors for a variety of disease-associated papain-like cysteine proteases. 
These first-generation compounds displayed second-order rate constants higher than 107 M−1 
s−1, but they had broad activity.7  Cathepsin S was the most easily inactivated enzyme 
followed by cathepsin L, cruzain, cathepsin K and cathepsin B, whereas the calpains were 
resistant to most vinyl sulfone inhibitors.7  
The reaction of a vinyl sulfone inhibitor with GSH showed a second-order rate constant 
smaller by seven orders of magnitude than that found against cysteine proteases. On the basis 
of this experiment, vinyl sulfones were considered to be stable toward circulating thiols.31   
To investigate selectivity over serine proteases, Palmer et al.31  targeted the serine protease 
human leukocyte elastase (HLE), using a vinyl sulfone bearing a peptide sequence 
complementary to this enzyme. The compound failed the inhibition. 
The specificity of vinyl sulfones for cysteine proteases has been rationalised in terms of 
the mechanism in Scheme 1.4. Protease-inhibitor X-ray crystal structures have uncovered the 
suggested hydrogen bonding interactions, and it has been proposed that the protonated 
histidine polarizes the vinyl group, giving the β-vinyl carbon a partial positive charge and 
promoting nucleophilic attack by the active site thiolate. Histidine also acts as a general acid 
by protonating the emerging negative charge at the α-carbon, forcing the reaction into 
irreversibility. In serine proteases, the active site histidine plays an opposite role, i.e. is 
unprotonated and acts as a general base. This situation is seen as the determining factor in the 
selectivity over serine proteases.5,7  
In view of these promising results, several vinyl sulfone analogues have been optimized 
for in vivo use against specifically enzymes. Prominent examples were accomplished in the 
targeting of the parasitic cysteine proteases (Table 1.3). 
Therefore, 1.2a is in pre-clinical studies for the treatment of Chagas disease.2  This 
compound rescued mice from this infection.7  On the basis of these data, extensive rat and dog 
toxicology tests have been conducted, along with pharmacokinetic analysis.2  It is expected 
that it will enter human clinical trials in a foresseable future.2  
Taking this lead compound and its analogue 1.2c, Roush et al.33  reasoned that spanning 
the inhibitor structure into the prime site region (S1’, S2’) could result in additional potency 
and selectivity against cruzain. The resultant compounds (1.2d, 1.5a and 1.6a) were 
characterised by a spacer unit between the sulfonyl group and the phenyl substituent. The 
function of this linker was to direct the phenyl ring into the prime site residue Trp177, 
probing their potential interaction.7,33  
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With this strategy, Roush et al.33  introduced vinyl sulfonate (e.g. 1.5a) and vinyl 
sulfonamide scaffolds (e.g. 1.6a) as inhibitors of cysteine proteases. These compounds 
(sulfonates in particular) revealed improved potency against cruzain comparatively to vinyl 
sulfones 1.2a,c.34  Unfortunately, they were inactive against Trypanosoma cruzi in tissue 
culture assays.34  To overcome this situation, the inhibitor structures were further manipulated 
on both prime and non-prime site. Thus, N-sulfonyl hydroxylamine vinyl sulfonamides 1.7 
were designed to combine the Michael acceptor reactivity of a sulfonate with the hydrogen 
bond capacity of a sulfonamide.34  The latter aspect contributes to the formation of the non-
covalent enzyme-inhibitor complex. These compounds were also expected to have improved 
aqueous solubility due to the incorporation of the P3 morpholinyl and N-methylpiperazinyl 
urea in addition to the possibility that the hydroxylamine unit might be partially ionized at 
physiological pH.34  This new generation of compounds found to be highly effective inhibitors 
of cruzain, with significant activity in tissue culture experiments.34  
 
 
 
Table 1.3 Vinyl sulfones and analogues: second-order rate constants for inactivation of cruzain and results 
of in vitro assays against Trypanosoma cruzi. 
 
N N
H
N
H
S
Ph
X
O
Ph
O Ph
O O
Cbz
N
H
N
H
S
X
Ph
O Ph
O O
Ph
N
H
O Ph
N N
H
N
H
S
X
O
Ph
O Ph
O O
1.2a X = NMe
1.2c X = O 
1.2d X = CH2
 
1.7a X = NMe
1.7b X = O 1.5a X = O
1.6a X = NH
  
 
Inhibitor k2 (M−1 s−1)a Survival of Trypanosoma cruzi treated J744 macrophagea 
None  6 (control) 
1.2a 419,500 > 24 
1.2c 181,000 > 24 
1.2d 1,400,000 6 
1.5a 16,800,000 Toxic 
1.6a 242,000 6 
1.7a 6,480,000 > 24 
1.7b 2,270,000 > 24 
a These values are from Roush et al.34  
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Vinyl sulfones were also evaluated as antimalarial agents (Table 1.4). In general, the 
presence of phenylalanine at the P2 position appears to be less effective for the malarial 
cysteine proteases.6  
Rosenthal et al.35  identified 1.2e as the compound that most effectively inhibited falcipain 
and also most effectively blocked parasite haemoglobin degradation, metabolic activity and 
development. Subsequently, the morpholine urea group of 1.2e was replaced with N-methyl 
piperazine urea to improve aqueous solubility and presumably bioavailability.36  One of the 
resultant analogues, 1.2f, cured about 40% of mice from malaria (Plasmodium vinckei).36  
Further studies afforded several related compounds, which included two potents N-
sulfonyl hydroxylamine vinyl sulfonamides (1.7c,d).16,34   
It is noteworthy that the differences between the second-order rate constants for inhibition 
of falcipains 2 and 3 are fairly small (Table 1.4b).16  Findings like this argue that drug 
discovery against these two enzymes will likely not to be complicated by the need to develop 
separate inhibitors.16   
 
Table 1.4 Vinyl sulfones and analogues: (a) IC50 values for falcipain-2 and cultured Plasmodium falciparum 
parasites; (b) second-order rate constants for inactivation of falcipains 2 and 3. 
 
N N
H
N
H
S
Ph
O
O
O Ph
O O
N N
H
N
H
S
N
O
O Ph
O O
N
H
O Ph
N N
H
N
H
S
X
O
O Ph
O O
1.2e 1.2f 1.7c X = NMe
1.7d X = O  
a 
 
Inhibitor IC50 (nM)a 
 rec-FP-2b Plasmodium falciparum W2 
1.2e 3.5/10c 22 
1.2f 2c  
1.7c 2.3 4.4 
1.7d 2.2 46 
a These values are from Shenai et al.16  b Recombinant falcipain-2. c The value of 10 nM (compound 1.2e) is from non-recombinant falcipain.36  It is herein 
included for comparison purposes with the value of 1.2f, which is also from non-recombinant falcipain.36  
 
b 
 
Inhibitor k2 (M−1 s−1)a
 Falcipain-2 Falcipain-3 
1.2e 78,600 57,100 
1.7c 74,700 147,000 
1.7d 411,000 407,000 
a These values are from Shenai et al.16  
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In summary, vinyl sulfones and their analogues have demonstrated marked potency 
against parasitic cysteine proteases. The reported efficacy of orally administered compounds 
in animal models, without undue toxicity to the host,36,37  has provided an important “proof of 
concept” for its use in vivo. As illustrated by the above representative compounds, major 
efforts exist to further improvement of the current leads. 
 
 
 
1.2.3.2 Synthesis 
 
Peptidyl vinyl sulfones 1.2g (Scheme 1.5) have been provided by Horner-Wadsworth-
Emmons reaction of N-Boc amino acid aldehydes 1.8a with phosphonates 1.9.31  Although 
small amounts of the vinyl sulfone Z-isomer cannot be excluded,38,39  E-vinyl derivatives have 
been the only to be characterised and evaluated against cysteine proteases.16,29,31,33,34  
Removal of the Boc group and subsequent coupling with N-protected amino acids give 
dipeptidyl derivatives 1.2h.16,31,33,34  
Dipeptidyl vinyl sulfonates 1.5b and vinyl sulfonamides 1.6b are usually achieved by 
following the above mentioned strategy, starting from the preparation of the monopeptidyl 
vinyl sulfonate 1.5c, which is converted into 1.5d to obtain the sulfonyl chloride 1.10a. This 
last intermediate is then reacted with the appropriate amine or phenol.16,33,34  Small variations 
to this general scheme have been reported, but the reasons for that were not given. Thus, 
intermediate 1.5d was also synthesised by the Horner-Wadsworth-Emmons reaction of the 
dipeptidyl aldehyde 1.8b with phosphonate 1.9 (R = OEt).33  Another variation concerns the 
incorporation of amino acid at the P2 position, which can be carried out after the substitution 
at the sulfonyl centre (1.5b/1.6b via 1.10b).16,34  
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Scheme 1.5 Synthetic pathway to vinyl sulfones and their analogues. 
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1.3 Introductory remarks on quinones 
 
Quinones present in their molecular skeleton a characteristic conjugated dione ring, which 
is incorporated in an aromatic system, e.g. a naphthalenyl ring (Figure 1.4).40  
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Figure 1.4 Representative chemical structures of quinones. Quinones occurring as benzo- (e.g. 1.11), 
naphtho- (e.g. 1.12) and anthraquinones (e.g. 1.13) represent the largest class of quinoid compounds.41  Isomeric 
forms exist due to the different positions of the carbonyl groups in the quinoid ring (e.g. 1.14a and 1.14b). 
 
This class of compounds is probably found in all living cells, where they, i.e. ubiquinones, 
function primarily as components of the electron transport chains involved in cellular 
respiration and photosynthesis. In addition, vitamin K2 (1.15a, Figure 1.5) is required to blood 
coagulation. Quinones also play a role in cellular defence (in animals and plants), because 
they effectively inhibit the growth of bacteria, fungi and parasites. 40,42  
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Figure 1.5 Vitamin K2. 
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Many of these substances are used in folk medicine and they have become the subject of 
intense research due to their interesting pharmacological, e.g. antitumour, trypanocidal, 
leishmanicidal, anti-inflammatory, antiviral, molluscicidal and antifungal properties.43,44  
Some have reached clinical use, such as mitomycin C 1.16, daunorubicin 1.17a and 
doxorubicin 1.17b (Figure 1.6), which are used as antineoplastic drugs.42  Among 
naphthoquinones, atovaquone (1.18, Figure 1.6) is an effective broad-spectrum antiprotozoal 
drug used against Plasmodium spp., Pneumocystis carinii, Babesia spp. and Toxoplasma 
gondii.45  Vitamin K analogues (1.15b, Figure 1.6) have found clinical use as haemostatics 
and radiosensitizers.42  
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Figure 1.6 Structures of mitomycin C (1.16), daunorubicin (1.17a), doxorubicin (1.17b) and atovaquone 
(1.18). Generic structure of menadione derivatives (1.15b). 
 
Unfortunately, the potential usefulness of quinones is limited by their toxicity, associated 
with effects such as myelosuppression, cardiomyopathy and haemolytic anaemia.42   
Their actions and toxicity are still difficult to understand, although at least two competing 
mechanisms have been identified: (i) their capacity to undergo redox cycling and (ii) their 
capacity to act as electrophiles.42   
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The redox cycle mechanism is complex and is still largely unknown (Scheme 1.6).40  
Briefly, quinones 1.19 are able to accept electrons through a process mediated by some 
reductases, e.g. NADPH-cytochrome P450 reductase. The first one-electron reduction leads to 
a semiquinone radical 1.20 that can be subsequently converted to a hydroquinone 1.21. 
Alternatively, hydroquinones 1.21 may be produced by reaction of quinones 1.19 with GSH 
or through a direct two-electron reduction mediated by the enzyme DT-diaphorase.42  
Hydroquinones 1.21 may lead to the production of reactive oxygen species or to a 
detoxification process, depending on their properties, i.e. redox potential.43  
Semiquinone radicals 1.20 are very unstable substances, toxic by themselves, which may 
be re-oxidized to the parent quinone 1.19, with the concomitant reduction of oxygen to 
superoxide anion radical.42,43  
Thus, quinones are involved in a cyclic process (a futile redox cycling) which leads to 
cytotoxic levels of hydrogen peroxide.42  In addition, they promote the depletion of GSH, 
compromising one of the cellular defences against oxidative stress.42  Disruption of the 
cellular environment might lead, in extreme situations, to the induction of apoptosis.40  
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Scheme 1.6 Formation of reactive oxygen species by redox cycling of quinones. Adapted from dos Santos et 
al.44  and O’Brien et al.42  
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Regarding the capacity of quinones to act as electrophiles, some compounds unsubstituted 
at one or several positions of the quinone ring can lead to the covalent modification of thiols 
or other vital physiological components, i.e. proteins, DNA and RNA.42,43  
The reactions of quinones with sulphur nucleophiles, including GSH, can be characterised 
as Michael-type additions, yielding as primary product the mono-substituted hydroquinone 
(e.g. 1.22, Scheme 1.7).41,42  
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Scheme 1.7 Michael-type addition of thiols to quinones. Exemplified for 1,4-benzoquinone 1.11. 
 
 
The site of attack by nucleophiles is largely influenced by the nature, i.e. electron-
donating or electron-withdrawing character, of the quinone substituents.41  Usually, the 
addition occurs at the position having the largest LUMO coefficient.46  
The substituents also determine the rate of the reaction, which is generally decreased by 
electron-donor groups (e.g. –Me and –OMe) and increased by electron-withdrawal ones (e.g. 
–Br).42  
The resultant adducts are not redox inert and may be re-oxidized, for example, by a 
second molecule of quinone or by oxygen. When a thiol-derived quinone, such as 1.23, 
possesses available sites for nucleophilic addition, it may react with an excess of thiol 
producing poly-substituted conjugates 1.24.41,42  
Most of the mechanistic schemes presented for quinones have been originated from 
studies under anaerobic conditions.41,42  Thus, they might be an oversimplification of the 
reactions occurring in aerobic systems, because, as mentioned above, the resultant adducts can 
be re-oxidized, causing oxidative stress as readily as or even more readily than the quinone.41  
The application of the mentioned mechanisms to biological systems requires even more 
caution, because the intracellular situation also involves the enzymatic catalysed reduction, 
which might greatly enhance the redox cycle.42  
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Whether a quinone acts as an electrophile, a redox cycler or as both is closely associated 
with its reduction potential. 
To undergo redox cycling, the quinone must have a reduction potential sufficiently high to 
allow efficient reduction by cellular reductases but no so high that it prevents the re-oxidation 
of hydro- and semiquinones.47  Thus, high reduction potentials have been related to quinones 
acting mainly by Michael addition.48  For example, 1,4-benzoquinone (reduction potential is 
+99 mV) is known to be cytotoxic only due to its electrophilic action, whereas 2,3-
dimethoxy-1,4-naphthoquinone, with a much lower reduction potential (−240 mV), was 
reported as a pure redox cycler.48   
Until recently, most of the drug investigations involving quinones, e.g. as antineoplastic 
drugs, have focused on the production of oxygen reactive species. However, the 
electrophilicity of this class is now being exploited in inhibitor design against 
enzymes/receptors containing a thiol residue at or near the active site, in order to achieve 
more selective cytotoxic compounds.49-51  In this context, compounds 1.25a,b (Figure 1.7) 
have been proposed as inhibitors of CDC25 phosphatases and a series of derivatives 1.26 has 
been developed to target vascular endothelial growth factor receptor-2 (VEGFR-2).51,52  
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Figure 1.7 Structures of Cpd 5 (1.25a) and NSC 95397 (1.25b). Generic structure of 2-(quinazolin-4-
ylamino)-[1,4] benzoquinone derivatives (1.26). 
 
An important issue in the design of inhibitors targeting cysteine enzymes is the selectivity 
over serine proteases. Studies involving 2-chloro-3-substituted-1,4-naphthoquinones have 
corroborated the possibility of achieving specificity, because these compounds showed to be 
potent inactivators of Human Cytomegalovirus Protease, a serine protease, but due to the 
covalent modification of a cysteine residue instead. In connection, the same compounds were 
tested against the prototypical serine proteases thrombin and human neutrophil elastase 
1. Introduction 
25 
(HNE). They failed the inhibition of the former and only one revealed moderate inhibition 
against HNE.53  
In spite of the potential toxicity associated with quinones, evidence exists that it should be 
possible to modulate this property by the appropriate choice of substituents. A strong 
argument in support of this view is the already mentioned atovaquone 1.18, which is 
considered to have an excellent safety profile and is tolerated by infants and small 
children.45,54  Interestingly and in clear contrast, its analogues (2-hydroxy-3-alkyl-1,4-
naphthoquinones) were reported as causing haemolytic anaemia and renal damage in rats.55  
In addition, atovaquone is orally effective. Its bioavailability is still considered far from 
satisfactory, but progresses have been made by reformulating it as a micronized suspension 
(the drug was originally released as a tablet).45  
 
 
1.4 Aims of the thesis 
 
The main aim of this project was to contribute to the ongoing research in the development 
of irreversible inhibitors of papain-like cysteine proteases. 
Initially, the work focused on the inactivation of falcipain-2, a cysteine protease which 
plays a crucial role in the life cycle of Plasmodium falciparum and is, therefore, an attractive 
antimalarial target. To achieve this goal, a series of vinyl sultam derivatives was designed and 
synthesised as potential inhibitors (Chapter 2). 
Vinyl sultam scaffold (1.27, Scheme 1.8) was chosen for three main reasons. Firstly, it is a 
cyclic isostere of vinyl sulfonamides 1.28, which inactivate cysteine proteases by irreversible 
alkylation of the active site Cys25 via Michael addition chemistry. Vinyl sulfonamides are 
particularly successful against cruzain and, as such, provide an interesting starting point for 
the rational design of inhibitors toward falcipain-2, due to the similarity between both 
enzymes. Secondly, vinyl sultams are structurally similar to α-methylene lactones, which are 
known acceptors for thiols.56,57  Finally, vinyl sultams appeared to be resistant to the blood 
pH, because previous investigations found that β-sultams, including vinyl derivatives, are 
sufficiently stable at neutral pH to be used as potential enzyme inhibitors.58,59  
In this context, it was reasoned that vinyl sultams would be able to reach the action site, 
i.e. the erythrocyte infected with the malaria parasite, and inactivate falcipain-2 by a 
mechanism identical to that of vinyl sulfonamides. 
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It should be noted that the vinyl sultam scaffold has been incorporated in the design of 
potent inhibitors against both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO), but the 
inactivation process does not involve nucleophilic addition to the vinylic moiety.60   
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Scheme 1.8 Approach to the design of potential irreversible inhibitors of cysteine proteases. 
 
 
In a second phase of this PhD project, commercial 1,4-naphthoquinone derivatives were 
screened for papain-inhibitory activity, on the basis of the known reactivity of quinones 
toward thiol nucleophiles and enzymes with thiol residues at or near the active site. These 
compounds revealed interesting results, and the 1,4-naphthoquinone moiety was further 
employed as an alternative building block for the design of novel inhibitors (Chapter 3). To 
the best of author’s knowledge, this thesis presents the first evaluation of this scaffold in the 
targeting of papain-like cysteine proteases. 
The potential inactivators were tested against falcipain-2, Plasmodium falciparum W2, 
papain and bovine spleen cathepsin B. For the two latter enzymes, the assessment of the 
inhibitory activity required the development of a methodology through the adjustment and 
validation of reported inhibition assays (Appendix I). 
The intrinsic chemical reactivity of the compounds was investigated by carrying out 
reactivity studies toward the simple thiol cysteine. 
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2. DIPEPTIDE VINYL SULTAMS 
 
This chapter is divided in three main parts: firstly, the synthesis of dipeptide vinyl sultams 
and of analogous vinyl sulfonamides; secondly, reactivity studies of those compounds toward 
cysteine; finally, the evaluation of vinyl sultams against papain, falcipain-2 and Plasmodium 
falciparum W2, in conjunction with molecular docking studies involving cruzain and papain.  
 
 
2.1 Synthesis 
 
2.1.1 Overall strategy 
 
With the aim of designing effective inhibitors for falcipain-2, the vinyl sultam scaffold 
was attached to a peptide moiety, Mu-Leu-Phe. The choice of this sequence was based on 
prior studies involving vinyl sulfones (Section 1.2.3.1), which identified the analogous 
segment Mu-Leu-Hph as the optimal sequence for this enzyme. A vinyl sultam with the Ac-
Phe-Phe moiety was also prepared according to the success of Cbz-Phe-Hph-VS-R vinyl 
sulfones against the homologous enzyme cruzain. Finally, on the basis of the representative 
vinyl sulfone inhibitors for falcipain/cruzain, the nitrogen atom of the sultam ring was 
connected either a benzyl or phenyl group. It was expected that this substituent could interact 
with the hydrophobic prime site (S1’, S2’) of the enzyme. 
The synthesis of the compounds began with the preparation of the sultam cores, which 
were subsequently linked to the peptide moiety according to the pathways illustrated in 
Scheme 2.1. 
Reported investigations provided vinyl sultams through: (i) intramolecular Heck 
reaction,61  (ii) cyclisation of chlorobutenesulfonamide in the presence of a base,62 (iii) direct 
coupling by an aldol-like reaction, followed by dehydration,60,63  and (iv) reaction of sultam 
ring with benzonitrile.64  In the present investigation, preparation of these compounds 
involved two approaches, an aldol-like reaction and Horner-Wadsworth-Emmons chemistry. 
Both strategies lay in the acidity of the hydrogens at the α-position to sulfonamide group, 
which can be removed to afford anions that react with electrophiles (an aldehyde in this case). 
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Scheme 2.1 Strategic routes for the synthesis of dipeptide vinyl sultams 2.1-2.4. These pathways were based 
on the ones reported for the analogous vinyl sulfones, which were described in Section 1.2.3.2. 
 
 
 
2.1.2 Strategies for sultam scaffolds 
 
2.1.2.1 β-Sultams 
 
Four main strategic routes exist for the preparation of the β-sultam ring 2.5 (Scheme 
2.2):58,59  
• N-S bond formation (corresponding to retrosynthetic analysis a), by cyclisation of 
hydrochlorides 2.6 and of derivatives 2.7; 
• N-C bond formation (retrosynthetic analysis b), by cyclisation of mesylates 2.8; 
• cycloadditions of sulfonylamines 2.9 with alkenes 2.10 (retrosynthetic analysis c); 
• cycloadditions of sulfenes 2.11 with imines 2.12 (retrosynthetic analysis d). 
Methods involving cycloadditions have been employed in the preparation of C-
substituted-β-sultams.58,59  However, their potential usefulness is considered limited by the 
difficulty in preparing the extremely reactive sulfonylamines 2.9 and sulfenes 2.11.65  
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Scheme 2.2 Main strategic routes for the preparation of the β-sultam ring. 
 
 
 
By N-S ring closure. Cyclisation of hydrochlorides 2.6 is usually carried out in anhydrous 
EtOAc, at rt. A base (aqueous ammonia or sodium carbonate) is required to remove the extra 
proton of the hydrochloride salt, allowing the attack of the nitrogen nucleophile to the 
sulfonyl centre with displacement of the chloride anion.65-67  The main variation in this 
method is on the route to compounds 2.6, which can be prepared (Figure 2.1): (i) from the 
oxidative chlorination of β-aminothiols 2.1365,66  or β-aminodisulfides 2.14,68  and (ii) from 
the chlorination of sulfonic acids 2.15 with POCl3/PCl5 mixtures either in tetrachloromethane 
or under solventless conditions.65-67,69  
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Figure 2.1 Generic structures of β-aminothiols (2.13), β-aminodisulfides (2.14) and 2-aminoethanesulfonic 
acids (2.15). 
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To the best of author’s knowledge, Baganz et al.68  were the first to synthesise a β-sultam 
from a hydrochloride (2.6a, Scheme 2.3), followed by Le Berre et al.,66  who obtained the 
unsubstituted β-sultam using taurine (2.15, R = H, Scheme 2.4) as starting material. 
Thereafter, this approach was employed in the synthesis of several N-alkyl-β-sultams (45-
95% yield).58,65,69  The method also allowed the preparation of two N-aryl-β-sultams (phenyl 
and 1-naphthyl),65,69  although more recent investigations58  were unable to reproduce the 
yields described for N-phenyl-β-sultam (50 and 82%) due to problems concerning the 
synthesis of N-phenyltaurine (2.15, R = Ph), its chlorination and cyclisation. 
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Scheme 2.3 Representation of the β-sultam synthesis carried out by Baganz et al. 
 
Taurine is commercially available, but most of its N-substituted analogues are not. 
These intermediates have been synthesised by several procedures, some of them characterised 
by their complexity and difficult work-up.70  Four main precursors have been used (Scheme 
2.4): ethenesulfonates 2.16, 2-chloroethanesulfonate 2.17a, 2-bromoethanesulfonate 2.17b 
and ethanolamine (2.18, R = H). Moreover, a German patent discloses the preparation of N-
methyltaurine (2.15, R = Me) from the sodium salt of vinylsulfonic acid 2.19.71  
Ethenesulfonates 2.16 are usually prepared by reaction of sulfonyl chloride 2.20a with an 
alcohol in the presence of pyridine (Scheme 2.5).72,73  Reaction between 2.16 and amines, i.e. 
aliphatic, primary or secondary, occurs preferentially via Michael addition instead of 
involving the attack to the sulfonyl centre. The resultant sulfonates 2.21 need not to be 
isolated and the process proceeds with the hydrolysis of the ester group to afford the taurines 
2.15.72  Isopropyl ethenesulfonate (2.16, R = iPr) has been employed in the synthesis of 
several N-alkyl taurine analogues (31-88% yield).65,67  It also allowed the preparation of the 
N-Ph taurine (2.15, R = Ph) in 98% yield,65  although more recent investigations resulted in a 
yield of 19%, which was ascribed to the poor nucleophilicity of the aniline amino group.58  
2-Chloroethanesulfonate 2.17a and 2-bromoethanesulfonate 2.17b allowed the preparation 
of taurine through the reaction with aqueous ammonia, in yields of 90% and 51%, 
respectively.70,71  The best outcome was accomplished by the study of different temperatures, 
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catalysts and reaction times. This study was also applied to N-methyltaurine, which was 
prepared in 80% yield from sodium 2-chloroethanesulfonate and anhydrous methylamine.71  
Both sodium chloro- and bromoethanesulfonates were used as starting materials in the 
synthesis of N-phenyltaurine, by reaction with aniline (60-80% yield).74  
Finally, the synthesis of taurine from ethanolamine involved the initial preparation of an 
intermediate (Scheme 2.4); e.g. hydrochlorides 2.22a,b,71,75,76  or hydrogen sulfate 2.22c,77  
through the reaction of ethanolamine with thionyl chloride, hydrobromic acid or fuming 
sulfuric acid, respectively. These intermediates were subsequently converted to taurine in the 
presence of sodium sulfite or bisulfite,71,76,77  with yields ranging from 50 to 80%. 
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Scheme 2.4 Main precursors for the preparation of 2-aminoethanesulfonic acid derivatives. 
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Scheme 2.5 Synthetic pathway to 2-aminoethanesulfonic acid derivatives from alkyl ethenesulfonates. 
 
The second approach to the N-S ring closure employs derivatives 2.7 (Scheme 2.6) and 
has been used in the preparation of N-alkyl-β-sultams either brominated at the α position (11-
80% yield) or not (42-74% yield).58,65  This process was first described by Le Berre et al.65  
and proceeds from the initial formation of ethenesulfonyl fluoride 2.23a, which cyclises 
spontaneously in the presence of two equivalents of a primary amine. The reaction is thought 
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to occur via an initial Michael addition followed by the attack of the amino nucleophile to the 
sulfonyl group with the departure of the hydrofluoric acid (HF), which is trapped by the 
second equivalent of amine.58,65  This strategy is based on the finding that for 2.23a the 
Michael type addition is a more favourable process than attack at the sulfonyl group, due to 
the poor ability of the fluoride anion to act as a leaving group. Its displacement only occurs 
when the amino group is part of the molecule and the entropic advantage allows the 
intramolecular ring closure to occur.58  Thus, the behaviour of ethenesulfonyl fluoride 2.23a 
contrasts with that of its chloro analogue 2.23b (Scheme 2.7) which, in the presence of an 
amine, affords acyclic sulfonamides 2.24a,b.78  For this reason, in the approach involving 
hydrochlorides 2.6, the amino group must be introduced before sulfonyl group activation. 
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Scheme 2.6 Synthesis of the β-sultam ring by cyclisation of 1-fluorosulfonyl-2-aminoethane derivatives. 
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Scheme 2.7 Products from the reaction of ethenesulfonyl chloride with amines. 
 
 
Ethenesulfonyl fluoride (2.23a, Scheme 2.8) may be prepared from ethenesulfonyl 
chloride 2.23b, from 2-chloroethanesulfonyl chloride 2.20a and from 2-chloroethanesulfonyl 
fluoride 2.20b. The route involving 2.20b and magnesium oxide was considered the most 
efficient.79  
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Scheme 2.8 Synthetic routes to ethenesulfonyl fluoride.  
 
 
By N-C ring closure. Synthesis of the β-sultam ring through N-C bond formation uses β-
hydroxysulfonamides 2.25 as key intermediates (Scheme 2.9), usually obtained from the 
addition of formaldehyde to a sulfonamide dianion 2.26. Hydroxysulfonamides 2.25 are 
converted to the more reactive mesylate esters 2.8 before the cyclisation step. The ring closure 
is achieved in the presence of a base, by the attack of the nitrogen nucleophile to the carbon 
bearing the mesylate leaving group. This strategy was first described by Thompson80  and was 
most recently adapted as an alternative synthetic approach for the preparation of N-aryl-β-
sultams (23-94% cyclisation step yield) to overcome problems concerning the method 
involving ethenesulfonates.58,67  
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Scheme 2.9 Synthetic pathway to β-sultam ring from β-hydroxysulfonamide mesylates. 
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2.1.2.2 γ- and δ-Sultams 
 
The preparation of γ- and δ-sultams is mainly achieved by similar approaches to those 
described for β-sultams, i.e. N-S bond formation and N-C bond formation (Scheme 2.10), 
although processes involving a C-C bond formation are also known (Scheme 2.11). 
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Scheme 2.10 Main strategic routes for the preparation of the γ- and δ-sultam rings.  
 
 
By N-S ring closure. A good general route to a wide variety of γ- and δ-sultams (2.27 and 
2.28, Scheme 2.10) is provided by the cyclisation of the corresponding hydrochlorides 2.29 
and 2.30.  
The unsubstituted δ-sultam (2.28, R = H) was obtained from both sulfonyl chloride (2.30, 
R = H, X = Cl) and bromide (2.30, R = H, X = Br) which were respectively prepared by 
chlorination and bromination of 2.32 (R = H).81,82  
When applied to N-substituted sultams, this approach requires the synthesis of the 
appropriate aminoalkanesulfonic acid 2.33/2.34 from the reaction of a primary amine with a 
sultone 2.35/2.3683-85  or with a haloalkanesulfonic acid 2.37/2.38.83  The latter can be 
prepared by reaction of a sultone 2.35/2.36 with a potassium halide.85,86  Chlorination of 
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2.33/2.34 is achieved in the presence of phosphorus pentachloride, phosphorus oxychloride, a 
mixture of both, or phosphorus trichloride.81,83,85,87  
 
By N-C ring closure. This synthetic approach involves the cyclisation of the 
sulfonamides 2.39/2.40 (Scheme 2.10) in the presence of a base. These intermediates are 
usually prepared by reaction of amines with chloroalkanesulfonyl chlorides 2.41/2.42.60,83-
85,87-89  
 
By C-C ring closure. Preparation of the γ- and δ-sultam rings by C-C bond formation is 
illustrated with the synthesis of the unsubstituted δ-sultam 2.28a (Scheme 2.11). The method 
employs N-(haloalkyl)alkanesulfonamides such as 2.43, which result from the reaction of an 
alkanesulfonyl halide 2.44 with an haloalkylamine hydrochloride 2.45. 88,90  Due to the acidity 
of the α-hydrogens in 2.43, cyclisation proceeds in the presence of a strong base, i.e. LDA or 
n-BuLi. 
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Scheme 2.11 Synthesis of δ-sultam by C-C ring closure. 
 
 
 
2.1.3 Synthesis of sultams core 
 
The preparation of N-substituted-β-, γ- and δ-sultams can be accomplished by two 
possible modes, one involving the modification at the nitrogen atom prior to cyclisation60,67,84  
and another involving the derivatisation of an unsubstituted sultam. The latter process has 
been used in the synthesis of N-alkyl-, acyl- and phosphoro-sultams.60,84,91,92  Previous in-
house work regarding the preparation of the unsubstituted β-sultam presented difficulties and 
the project was dropped. Thus, the present study focused exclusively on the cyclisation of N-
substituted intermediates. 
2. Dipeptide Vinyl Sultams 
38 
2.1.3.1 β-Sultams 
 
N-Phenyl-β-sultam 
 
Synthesis of N-phenyl-β-sultam 2.5a (Scheme 2.12) was achieved by cyclisation of the 
mesylate 2.8a, as described by Page et al.,67  although with a different route to the 
hydroxysulfonamide intermediate 2.25a. Thus, Page et al. prepared this compound by 
reaction of formaldehyde with a sulfonamide dianion (Scheme 2.9). In the present 
investigation, it was synthesised in comparable yield (39% versus 53%67 ) from 
ethenesulfonamide 2.46a.  
It is known that ethenesulfonamides, as 2.46a, may be provided in substantial yield from 
the reaction of 2-chloroethanesulfonyl chloride 2.20a with arylamines, which is rationalised in 
terms of an elimination-addition mechanism (E1cB) involving a sulfene intermediate 2.47 
(Scheme 2.13).93,94   
Thus, ethenesulfonamide 2.46a was prepared using a modified reported procedure, in 
comparable yield (65% versus 72%93 ). Aniline was not used in excess and the temperature 
was kept at −10 ºC to prevent conjugate addition of the amine to the newly formed double 
bond of the ethenesulfonamide. The hydrochloric acid from the reaction was trapped by TEA. 
The presence of a mono-substituted double bond was confirmed by the NMR signals for three 
olefinic protons (δ = 5.94, dd, J = 0.4 and 9.7 Hz; δ = 6.27, dd, J = 0.4 and 16.5 Hz; δ = 6.54, 
dd, J = 9.7 and 16.5 Hz).  
Synthesis of ethenesulfonamide 2.46a was initially attempted in toluene67  using 2 mol eq 
of aniline and stirring for 24 h at rt. Two products were afforded; firstly, the unusual93  
sulfonamide 2.48 (3% yield, Figure 2.2) and secondly, 2.46a (37% yield). The procedure was 
repeated under reflux (2 h) leading to 2.46a in a similar yield (31%), but no 2.48 could be 
detected. 
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Scheme 2.12 Synthesis of N-phenyl-β-sultam by cyclisation of N-phenyl-2-hydroxyethanesulfonamide 
mesylate. Reagents and conditions: (i) NH2Ph, TEA, DCM, −10 ºC, 20 min; (ii) NaOH (aqueous solution), 
reflux, 3 days; (iii) MeSO2Cl, TEA, dry DCM, 0 ºC, N2, 30 min; (iv) Na2CO3, dry DMSO, 60 ºC, N2, 1 h.  
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Scheme 2.13 Mechanism of the formation of ethenesulfonamides. 
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Figure 2.2 Structure of 2-chloro-N-phenylethanesulfonamide. 
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The next step, i.e. the hydroxylation of ethenesulfonamide 2.46a, was carried out in the 
presence of an aqueous solution of sodium hydroxide to obtain 2.25a as a sodium salt that 
was subsequently neutralized by the addition of conc. hydrochloric acid. The subsequently 
conversion of 2.25a into its mesylate ester 2.8a was initially carried out with 1 mol eq of 
mesyl chloride and 1 mol eq of TEA, in dry DCM.67  Unfortunately, it was impossible to 
reproduce the yield of the literature (21% versus 62%67 ). Employing 1.5 mol eq of both 
mesyl chloride and TEA improved the outcome of the reaction from 21 to 46%. Purification 
of 2.8a by trituration from ether was previously described.67  In the present work, better 
results were found by washing crude product with cold chloroform. 
Finally, cyclisation was achieved as described, although in a poor yield (9% versus 
42%58,67 ). As expected,58  the 1H NMR spectrum of the reaction medium showed the presence 
of two compounds (Scheme 2.14); (i) the major product N-phenyl-β-sultam 2.5a, which was 
purified by crystallization from a mixture of EtOH/water69  and (ii) the elimination product 
2.46a, which was not isolated.  
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Scheme 2.14 Reaction products from N-phenyl-2-hydroxyethanesulfonamide mesylate. 
 
 
To overcome the low yield obtained for N-phenyl-β-sultam 2.5a, two further synthetic 
routes were attempted: (i) C-C bond formation by cyclisation of compounds 2.49 (Scheme 
2.15) and (ii) N-S bond formation by cyclisation of hydrochloride 2.6b (Scheme 2.16). 
To the best of author’s knowledge, β-sultams have never been achieved by C-C ring 
closure. This approach was exploited by two possible routes, one involving intermediate 
2.49a and another involving mesylate 2.49b. In both modes, cyclisation was expected to 
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occur in the presence of a deprotonating agent, i.e. LDA or n-BuLi, due to the attack of the α-
methanesulfonamide anion to the carbon bearing the leaving group, i.e. chloro or mesylate 
group. 
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Scheme 2.15 Attempted synthesis of N-phenyl-β-sultam by cyclisation of N,N-disubstituted-
methanesulfonamides. Key intermediates are highlighted by a blue box. Reagents and conditions: (i) NH2Ph, 
toluene, reflux, 2 h; (ii) paraformaldehyde, chlorotrimethylsilane, DCM, reflux, 21 h.  
 
 
 
Preparation of the intermediate 2.49a required the initial synthesis of sulfonamide 2.50, 
which was then reacted in the presence of paraformaldehyde and chlorotrimethylsilane.95  The 
reaction was monitored by 1H NMR spectroscopy until the signal integral ratio CH2Cl : CH3S 
: Ph became 2:3:5. The reported reaction time is 24 h (94% yield).95  In the present study, the 
reaction did not proceed further between 5 h (81% yield) and 21 h (86% yield). Attempts to 
carry out the cyclisation of 2.49a into the N-phenyl-β-sultam 2.5a failed (Table 2.1). 
The route to mesylate 2.49b also started from sulfonamide 2.50, which was treated with 
an aqueous formaldehyde solution 37% (5.6 mol eq) and potassium carbonate (1.0 mol eq) in 
THF,96  in order to obtain the N-hydroxymethylsulfonamide 2.51. However, after refluxing for 
6 h and stirring for 3 days at rt, only starting material was recovered. This is a rather similar 
result from that observed in the synthesis of the carbonyl analogues, acyclic tertiary N-
hydroxymethylamides, which are hardly prepared from the corresponding amides.95  
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Table 2.1 Conditions for the synthesis of N-phenyl-β-sultam from 2.49a. 
 
Base/mol eq Solvent/Temperature/Reaction time TLC 1H NMR 
n-BuLi /1.2 dry THF/−78 ºC/N2/20 min complex mixture  
n-Buli/2.6 dry THF/−78 ºC/N2/30 min complex mixture  
LDA/2.6 dry THF/−78 ºC/N2/30 min complex mixture  
NaH/2.0 (a) dry THF /0 ºC/N2, (b) rt/N2/3 h, (c) reflux/4 h, (d) 
rt/2 days 
 starting material 2.49a 
 
 
 
The second mentioned approach to N-phenyl-β-sultam 2.5a (Scheme 2.16), began with 
the attempt to prepare derivative 2.15a from two possible starting materials, sodium 2-
chloroethanesulfonate 2.17a and N-phenyl-2-aminoethanol 2.18a. 
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Scheme 2.16 Attempted synthesis of N-phenyl-β-sultam by cyclisation of 2-(phenylamino)ethanesulfonyl 
chloride hydrochloride. The key intermediate is highlighted by a blue box. 
 
 
The preparation of 2.15a from 2.17a has been previously investigated.74  Based on the 
reported procedure, 2.17a and aniline (4.0 mol eq) were heated at 165 ºC for 8 h, under 
agitation, during which time the mixture turned brown. Upon work-up, this afforded a brown 
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solid. 1H NMR (60 MHz, D2O/d6-DMSO) spectrum showed no signals related to 2.15a or 
another identifiable structure. 
This procedure used aniline in a small volume, and thus to improve the contact between 
the starting materials another experiment was performed, in which 2.17a was suspended in 
toluene. This solvent was chosen due to the employment of aromatic solvents in the 
preparation of 4-aminobutanesulfonic acids (2.34, Scheme 2.10).83  The reaction mixture was 
refluxed for 24 h, after which a precipitate still remained; work-up afforded a solid that gave a 
complex spectrum lacking any signals for 2.15a. 
 
Alternatively, preparation of 2.15a was tried from 2.18a. This approach involved the 
initial attempt to prepare intermediate 2.22d, as reported for 2-chloroethylamine (2.22a, 
Scheme 2.4).75  Thus, thionyl chloride (9.7 mmol) was added dropwise to a solution of 2.18a 
(7.3 mmol) in DCM (5 mL). On mixing the reactants, the medium turned from yellow to 
brown with evolution of hydrogen chloride. TLC (EtOAc) indicated the formation of a new 
compound with a higher Rf value and that no 2.18a remained. The solvent was evaporated to 
give a brown solid, whose complex 1H NMR (300 MHz, CDCl3) spectrum was inconsistent 
with the desired product and could not be assigned to another structure. 
Previous studies were also unsuccessful in this approach.74  Although no details of the 
reaction were given, the result was ascribed to the complete polymerisation of 2.22d through 
the attack of the nitrogen nucleophile to the carbon bearing the chloro leaving group. On the 
other hand, it was found that the chlorination of ethanolamine is better achieved starting from 
the hydrochloride than from the free base, which was related to the formation of thionylamine 
in the latter case.75  Thus, it may be that prior neutralization of 2.18a with conc. hydrochloric 
acid could lead to a different result, but due to time limitations, no further attempts were 
made. 
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N-Benzyl-β-sultam 
 
Initially, preparation of N-benzyl-β-sultam 2.5b (Scheme 2.17) involved the attempted 
cyclisation of the mesylate 2.8b, but the process failed. Usually, this method leads to the 
formation of the ethenesulfonamides 2.46 as by-products, in minor amounts.58  However, 
when applied to mesylate 2.8b, it afforded the ethenesulfonamide 2.46b as the only product 
(24% yield). Other experimental attempts involving variation of the base, solvent and 
temperature, remained unsuccessful (Table 2.2). 
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Scheme 2.17 Attempted synthesis of N-benzyl-β-sultam. Key intermediates are highlighted by a blue box. 
Reagents and conditions: (i) NH2Bz, 100 ºC, 2 h; (ii) KF, dioxane/water, rt, 2 h. 
 
Table 2.2 Conditions for the cyclisation of N-benzyl-2-hydroxyethanesulfonamide mesylate into N-benzyl-
β-sultam. 
 
Base Solvent/Temperature/Reaction time 1H NMR 
Na2CO3 (1 mol eq) 
dry DMSO/60 ºC/N2/30 min 
dry THF/reflux/2 h 
2.46b 
2.8b 
Na2CO3 (3 mol eq) 
dry DMSO/60 ºC/N2/1 h 
dry THF/reflux/10 h 
2.46b 
2.8b 
TEA (1 mol eq) 
dry DMSO/60 ºC/N2/30 min 
dry THF/reflux/45 min 
2.46b 
2.8b 
TEA (3 mol eq) dry THF/reflux/22 h complex mixture 
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Two further synthetic routes were attempted (Scheme 2.17), one involving hydrochloride 
2.6c and another involving ethenesulfonyl fluoride 2.23a. 
The route involving 2.6c began with the attempted preparation of 2.15b. This compound 
has been previously prepared from isopropyl ethenesulfonate 2.16a, which is usually achieved 
by adding dry isopropanol to sulfonyl chloride 2.20a, in the presence of pyridine.65,67  
Following the described procedure for 2.16a, a yellow liquid was afforded that upon 
attempted purification by distillation, under reduced pressure (39 mmHg), turned the mixture 
dark brown and led to no distilled products. Decomposition of 2.16a by distillation at 
pressures greater than 5 mmHg has been previously observed.73  
Thereafter, 2.15b was achieved from 2.17a by following a similar procedure to the one 
described for its phenyl analogue 2.15a. However, attempted conversion of 2.15b into 2.6c by 
refluxing it with phosphorus oxychloride (18 eq) until complete dissolution (ca. 15 min) 
failed; both 1H NMR (300 MHz, CDCl3) and ESI-MS analyses of the product after work-up 
were inconsistent with 2.6c and could not be assigned to another structure. 
 
The route involving ethenesulfonyl fluoride 2.23a, began with the synthesis of 2.20b,79  
the identity of which was confirmed by the comparison of its boiling point and spectroscopic 
data with those in the literature.58,79  Although 1H and 13C NMR spectra of 2.20b are known, 
the compound is basically characterised by its boiling point, mass or elemental analysis, and 
by its IR spectrum.58,79  The latter showed an increase in the frequencies of sulfonyl stretching 
vibrations in comparison with the IR spectrum of its precursor 2.20a. 
The next step, i.e., preparation of 2.23a, was attempted by treating 2.20b with TEA or 
magnesium oxide.58,79  Both methods afforded yellow oils that gave NMR spectra (60 MHz, 
CDCl3) inconsistent with the desired product and impossible to assign. 
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2.1.3.2 γ-Sultams 
 
The synthesis of N-phenyl- and N-benzyl-γ-sultams 2.27a,b (Scheme 2.18) was 
accomplished by cyclisation of the corresponding sulfonamides 2.39a,b in the presence of a 
base.  
 
Cl SO2Cl N
SO2
R
Cl SO2NHR
(i)
2.41a 2.27a R = Ph, 49% (2 steps)
2.27b R = Bz, 79% (2 steps)
(ii)
2.39a R = Ph
2.39b R = Bz  
 
Scheme 2.18 Synthesis of N-phenyl- and N-benzyl-γ-sultams. Reagents and conditions: (i) NH2Ph, TEA, 
DCM, reflux, 1 h or NH2Bz, DCM, −10 ºC, 1 h; (ii) NaOH, TEA, MeOH, reflux. 
 
The literature reports the preparation of N-benzyl-γ-sultam 2.27b by C-C bond formation 
through n-BuLi mediated cyclisation of the mesylate 2.49c (Figure 2.3) but, to the best of 
author’s knowledge, this sultam has not been formed from the sulfonamide 2.39b, which was 
obtained from the reaction of benzylamine with sulfonyl chloride 2.41a. To prevent the 
formation of 2.52a (Figure 2.4), reaction was carried out at −10 ºC and benzylamine was 
employed in a 2:1 molar ratio to sulfonyl chloride 2.41a.85  The second equivalent of amine 
was used to trap hydrochloric acid from the reaction.  
After the cyclisation step,85  purification of N-benzyl-γ-sultam 2.27b from the remaining 
TEA and sulfonamide 2.39b, was achieved by washing the crude product with hydrochloric 
acid 5% (w/v) and 2M-sodium hydroxide. 
 
 
Me
MsO
N
S
OO
Bz
2.49c  
 
Figure 2.3 N-(2-Methanesulfonyloxyethyl)-N-benzylmethanesulfonamide mesylate 2.49c. Its cyclisation to 
N-benzyl-γ-sultam was reported in 74% yield.97  
2. Dipeptide Vinyl Sultams 
47 
 
RHN SO2NHR
2.52a R = Bz
2.52b R = Ph  
 
Figure 2.4 N-Benzyl-3-(benzylamino)propane-1-sulfonamide (2.52a) and N-phenyl-3-
(phenylamino)propane-1-sulfonamide (2.52b). 
 
 
The synthesis of N-phenyl-γ-sultam 2.27a was reported by two possible routes, one 
involving the cyclisation of sulfonyl chloride 2.29a85  (Figure 2.5) and another via the 
formation of sulfonamide 2.39a.83,84  As already mentioned, the present investigation followed 
this latter route (Scheme 2.18). Thus, N-phenyl-γ-sultam was achieved as described for the N-
benzyl analogue, except that after several unsuccessful attempts the preparation of the 
sulfonamide 2.39a required reflux conditions (Table 2.3). Even so, no formation of 2.52b 
(Figure 2.4) could be detected, which probably reflects the poor nucleophilicity of aniline. 
 
 
PhH2N SO2Cl
2.29a
+
 
 
Figure 2.5 Structure of 3-(phenylamino)propanesulfonyl chloride 2.29a. 
 
 
 
Table 2.3 Conditions for the synthesis of 3-chloro-N-phenylpropane-1-sulfonamide 2.39a from 2.41a. 
 
Basea/1 mol eq Solvent/Temperature/Reaction timeb TLC 1H NMR 
NH2Ph DCM/−10 ºC/1 h starting material  
TEA DCM/−10 ºC/8 h new compound impure 2.39a (40% crude yield) 
2.39a (2% yield after chromatography) 
TMPc DCM/−10 ºC/9 h new compound impure 2.39a (55% crude yield) 
a These bases were employed to trap hydrochloric acid from the reaction. In all cases, aniline (1 mol eq) was used to react with 3-chloropropanesulfonyl 
chloride 2.41a. b Work-up: reaction medium was washed with hydrochloric acid 5% (w/v) and saturated sodium chloride solution, dried with anhydrous 
magnesium sulfate and evaporated. c 2,2,6,6-Tetramethylpiperidine. 
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2.1.3.3 δ-Sultams 
 
Previous investigations have prepared N-phenyl- and N-benzyl-δ-sultams 2.28b,c 
according two approaches: (i) N-S bond formation by cyclisation of hydrochlorides 
2.30a,b83,90  (Scheme 2.19) and (ii) N-C bond formation by cyclisation of sulfonamides such 
as 2.40a (Scheme 2.20).83,89  The present work exploited both routes, starting from sultone 
2.36.  
In the first approach (Scheme 2.19), the sultone 2.36 was reacted with the appropriate 
amine to afford the sulfonic acids 2.34a,b. This step followed the procedure reported for 
aniline, under solventless conditions.98  The medium solidified as the reaction proceeds and, at 
the end, it gives a glassy solid. 
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Scheme 2.19 Synthesis of N-phenyl- and N-benzyl-δ-sultams by cyclisation of the corresponding 1-
chlorosulfonyl-4-aminobutane hydrochlorides. Reagents and conditions: (i) NH2Ph, 100 ºC; (ii) POCl3, reflux, 
90 min; (iii) Na2CO3, EtOAc, rt. 
 
 
Concerning the following step, previous investigations chlorinated 2.34a with phosphorus 
trichloride,83  whereas chlorination of 2.34b was achieved with phosphorus oxychloride.90  In 
the present study, phosphorus oxychloride was preferred, only because it was available. The 
process was carried out using the procedure reported for the 2-o-toluidine analogue,83  that 
uses phosphorus oxychloride as solvent. TLC and 1H NMR analyses were ineffective in 
monitoring the reaction, thus it was kept during the time reported (90 min),83  and then the 
excess phosphorus oxychloride was evaporated to afford hydrochlorides 2.30a,b.  
This latter type of intermediates is, according to the literature,83  converted into δ-sultams 
by treatment with cold water, followed or not by the addition of a sodium hydroxide solution 
to render the medium alkaline. Under these conditions, sultams separate in a crystalline 
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form.83  However, in the present work, mixing the crude compound 2.30a with a 2M-sodium 
hydroxide solution did not afford the desired sultam, even after several days at 4 ºC. Thus, 
cyclisation was attempted by following the procedure used for γ-sultams (Section 2.1.3.2), i.e. 
by refluxing a 1:1:1 molar mixture of sodium hydroxide : TEA : 2.30a in MeOH, but the 
process failed. TLC analysis (ethyl ether) of the reaction mixture showed the disappearance of 
the starting material, but no product could be detected. In addition, 1H NMR spectrum (300 
MHz, CDCl3) was inconsistent with both N-phenyl-δ-sultam 2.28b and starting material 2.30a 
structures. Finally, δ-sultams were achieved by employing the conditions commonly used in 
the cyclisation of 1-chlorosulfonyl-2-aminoethane hydrochlorides 2.6 to β-sultams, i.e. by 
stirring the appropriate hydrochloride with sodium carbonate in EtOAc.67  
The main difficulties arising from this first route to δ-sultams were in purifying the 
intermediates and in monitoring the reaction progress. Thus, attempted crystallization of 
sulfonic acid 2.34a from a mixture of EtOH/water98  was unsuccessful. 1H NMR spectra (60 
MHz, d6-DMSO) of this compound and of its chloro derivative 2.30a appeared as mixtures 
and the mass analyses were inconsistent with the required structures.  
Overall, the process is mainly controlled by the solidification of the contents, in the first 
step (solventless conditions), and by the dissolution of the resultant material in phosphorus 
oxychloride, which occurs in the second step.  
It is noteworthy that in the literature,83,90  this route usually proceeds from the sultone 2.36 
into the δ-sultam without isolation of the intermediates. 
 
The second mentioned approach, i.e. cyclisation of 4-halobutanesulfonamides, was 
employed in an alternative preparation of N-benzyl-δ-sultam 2.28c (Scheme 2.20).  
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Scheme 2.20 Synthesis of the N-benzyl-δ-sultam by cyclisation of the 4-bromo-N-
benzylbutanesulfonamide. Reagents and conditions: (i) KBr, MeOH, reflux, 48 h; (ii) PCl5; (iii) NH2Bz, DCM, 
−10 ºC, 1 h; (iv) NaOH, TEA, MeOH, reflux. 
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The first step consisted in the preparation of sulfonate 2.38a from the known reaction of 
sultone 2.36 with potassium bromide.98  TLC analysis (DCM, iodine chamber) indicated that 
production of a more polar compound had occurred and that no sultone 2.36 remained, but the 
1H NMR (300 MHz, d6-DMSO) spectrum was inconclusive and the mass spectrum was 
inconsistent with the desired structure. On the other hand, IR analysis supported the formation 
of 2.38a, through the exhibition of characteristic sulphur-oxygen stretching vibrations for 
sulfonate salts (1351, 1198, 1172, 1058 cm−1). Based on this observation, the product was 
allowed to proceed into the chlorination step, which was carried out using phosphorus 
pentachloride at rt, as described for the chlorination of the analogous 3-bromopropane-1-
sulfonate.85   
The formation of sulfonyl chloride 2.42a was suggested: (i) by TLC analysis (DCM, 
iodine chamber), which revealed the formation of a compound with a higher Rf value, (ii) by 
the exhibition in the IR spectrum of sulfonyl stretching vibrations (1380, 1170 cm−1) at higher 
frequencies than those of the precursor 2.38a and (iii) by three multiplets in the 1H NMR 
spectrum (60 MHz, CDCl3). Although this latter also revealed the presence of impurities, 
2.42a was immediately used in the preparation of the sulfonamide 2.40a, which was 
subsequently cyclised.  
The 1H NMR spectrum of the final product was consisted with the structure of N-benzyl-
δ-sultam 2.28c but also revealed the presence of impurities. This route led to a lower yield 
(18%, crude yield, 4 steps) than the mentioned cyclisation of hydrochlorides 2.30a,b (Scheme 
2.19). Thus, no purification was performed and this route was no further exploited. 
 
 
 
2.1.4 Synthesis of dipeptide vinyl sultams 
 
2.1.4.1 Aminoacid and dipeptidyl aldehydes 
 
N-Boc-S-Phenylalaninal. The preparation of N-Boc-S-phenylalaninal 2.53 consisted in 
the reduction by lithium aluminium hydride of the corresponding hydroxamate 2.54 derived 
from N-Boc-S-phenylalanine 2.55 (Scheme 2.21).99  
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Scheme 2.21 Synthesis of N-Boc-S-phenylalaninal from N-Boc-S-phenylalanine via hydroxamate. Reagents 
and conditions: (i) (1) isobutyl chloroformate, TEA, DCM, −10 ºC, 30 min, (2) O, N-dimethylhydroxylamine 
hydrochloride, rt, overnight; (ii) (1) LiAlH4, dry THF, 0 ºC, 30 min, (2) KHSO4 (aqueous solution), 83% yield. 
Hydrogen bonds are in grey. 
 
 
The main difficulty arising from the synthesis of aldehydes is in the further reduction of 
these products to alcohols. The method mentioned above allows the reaction to be stopped at 
the aldehyde state due to intramolecular complexation of lithium salts 2.56, which provide the 
aldehydes by hydrolysis.99  The method also affords crude aldehydes in high yield (86-96%) 
and sufficiently pure to avoid further purification, e.g. silica gel chromatography, which may 
lead to racemisation.99  
The synthesis of hydroxamate 2.54 was initially performed with BOP99  and TBTU as 
coupling reagents, but isobutyl chloroformate33  became a suitable alternative due to its 
availability and lower price. DCC was also employed following the BOP procedure (reaction 
time: 5 to 15 h), but TLC analysis (n-hexane/EtOAc 1:1) revealed several products. 
Nevertheless, the formation of 2.54 was supported by the 1H NMR spectrum (60 MHz, 
CDCl3) through the observation of two singlets at δ 3.17 and δ 3.67, consistent with the 
methyl groups of the hydroxamate function.  
Subsequent conversion of 2.54 to aldehyde 2.53 proceeded according to Fehrentz et al., in 
comparable yield (83% versus 86%99 ). 
Previous investigations also achieved 2.53 from N-Boc-S-phenylalanine methyl ester 
using DIBAL as reducing agent.29  In the present work, this route was also exploited through 
the N-Boc protection100  of ethyl ester 2.57 (Scheme 2.22) and its subsequent reduction with 
DIBAL (3.3 mol eq). Instead of the aldehyde, the process afforded the alcohol 2.58. Then, the 
reaction was carried out under the same conditions, but varying DIBAL equivalents. When 1 
mol eq was used, a mixture of the N-protected ester 2.59 and a trace amount of aldehyde 2.53 
was observed, whereas 2 mol eq yielded a mixture of alcohol 2.58, aldehyde 2.53 and ester 
2.59. 
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Scheme 2.22 Attempted synthesis of N-Boc-S-phenylalaninal from N-Boc-S-phenylalanine ethyl ester. 
Reagents and conditions: (i) Boc anhydride, TEA, THF, 0 ºC to rt, 2.5 h; (ii) (1) DIBAL, dry THF, −78 ºC, N2, 1 
h, (2) MeOH, potassium sodium (+) tartrate (aqueous solution), rt, 1.5 h. 
 
 
Dipeptidyl aldehydes. Reported investigations achieved the preparation of dipeptidyl 
aldehydes by the strategy described for N-Boc-S-phenylalaninal 2.53.33  In the present study, 
the synthesis of aldehydes 2.60a,b was also tried, although with a different route to the 
hydroxamate intermediates 2.61 (Scheme 2.23). Thus, in the literature33  the dipeptidyl 
hydroxamates were prepared by coupling an α-amino hydroxamate with N-protected amino 
acids, whereas in the syntheses of 2.61 the hydroxamate function was introduced after the 
dipeptide formation. 
The process began with the preparation of dipeptidyl esters 2.62 which were hydrolized to 
the corresponding acids 2.63.101  These latter compounds were converted into hydroxamates 
2.61, which were tentatively reducted to aldehydes 2.60. After 2.5 h, the reaction involving 
hydroxamate 2.61a was quenched to afford a 2:1 mixture of aldehyde 2.60a and starting 
material 2.61a (showed by the signal integral ratio in the 1H NMR spectrum). For 
hydroxamate 2.61b, a 30 min reaction yielded a 1:1 mixture of 2.60b and 2.61b (showed by 
the signal integral ratio in the 1H NMR spectrum). Nevertheless, crude aldehyde 2.60b was 
employed in a Horner-Wadsworth-Emmons reaction described in Section 2.1.4.4. 
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Scheme 2.23 Synthesis of dipeptidyl aldehydes. Reagents and conditions: (i) 1M-NaOH, THF, reflux, 25 min; 
(ii) (1) TBTU, TEA, DCM, rt, 30 min, (2) O, N-dimethylhydroxylamine hydrochloride, TEA, rt, 13 h; (iii) (1) 
LiAlH4, dry THF, 0 ºC, 30 min; (2) KHSO4 (aqueous solution). 
 
 
2.1.4.2 Aldol-type reaction of sultam carbanions 
 
The aldol-like reaction involved a direct coupling between N-Boc-S-phenylalaninal 2.53 
and the anion of N-phenyl-γ-sultam 2.27a (Scheme 2.24). The reactants were employed at the 
same molar ratio of Horner-Wadsworth-Emmons reaction and the process followed the same 
procedure. The medium was fractionated by column chromatography on silica gel (n-
hexane/EtOAc 1:1), affording aromatic impurities and the starting sultam (64% recovered), 
instead of the desired hydroxylated product 2.64. This route was no further investigated. 
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Scheme 2.24 Synthesis of E- and Z-vinyl sultams via an aldol-like reaction. Reagents and conditions: (i) n-
BuLi, dry THF, N-Boc-S-phenylalaninal 2.53, −78 ºC to rt, N2, 1 h. 
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2.1.4.3 Sultam phosphonates 
 
The first approach to sultam phosphonates 2.65 and 2.66 (Scheme 2.25) consisted in the 
preparation of 2.66a from sultam 2.28b, in a two step reaction: (i) formation of 2.28b anion 
by deprotonation with n-BuLi, and (ii) reaction of this anion with diethyl chlorophosphate. 
The reaction was performed under method A conditions38,64  (Table 2.4), employing 1 mol eq 
of diethyl chlorophosphate, 2 mol eq of n-BuLi and 2 mol eq of 2.28b. These two latter 
reactants must be used in excess because the α-hydrogen of sultam phosphonates is more 
acidic than those of sultams. Thus, the sultam anion deprotonates the newly formed sultam 
phosphonate, regenerating the sultam which is the first compound to be eluted from the 
column during the chromatographic purification process. 
When method A conditions were applied to the other sultams it furnished either 
decomposition or poor yields. For these reasons, conditions B and C were investigated. In 
general, LDA at −78 ºC afforded higher yields of the sultam phosphonates than n-BuLi either 
at −78 ºC or rt. 
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Scheme 2.25 Synthesis of E- and Z-vinyl sultams through Horner-Wadsworth-Emmons chemistry. 
Reagents and conditions: (i) (1) LDA, dry THF, −78 ºC, N2, 10 min, (2) (EtO)2POCl, −78 ºC, N2, 1 h; (ii) n-
BuLi, dry THF, N-Boc-S-phenylalaninal 2.53, −78 ºC to rt, N2, 20 min. 
 
 
Table 2.4 Conditions for the synthesis of sultam phosphonates. 
 
Yield (%) Phosphonate 
Method A Method B Method C 
2.65a 27 56   65 
2.65b 0  43 
2.66a 48  45 
2.66b 15  34 
Method A: n-BuLi, dry THF, rt, N2; Method B: n-BuLi, dry THF, −78 ºC, N2; Method C: LDA, dry THF, −78 ºC, N2. 
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NMR spectral characterisation. NMR signal assignments for sultam phosphonates were 
effected using DEPT and 2D NMR techniques (1H-1H COSY and HMQC). Table 2.5 lists the 
data for 2.65a as a typical example. The main features in the spectra are (i) the complexity of 
the 1H NMR signals comparatively to the ones showed by the sultam precursors, and (ii) the 
splitting of the carbon signals due to the 13C-31P couplings. 
Sultam phosphonates were isolated as a mixture of the two possible enantiomers because 
the molecules have an asymmetrical carbon atom (shown by an asterisk in Figure 2.6). Due to 
the existence of a stereocentre, the two protons of each methylene group are diastereotopic to 
one another. Thus, each gives separate 1H NMR signals except in cases when the resonance 
frequencies are accidentally the same. Another consequence of the sultam phosphonates 
chirality is that pentavalent phosphorus atom became a prochiral centre. Therefore, the 
methylene and methyl groups from each ethyl component are non-equivalent giving an ABX3 
spin system.102  This situation cannot be easily deduced from the complex proton signals, but 
it is rather clear in the 13C NMR spectrum, which exhibited two separate signals for 
methylene groups 1 and 1’ whereas the similar resonances of methyl groups 2 and 2’ led to an 
obscure signal classified as a multiplet. The 13C NMR spectrum also showed the characteristic 
doublet splittings with JCP of 143.6, 4.8 and 9.0 Hz (average values), consistent with 1J, 2J and 
3J couplings of the 31P and 13C nucleus.103  
 
 
 
Table 2.5 NMR data of 2.65a [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) 
CH2N 3.82 ma 45.8 d (10.1) 
CHCH2 2.70-2.83 m 21.9 d (3.0) 
CH 3.80 ma 55.9 d (149.9) 
[OCH2]a 4.28 mb 63.7 d (6.0) 
[OCH2]b 4.34 mb 64.4 d (6.0) 
[CH3]a 1.37−1.40 mc 16.4−16.5 md 
[CH3]b 1.37−1.40 mc 16.4−16.5 md 
Ph 7.16-7.20 m (1H) 125.2 
 7.26-7.29 m (2H) 120.5 
 7.34-7.38 m (2H) 129.4 
  137.3 
a Overlapped signals. δ Values from HMQC spectrum; b Overlapped signals. δ Values from HMQC spectrum; c Overlapped signals; d Overlapped signals. 
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Figure 2.6 Diastereotopic groups and stereocentre in sultam phosphonates. 
 
 
 
 
2.1.4.4 Horner-Wadsworth-Emmons reaction 
 
To the best of author’s knowledge, this thesis presents the first application of the Horner-
Wadsworth-Emmons reaction to sultams. This method has been widely applied to the 
synthesis of vinyl sulfones and their analogues. In such cases, it is performed using sodium 
hydride,31,34,104  n-BuLi,33  or more rarely, sodium methoxide.39  Although no details of the 
reaction were given, it was reported that sodium hydride improved the reaction outcome over 
n-BuLi.34  
Thus, sodium hydride was used as deprotonating agent in the attempted Horner-
Wadsworth-Emmons reaction of phosphonate 2.65a and N-Boc-S-phenylalaninal 2.53, 
following a procedure described for α,β-unsaturated sulfonate and carboxyl derivatives.29  
The process afforded three products, whose 1H NMR spectra were consistent with: (i) a 
mixture of vinyl sultam 2.67a and aldehyde 2.53, (ii) vinyl sultam 2.67b and (iii) the 
regenerated N-phenyl-γ-sultam 2.27a. 
Then, adopting a procedure with n-BuLi38  provided E- and Z-vinyl sultams 2.67-2.70 
(Scheme 2.25 and Table 2.6) with a short reaction time (after 20 min, sultam phosphonates 
were completely transformed). The E/Z ratio is consistent with the general observation that 
phosphonates with alkyl groups give mostly the thermodynamically more stable E-
olefins.39,105  
 
2’ 1’
12
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Table 2.6 Yields and ratio of E/Z isomers. 
 
Phosphonate Product E/Z Yield (%) E/Z ratio 
2.65a 2.67a E   60 79:21 
 2.67b Z 16  
2.65b 2.68a E 58 67:33 
 2.68b Z 29  
2.66a 2.69a E 65 90:10 
 2.69b Z 7  
2.66b 2.70a E 54 86:14 
 2.70b Z 9  
 
 
Despite being recognised that the strongly basic conditions of the Horner-Wadsworth-
Emmons reaction might lead to the aldehyde’s racemisation,29  optical rotations of the 
resultant E/Z vinyl sulfones are rarely given. When this property is reported, it refers almost 
always to the coupled processed products, i.e. dipeptide vinyl sulfones and their analogues. 
Nevertheless, in the pioneering work of Hanzlik et al.,29  it was stressed the substantial optical 
activity of the obtained Horner-Wadsworth-Emmons reaction products. No attempt was made 
to determine the enantiomeric purity of those compounds, because it was considered that there 
was no reason to expect substantial racemisation. Similarly, the vinyl sultams herein 
described showed a significant optical activity (Table 2.7). 
 
 
Table 2.7 Optical rotations, [ ]21Dα , of E/Z isomers. 
 
Compound E/Z Optical rotation c 
2.67a E   +29 0.14 
2.67b Z +57 0.93 
2.68a E +31 0.10 
2.69a E +13 0.13 
2.70a E +24 0.13 
 
 
 
Condensation of sultam phosphonates with peptidyl aldehydes. Another approach to 
dipeptide vinyl sultams involved the Horner-Wadsworth-Emmons reaction between sultam 
phosphonate 2.66a and crude aldehyde 2.60b (Scheme 2.26). After chromatography, the 1H 
NMR spectrum of the reaction product showed a mixture of two olefinic compounds, which 
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cannot be separated. Mass spectra measurements supported the existence of the expected 
structure 2.71 through the observation of the ions at m/z 608 (MNH4+) and 613 (MNa+) (rel. 
int. 52 and 100, respectively). 
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Scheme 2.26 Attempted synthesis of dipeptide vinyl sultams from dipeptidyl aldehydes. Reagents and 
conditions: 2.66a, n-BuLi, dry THF, −78 ºC to rt, N2, 20 min. 
 
 
NMR spectral characterisation. Stereochemistry of vinyl sultams came from the 
examination of the chemical shifts of vinyl and methine protons (Table 2.8). This process was 
reported as a reliable criterion for stereochemical assignment of vinyl sulfonates:38  as a result 
of the deshielding effect of the sulfonyl group, the vinyl proton resonance is generally found 
downfield in the E-isomer compared to the Z-isomer, whereas the methine proton signal 
appears upfield. Stereochemistry was further supported by means of NOESY spectrum, on the 
basis of a NOE cross-peak between the vinyl and =CCH2 protons in the Z-isomer 2.70b 
(Figure 2.7). 
 
 
Table 2.8 Chemical shifts δ and coupling constants J [400 MHz (1H), CDCl3] for vinyl and methine protons 
of E/Z isomers. 
 
Compound E/Z δCH= δCHCH2Ph 
2.67a E 6.31 brd (8.8)  4.53 brs 
2.67b Z 6.35 brs 4.91 m 
2.68a E 6.29 brd (9.2) 4.48 m 
2.68b Z 6.26 brs   4.96 m 
2.69a E 6.24 brd (8.8)  4.71 m 
2.69b Z 6.12 brs  5.10 brs 
2.70a E 6.21 d (9.6)  4.68-4.74 m 
2.70b Z 5.98 brs 5.17 brs 
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Figure 2.7 Relevant NOE correlations observed for 2.70b. 
 
 
 
2.1.4.5 Dipeptide vinyl sultams 
 
Deprotection (removal of Boc protecting group) 
 
The N-Boc group of diastereomers 2.67-2.70 was easily cleaved with TFA100,106  to afford 
either free amines 2.72-2.74 or hydrochloride 2.75 (Scheme 2.27), which were further 
processed to provide dipeptide vinyl sultams. 
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Scheme 2.27 Removal of the N-Boc protecting group of E- and Z-vinyl sultams. Reagents and conditions: (i) 
(1) TFA 50% (w/v DCM solution), rt, 20 min, (2) K2CO3 30% (w/v aqueous solution); (ii) 2.67a, TFA 50% (w/v 
DCM solution), rt, 20 min. 
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Coupling with aminoacids and endcapping of the dipeptide moiety 
 
The first attempt to the synthesis of dipeptide vinyl sultam 2.1 (Scheme 2.28) used TBTU 
as coupling reagent (see experimental for 2.54 in Section 5.1.4.5). After the usual work-up 
and fractionation on preparative TLC plates (DCM/EtOAc 1:1 as eluent), the mass spectrum 
of the product (30 mg) was consisted with the structure 2.1 [m/z (rel. int.) 550 (MNH4+) (72)], 
but 1H NMR spectrum (400 MHz, CDCl3) revealed significant impurities.  
TBTU was used in the preparation of hydroxamates along this investigation. Although 
successful, products from regular syntheses occasionally presented the impurity pattern 
mentioned above. For this reason, the synthesis of 2.1 was tried with another coupling 
reagent, the DCC/HOBt method,106  which afforded the desired vinyl sultam, although in a 
poor yield. 
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Scheme 2.28 Synthesis of dipeptide vinyl sultam 2.1. Reagents and conditions: N-Ac-S-phenylalanine, TEA, 
HOBt, DCC, DCM, rt, 3 days. 
 
 
The synthesis of dipeptide vinyl sultams 2.2-2.4 from free amines 2.72-2.74 proceeded 
according two approaches: (i) step-wise introduction of leucinyl and morpholinylcarbonyl 
substituents (Scheme 2.29) and (ii) direct attachement to N-Mu-S-phenylalanine (Scheme 
2.30). 
The strategy in Scheme 2.29 began with the condensation of free amines 2.72-2.74 with 
N-Boc-S-leucine-N-hydroxysuccinimide ester under standard peptide coupling conditions.101  
The resultant dipeptide vinyl sultams 2.76-2.78 were N-Boc deprotected and allowed to react 
with 4-morpholinecarbonyl chloride. Because some intermediates were not achieved in 
sufficient quantity to follow into the next step, the overall process gave four of the possible 
eight dipeptide vinyl sultams. 
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Scheme 2.29 Synthesis of dipeptide vinyl sultams 2.2-2.4. Reagents and conditions: (i) N-Boc-S-leucine-N-
hydroxysuccimide ester, TEA, dry THF, rt, 14-48 h, (ii) (1) TFA 50% (w/v DCM solution), rt, 20 min, (2) 
K2CO3 30% (w/v aqueous solution); (iii) 4-morpholinecarbonyl chloride, TEA, dry THF, rt, 14-16 h. 
 
 
The strategy in Scheme 2.30 required the initial synthesis of N-Mu-S-phenylalanine 2.82 
and its attempted condensation with hydrochloride 2.75, through BOP-mediated coupling99  
(see experimental for 2.54 in Section 5.1.4.5). The usual work-up and fractionation on 
preparative TLC plates (EtOAc as eluent) afforded two products, whose 1H NMR spectra 
(400 MHz, CDCl3) lacked the signals for 2.83 and could not be assigned to another structure. 
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Scheme 2.30 Attempted synthesis of a dipeptide vinyl sultam from N-Mu-S-phenylalanine. Reagents and 
conditions: (1) BOP, TEA, DCM, rt, 5 min, (2) O, N-dimethylhydroxylamine hydrochloride, TEA, rt, 2 h. 
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NMR Spectral characterisation 
 
Due to the peptidyl moiety, dipeptide vinyl sultams contain two stereocentres (shown by 
asterisks in Figure 2.8) and several prochiral carbon atoms. Methylene protons are therefore 
diastereotopic to one another. Because these geminal protons couple with each other and with 
the neighbours, inspection of the 1H NMR spectra frequently revealed dd and ddd signals, 
along with more complex patterns rationalised by diagrams (Figures 2.9 and 2.10 and Tables 
2.9-2.13). Very often, the signals lack some of the theoric lines due to co-incident peaks. In 
such cases, the remaining parameters were deduced by manual calculation. 
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Figure 2.8 Stereocentres in dipeptide sultams. 
 
 
 
The signal at δ 2.98 dddd for compound 2.74a (Figure 2.9) was assigned to one of the 
allylic methylene protons on the basis of the small constant of ca. 1 Hz, consistent with an 
allylic coupling.107  
For leucine derivatives, the isopropyl methyl groups CH(CH3)2 exhibited a doublet for 
each methyl group protons, except when accidental overlap occurred leading to a broad 
douplet or to a not well resolved multiplet. In the 13C NMR spectrum, two separate signals 
were also found for each methyl carbon. These observations are explained by the fact that 
these two methyl groups are attached to a prochiral carbon atom and are therefore 
diastereotopic. 
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Figure 2.9 Observed 1H NMR dddd 
signal and splitting pattern diagram for 
one allylic methylene proton of 
compound 2.74a. 
Constant not shown is 1.2 Hz (allylic 
coupling).  
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Figure 2.10 Observed 1H NMR double triplet signal and 
splitting pattern diagram for the vinylic proton of compound 
2.72b.  
The 2.0 Hz constant corresponds to the allylic coupling. 
J 3 = 9.8 Hz
     2.0 Hz      2.0 Hz
     2.0 Hz     2.0 Hz      2.0 Hz     2.0 Hz
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Table 2.9 NMR data of 2.1 [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) DEPT 1H-1H COSY 
N-Ac-Phe     
CHHPh 2.99 brd (6.8) 38.7 CH2 CHCH2, Ph (7.07-7.32 m) 
CHHPh   CH2 CHCH2, Ph (7.07-7.32 m) 
CHCH2 4.65-4.70 m 54.3 CH NH (N-Ac-Phe), CH2Ph 
NH 6.25 d (8.0)   CHCH2 
CH3 1.94 s 23.3 CH3  
CH3CO  170.0c C  
COCH  170.2c C  
Phe     
CHHPh 2.73-2.82 ma 40.6 CH2 CHCH2, CHHPh 
CHHPh 2.53 dd (8.9; 13.4)   CHCH2, CHHPh 
CHCH2 4.82 ddd (5.6; 8.9; 18.0) 48.0 CH NH (Phe), CH=, CH2Ph 
CH= 6.17 d (10.0) 130.5 CH CHCH2, =CCH2 
NH 6.88 brd (8.0)b   CHCH2 
sultam core     
=C  141.0d C  
=CCHH 2.73-2.82 ma 27.2 CH2 CH=, CH2CH2CH2 
=CCHH 2.56-2.65 m   CH=, CH2CH2CH2 
CH2CHHCH2 1.81 m 26.2 CH2 CH2N, =CCH2, CH2CHHCH2 
CH2CHHCH2 1.34 m   CH2N, =CCH2, CH2CHHCH2 
CH2N 3.63-3.78 m 53.3 CH2 CH2CH2CH2 
aromatic 7.07-7.32 m 127.0 CH CH2Ph (N-Ac-Phe) 
  127.0 CH  
  127.1 CH  
  127.3 CH  
  128.6 CH  
  128.7 CH  
  129.1 CH  
  129.4 CH  
  129.6 CH  
  136.2d C  
  136.4d C  
  140.2d C  
a Overlapped signals; b Not well resolved signal; c δ Values are interchangeable; d δ Values are interchangeable. 
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Table 2.10 NMR data of 2.2 [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) DEPT 1H-1H COSY 
Mu     
CH2O 3.69 m 66.4 CH2 CH2N 
CH2N 3.27-3.39 m 44.0 CH2 CH2O 
CO  157.5 C  
Leu     
CH3 0.90-0.93 ma 22.1 CH3 CH(CH3)2 
CH3 0.90-0.93 ma 23.0 CH3 CH(CH3)2 
CH(CH3)2 1.61 mb 24.8 CH CH(CH3)2 
CH2 1.54 mb 40.8e CH2 CHNH 
CHNH 4.22−4.29 m 52.7 CH NH (Leu), CH2 
NH 4.55 mc   CHNH 
CO  172.7 C  
Phe     
CH2Ph 2.76-3.01 md 40.5e CH2 CHCH2 
CHCH2 4.52 mc 49.6 CH NH (Phe), CH=, CH2Ph 
CH= 6.28 td (2.6; 9.2) 130.1 CH CHCH2, =CCH2 
NH 6.94 d (8.0)   CHCH2 
sultam core     
=C  138.8f C  
=CCHH 2.76-3.01 md 21.8 CH2 CH=, =CCHH 
=CCHH 2.11-2.19 m   CH=, =CCHH 
CH2N 2.76-3.01 md 43.2 CH2  
CHHPh 4.09 d (14.0) 47.9 CH2 Ph (7.17-7.36 m) 
CHHPh 4.14 d (14.0)   Ph (7.17-7.36 m) 
aromatic 7.17-7.36 m 127.0 CH CH2Ph (sultam core) 
  128.1 CH  
  128.6 CH  
  128.7 CH  
  128.7 CH  
  129.6 CH  
  134.9g C  
  136.1f C  
a Overlapped signals; b Overlapped signals, δ values from HMQC spectrum; c Overlapped signals, δ values from 1H-1H COSY spectrum; d Overlapped 
signals; e δ Values are interchangeable; f δ Values are interchangeable; g This carbon was assigned to the aromatic ring of sultam core, on the basis of 
observed HMBC 2JCH coupling between its resonance and the methylene protons NCH2Ph. 
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Table 2.11 NMR data of 2.3 [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) DEPT 1H-1H COSY 
Mu     
CH2O 3.68 m 66.4 CH2 CH2N 
CH2N 3.28-3.41 m 44.0 CH2 CH2O 
CO  157.4 C  
Leu     
CH3 0.90-0.93 ma 22.2 CH3 CH(CH3)2 
CH3 0.90-0.93 ma 23.0 CH3 CH(CH3)2 
CH(CH3)2 1.62 mb 24.8 CH CH(CH3)2 
CH2 1.55 mb 41.3 CH2 CHNH 
CHNH 4.28-4.34 m 52.9 CH NH (Leu), CH2 
NH 4.90 mc   CHNH 
CO  172.8 C  
Phe     
CHHPh 3.02 dd (5.8; 13.4) 40.9 CH2 CHCH2, CHHPh 
CHHPh 2.75 md   CHCH2, CHHPh 
CHCH2 4.92 mc 47.8 CH NH (Phe), CH=, CH2Ph 
CH= 6.26 d (9.6) 130.6 CH CHCH2 
NH 7.07 d (8.0)   CHCH2 
sultam core     
=C  136.3e C  
=CCHH 2.85 md 27.2 CH2 CH2CH2CH2 
=CCHH 2.62 ddd (4.0; 8.0; 14.4)   CH2CH2CH2 
CH2CHHCH2 1.79-1.88 m 26.2 CH2 CH2N, =CCH2, CH2CHHCH2 
CH2CHHCH2 1.43 mb   CH2N, =CCH2, CH2CHHCH2 
CH2N 3.71-3.75 m 53.4 CH2 CH2CH2CH2 
aromatic 7.16-7.34 m 126.9 CH  
  126.9 CH  
  127.2 CH  
  128.7 CH  
  129.1 CH  
  129.5 CH  
  140.5e C  
  141.1f C  
a Overlapped signals; b Overlapped signals, δ values from HMQC spectrum; c Overlapped signals, δ values from 1H-1H COSY spectrum; d Overlapped 
signals, δ values from 1H-1H COSY spectrum; e δ Values are interchangeable; f This carbon was assigned to an aromatic ring on the basis of observed 
HMBC 2JCH coupling with aromatic protons. 
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Table 2.12 NMR data of 2.4a [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) DEPT 1H-1H COSY 
Mu     
CH2O 3.67-3.71 ma 66.4 CH2 CH2N 
CH2N 3.37 mb 44.0 CH2 CH2O 
CO  157.5 C  
Leu     
CH3 0.92-0.94 mc 22.2 CH3 CH(CH3)2 
CH3 0.92-0.94 mc 23.0 CH3 CH(CH3)2 
CH(CH3)2 1.60 md 24.9 CH CH2, CH(CH3)2 
CH2 1.56 md 41.4 CH2 CH(CH3)2 
CHNH 4.31-4.36 m 53.0 CH NH (Leu) 
NH 4.90-4.98 me   CHNH 
CO  172.8 C  
Phe     
CHHPh 3.12 mf 41.0 CH2 CHCH2, CHHPh, Ph (7.21-7.36 m) 
CHHPh 2.75 dd (10.0; 13.2)   CHCH2, CHHPh 
CHCH2 4.90-4.98 me 47.9 CH NH (Phe), CH=, CH2Ph 
CH= 6.24 d (10.0) 131.7 CH CHCH2, =CCH2 
NH 7.16 d (7.6)   CHCH2 
sultam core     
=C  138.9g C  
=CCH2 2.60 m 27.0 CH2 CH=, CH2CH2CH2 
CH2CHHCH2 1.10 m 23.0 CH2 CH2CHHCH2, =CCH2, CH2N 
CH2CHHCH2 1.56 md   CH2CHHCH2, =CCH2, CH2N 
CH HN 3.30 mb 47.4 CH2 CH HN, CH2CH2CH2 
CH HN 3.07 mf   CH HN, CH2CH2CH2 
CHHPh 4.03 d (14.0) 50.2 CH2 CHHPh 
CHHPh 3.67-3.71 ma   CHHPh 
aromatic 7.21-7.36 m 127.0 CH CHHPh 
  127.8 CH  
  128.4 CH  
  128.6 CH  
  128.8 CH  
  129.5 CH  
  136.0h C  
  136.6g C  
a Overlapped signals; b Overlapped signals, δ values from HMQC and 1H-1H COSY spectra; c Overlapped signals; d Overlapped signals, δ values from 
HMQC and 1H-1H COSY spectra; e Overlapped signals; f Overlapped signals, δ values from HMQC and 1H-1H COSY spectra; g δ Values are 
interchangeable; h This carbon was assigned to the aromatic ring of sultam core, on the basis of observed HMBC 2JCH coupling between its resonance and 
the methylene protons NCH2Ph. 
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Table 2.13 NMR data of 2.4b [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) DEPT 1H-1H COSY 
Mu     
CH2O 3.66 m 66.4 CH2 CH2N 
CH2N 3.30 ma 43.9 CH2 CH2O 
CO  157.4 C  
Leu     
CH3 0.87-0.90 mb 22.1 CH3 CH(CH3)2 
CH3 0.87-0.90 mb 23.0 CH3 CH(CH3)2 
CH(CH3)2 1.55 mc 24.8 CH CH(CH3)2, CH2 
CH2 1.43 mc 40.9d CH2 CHNH, CH(CH3)2 
CHNH 4.24-4.29 m 52.6 CH NH (Leu), CH2 
NH 4.87 d (8.0)   CHNH 
CO  172.8 C  
Phe     
CHHPh 3.00 brd (13.4) 41.0d CH2 CHCH2, Ph (7.22-7.43 m) 
CHHPh 3.06 brd (13.4)   CHCH2, Ph (7.22-7.43 m) 
CHCH2 5.46-5.54 m 49.0 CH CH=, CH2Ph, NH (Phe) 
CH= 5.96 d (8.8) 136.1 CH CHCH2, =CCH2 
NH 6.74 d (6.8)   CHCH2 
sultam core     
=C  135.9e C  
=CCH2 2.65-2.79 m 34.8 CH2 CH=, CH2CH2CH2 
CH2CH2CH2 1.75 mc 23.4 CH2 =CCH2, CH2N 
CH2N 3.45 ma 47.5 CH2 CH2CH2CH2 
CHHPh 4.11 d (14.6) 50.4 CH2  
CHHPh 4.18 d (14.6)    
aromatic 7.22-7.34 m 126.8 CH CH2Ph (Phe) 
  127.8 CH  
  128.5 CH  
  128.5 CH  
  128.6 CH  
  129.6 CH  
  136.1e C  
  137.1f C  
a Overlapped signals, δ values from 1H-1H COSY spectrum; b Overlapped signals, c Overlapped signals, δ values from 1H-1H COSY spectrum; d δ Values are 
interchangeable; e δ Values are interchangeable; f This carbon was assigned to the aromatic ring of phenylalanine, on the basis of observed HMBC 2JCH 
coupling between its resonance and the methylene protons CH2Ph (Phe). 
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2.1.5 Synthesis of vinyl sulfonamides 
 
Vinyl sulfonamides 2.84 (Scheme 2.31) were synthesised for comparison studies on 
chemical reactivity. Beyond the N-Ph substituent, the nitrogen atom was attached to a methyl 
group to better mimick the substitution pattern of the sulfonamide function in sultams.  
The process required the initial preparation of sulfonamide 2.85 by a commonly procedure 
involving mesyl chloride and N-methylaniline. Alternatively, the compound was obtained 
through the recycling of N-phenylmethanesulfonamide 2.50 (Scheme 2.15, Section 2.1.3.1), 
using a Williamson ether synthesis adapted procedure.108  
The following step involved the conversion of sulfonamide 2.85 to phosphonate 2.86. The 
main variation in this synthesis comparatively to the one of sultam phosphonates is the 
employment of TMEDA. This agent was used in reactions involving methanesulfonamides 
and n-BuLi with the purpose of increase reactivity and solubility of the sulfonamide 
anion.58,67  Phosphonate 2.86 was only partially purified by column chromatography. 
However, it can be concluded that the yield was poor (about 11%). This result may be due to 
the rt conditions, but the process was not optimized. 
Horner-Wadsworth-Emmons afforded the expected E-vinyl derivative along with small 
amounts of the Z-isomer.29,33,38,39  The latter compound was impure and in insufficient 
quantity for further purification (14 mg). 
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Scheme 2.31 Synthesis of vinyl sulfonamides. Reagents and conditions: (i) (1) n-BuLi, TMEDA, dry THF, rt, 
N2, 10 min, (2) (EtO)2POCl, rt, N2, 1 h; (ii) n-BuLi, dry THF, N-Boc-S-phenylalaninal 2.53, −78 ºC to rt, N2, 20 
min. 
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NMR spectral characterisation of the sulfonamide phosphonate. Similarly to sultam 
phosphonates, the NMR spectra of sulfonamide phosphonate 2.86 reflected the coupling of 
the 31P with 1H and 13C nuclei (Table 2.14). However, because 2.86 lack a stereocentre, it 
showed a much simpler 1H NMR spectrum. Thus, the methylene group CH2SO2 showed a 
doublet splitting pattern with the one-bond coupling constant 31P-1H of 16.8 Hz and the 
methylene groups of the ethyl substituents exhibited a double quartet (Figure 2.11).38,107  For 
the methyl groups CH3CH2O-, the 31P-1H coupling is not resolved but it is revealed by the 
broadening of the characteristic triplet. 
 
 
 
 
Table 2.14 NMR data of 2.86 [400 MHz (1H), 100.61 MHz (13C), CDCl3]. 
 
Position 1H 13C (HMQC) 
OCH2CH3 1.37 brt (7.1) 16.3 d (6.0) 
OCH2CH3 4.24 qd (7.1; 8.0) 63.5 d (7.0) 
CH3 3.44 s 39.2 
CH2SO2 3.56 d (16.8) 46.1 d (139.9) 
Ph 7.31-7.35 m (1H) 127.8 
 7.42 t (8.0) (2H) 129.5 
 7.49 d (8.0) (2H) 126.9 
  140.8 
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JHP = 8.0 Hz
J 3 = 7.1 Hz J 3 = 7.1 Hz
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Figure 2.11 Observed 1H NMR 
double quartet signal and 
splitting pattern diagram for the 
methylene protons OCH2CH3 of 
compound 2.86. 
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2.2 Kinetic study of the reaction with cysteine 
 
2.2.1 Introductory remarks 
 
As stated earlier (Section 1.4), the development of vinyl sultams as inhibitors of cysteine 
proteases was based on the hypothesis that this scaffold would be a Michael acceptor for 
thiols. This situation was confirmed during the time course of the present investigation, by 
Merten et al.,61  who afforded the adducts 2.87-2.88 of the reaction between bicyclic α-
methylene-γ-sultams 2.89-2.90 and thiols 2.91 and 2.92 (Scheme 2.32). Nevertheless, a search 
of the literature indicated that no kinetic evaluation existed for such reactions. 
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Scheme 2.32 Adducts from the reaction of α-methylene-γ-sultams with thiols.61  
 
 
The present work assessed the reactivity of vinyl sultams and compared it with the one of 
an analogous vinyl sulfonamide. The analysis was carried out by UV spectrophotometry at pH 
6.9, at 25 ºC, using cysteine as a model thiol. Cysteine was employed in large excess to ensure 
pseudo-first-order kinetics. 
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2.2.2 Results and Discussion 
 
The reactivity studies began with the selection of the wavelength to be used in the kinetic 
measurements. With this goal, the reaction of cysteine with each of the vinyl sultams/vinyl 
sulfonamide was followed by repeated spectral scanning over the wavelength range of 350 to 
200 nm. The first recorded spectrum showed to be similar to the one of the compound in 
buffer lacking cysteine. This situation is indicative that no reaction had occurred during the 
initial period of mixing of the reactants. 
The kinetic measurements were performed at the wavelength which showed a maximum 
absorbance variation during the reaction progression.  
Then, the pseudo first-order rate constants, kobs, were determined by following the 
variation of absorbance until a plateau region had been reached. Plotting kobs values 
(Appendix II) versus the total cysteine concentration, [cys]t, resulted in a linear correlation 
(Figure 2.12) with an intercept at [cys]t = 0 indistinguishable from zero (Equation 2.1). This is 
consistent with the absence of spontaneous reaction by solvent or catalysis by HO− or H+. 
In addition, the second-order rate constants, kcat, were estimated from the slope of the 
least-squares regression lines. 
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Figure 2.12 Plot of the pseudo first-order rate constants, kobs, for the reaction of vinyl sultam 2.69b with 
cysteine, against the total cysteine concentration at pH 6.93 (α = 5.8 × 10−2) at 25 ºC and ionic strength 0.5 
M. Points are experimental and line is theoretical for kcat 0.14 M−1 s−1. 
 
kobs = kcat[cys]t                                                                                                                                     (2.1) 
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The second-order rate constant, kcat, is given by Equation 2.2, where kcys(1 − α) and kcys−α 
are respectively the contribution of undissociated cysteine and of its thiolate to the overall 
reaction. The parameter α is the fraction of cysteine present as conjugate base, α = 
[cys−]/[cys]t, which is dependent on the reaction pH value. 
 
kcat = kcys(1 − α) + kcys−α                                                                                                                     (2.2) 
 
A plot of the pseudo first-order rate constants, kobs, against the concentration of the 
thiolate anion of cysteine, [cys−], (Figure 2.13) gave, according to Equation 2.3, a slope 
corresponding to the second-order rate constant for the reaction with the thiolate anion, kcys−.  
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Figure 2.13 Plot of the pseudo first-order rate constants, kobs, for the reaction of vinyl sultam 2.69b with 
cysteine, against the cysteine thiolate concentration at pH 6.93, at 25 ºC and ionic strength 0.5 M. Points 
are experimental and line is theoretical for kcys− 2.66 M−1 s−1. 
 
kobs = kcys−[cys−]                                                                                                                                  (2.3) 
 
In addition, the intercept at [cys−] = 0 is indistinguishable from zero, indicating that there 
is no detectable reaction for the undissociated thiol. Thus, Equation 2.2 is simplified to 
Equation 2.4, and kcys− values could be alternatively determined by kcys− = kcat/α. The values 
obtained by both methods are in good agreement and are listed in Table 2.15. 
 
kcat = kcys−α                                                                                                                                          (2.4) 
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Table 2.15 Cysteine-catalysed second-order rate constants, kcys−, for vinyl sultams and for an analogous 
vinyl sulfonamide. 
 
Compound kcys− (M−1 s−1) 
  Method Aa Method Bb 
BocNH
N
SO2
Ph
Ph
 
2.67a 1.93 1.94 
BocNH
O2S N
Ph
Ph
 
2.67b 2.11 2.15 
BocNH
N
SO2
Ph
Bz
 
2.68a 2.42 2.41 
BocNH
Ph
O2S N
Ph  
2.69b 2.66 2.65 
BocNH S
N
Me
O O
Ph
Ph  
2.84a 2.49 2.44 
a From the slope of kobs versus [cys−]. b From kcys− = kcat/α. 
 
 
Overall, it is immediately clear that the studied vinyl sultams are similarly reactive toward 
cysteine, independently of the ring size (2.67b versus 2.69b), geometry of the double bond 
(2.67a versus 2.67b) or nitrogen substituent (2.67a versus 2.68a).  
These compounds also showed to be as reactive as the analogous vinyl sulfonamide 2.84a. 
This result suggested a similarity in the inhibitory action on cysteine proteases. Bearing in 
mind that vinyl sulfonamides are established inhibitors of cruzain, this result corroborated the 
initial hypothesis (Section 1.4) that vinyl sultams scaffold would be a potential structure for 
the design of inhibitors against cruzain-related cysteine proteases, such as falcipain. 
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2.3 Inhibitory activity against papain, falcipain-2 and Plasmodium 
falciparum 
 
This work afforded five dipeptide vinyl sultams 2.1-2.4, along with eight mono-
substituted precursors 2.67-2.70, whose structures are conveniently repetead in this section 
(Figure 2.14). 
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Figure 2.14 Compounds assayed for inhibitory activity against cysteine proteases. 
 
 
These compounds were screened for effectiveness against papain, using the procedure 
described in Appendix I. Their solubility in the assay buffer limited testing at 50 µM, what 
could not be overcome by adding an extra volume of DMSO (in the enzyme-inhibitor 
incubation medium, the concentration of this solvent is usually 5%; in this case it was 
employed up to 10%). No inhibition could be detected after 30 min of incubation. In addition, 
the free amine 2.73a, which did not reveal solubility problems, failed the inhibition up to 500 
µM. 
The lack of papain-inhibitory activity of compounds bearing a Phe residue directly 
attached to the “warhead” was already reported, in a study involving vinylogous amino acid 
esters. The situation was ascribed to a binding mode where the Michael acceptor is far from 
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the reach of the sulphur of Cys25 due to the interaction between Phe and the S2 hydrophobic 
subsite of papain.28  
Only dipeptide derivatives 2.1-2.4 were evaluated against falcipain-2 (the main target of 
this project) and Plasmodium falciparum W2. These studies were carried out by Dr. Philip J. 
Rosenthal’s group (University of California), following a reported protocol.16  
The compounds showed some activity against falcipain-2, albeit modest (Table 2.16).  
 
 
Table 2.16 IC50 values of vinyl sultams for falcipain-2 and Plasmodium falciparum W2. 
 
Inhibitor IC50 (µM) 
 rec-FP-2a Plasmodium falciparum W2 
2.1 26.5 >10 
2.2 48.4 >10 
2.3 31.4 >10 
2.4a 13.7 7.8 
2.4b 23.6 >10 
1.2eb 0.0035 0.022 
a Recombinant falcipain-2. b Mu-Leu-Hph-VS-Ph (from Table 1.4a in Section 1.2.3.1). 
 
 
The derivative 2.4a exhibited the best IC50 value (13.7 µM), which was consistently 
accompanied by the most favourable activity against Plasmodium falciparum W2. Though the 
range of compounds is limited, the data presented suggested that the ring size (2.2 versus 
2.4a), the geometry of the double bond (2.4a versus 2.4b) and the nitrogen substituent (2.3 
versus 2.4a) may have some impact on activity. As shown by the data for compounds 2.1 and 
2.3, substitution of the Ac-Phe by the Mu-Leu moiety has little effect on activity. 
Overall, what is immediately clear from these results is that dipeptide vinyl sultams are 
significantly less active (≈10−4-fold) than their acyclic analogues, vinyl sulfones (see data for 
1.2e). 
Developing conformationally restricted analogues, i.e. incorporation of ring moieties, is a 
commonly used approach to probe the binding site of receptors and to further improve 
activity.109  It may, however, result in the opposite effect, by interfering with target binding, 
leading to a substantial reduction in the activity when compared to their acyclic counterparts. 
A situation like this was found in the development of cyclic peptide aldehydes as cysteine 
protease inhibitors.110  The hypothesis that a similar explanation could be applied to vinyl 
sultams 2.1-2.4 was investigated by performing molecular modelling studies with the more 
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potent inhibitors 2.4a,b. At that time, the crystal structure of falcipain-2 had not been 
released, but the similarity between this enzyme and cruzain was already recognised on the 
basis of 40% homology in the mature domain and about 90% for the binding site 
residues.111,112   
Molecular modelling was therefore carried out on the 1F2A crystal structure,20,24  a 
complex between cruzain and the vinyl sulfone Cbz-Phe-Hph-VS-Bz (1.2d in Section 
1.2.3.1). The calculations were performed by Dr. Rita C. Guedes (from the Faculty of 
Pharmacy, University of Lisbon).  
The top 10 solutions (i.e. those with the highest fitness score) were visually analysed for: 
(i) the hydrophobic and hydrophilic interactions between the ligand and enzyme surfaces and 
(ii) the distance between the β-carbon atom of the Michael acceptor system and the catalytic 
cysteine residue. 
As mentioned earlier (Section 1.2.3.1), 1.2d is a fairly good inhibitor for cruzain. When 
the compound was docked into the active site of cruzain (Figure 2.15a), it bound as 
reported,24  i.e., seven conformations presented hydrogen bonding interactions between the 
sulfonyl oxygen atoms and the imidazole NH of His159, indole NH of Trp177 and one of the 
NH of Gln19, while all 10 inspected conformations present the Phe side chain sitting in the S2 
pocket of the enzyme, which is lined with hydrophobic residues Leu67, Ala133 and Leu157. 
Additional hydrogen bonding to the carbonyl oxygen atom of Gly66 enables further 
stabilization of the non-covalent complex. This conformation presents the β-carbon atom of 
the vinyl sulfone system in proximity (3.6-3.8 Å) to the sulphur atom of Cys25, as would be 
expected for Michael addition chemistry. 
Interestingly, modelling the interaction of E-isomer 2.4a with cruzain revealed that the top 
ranking conformation sits in the active site with an inverted orientation when compared to 
1.2d, the N-benzyl-δ-sultam moiety being accommodated in the S2 subsite through stabilizing 
van der Waals interactions with Leu67, Ala133 and Leu157 (Figure 2.15b). The most striking 
observation was that the sulphur atom of Cys25 is in the vicinity (3.4 Å) of the β-carbon and 
positioned 20º out off of the plane defined by the carbon-carbon double bond, thereby 
disfavouring Michael addition of cysteine to the β-carbon atom of the vinyl sultam system. 
This type of reaction requires the sulphur nucleophile to approach the carbon atom almost 
perpendicularly to the double bond plane in order to achieve optimal orbital overlap. 
In contrast, the preferred conformation of the Z-isomer 2.4b is positioned in the active site 
of cruzain similarly to 1.2d, that is, with the Leu side chain occupying the S2 pocket (Figure 
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2.15c). However, the Cys25(S)-Cβ distance is probably too long (ca. 4.0 Å) for nucleophilic 
attack of cysteine to take place. 
Taken together, these docking results suggest that the δ-sultam ring increases the degrees 
of freedom of ligand binding to cruzain when compared with the acyclic vinyl sulfone 
analogue, leading to enzyme-inhibitor complexes that do not favour Michael addition 
chemistry. 
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b1 
 
b2 
 
c1 
 
c2 
 
Figure 2.15 Gold-generated active site interaction of cruzain with 1.2d (a), 2.4a (b) and 2.4b (c). Figure 
generated using Pymol software.26  
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Vinyl sultams 2.4a,b were also docked into the active site of papain (PDB code: 
1PPN)20,113  as outlined in Figure 2.16. 
For 2.4a, seven of the top 10 solutions presented the N-benzyl-δ-sultam moiety being 
incorporated in the S2 subsite defined by Pro68, Val133 and Val157, and a Cys25(S)-Cβ 
distance ranging from 4.6 to 4.9 Å. All docked conformations of 2.4b showed the N-benzyl-δ-
sultam in the S2 pocket. 
Clearly, these results suggest that molecular recognition of 2.4a,b by papain leads to 
enzyme-inhibitor complexes that are conformationally unfavourable to conjugate addition of 
Cys25 to the vinyl sultam, as required for enzyme inactivation. 
 
 
 
a 
 
 
b 
 
Figure 2.16 Gold-generated active site interaction of papain with 2.4a (a) and 2.4b (b). Figure generated 
using Pymol software.26  
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3. 1,4-NAPHTHOQUINONE DERIVATIVES 
 
The present chapter focuses on the inhibition kinetics of papain and bovine spleen 
cathepsin B by naphthoquinones, including commercially available compounds and some new 
derivatives, for which the synthesis is described. These compounds were also evaluated 
against falcipain-2, Plasmodium falciparum W2 and porcine pancreatic elastase. 
Investigations on reactivity toward cysteine were carried out to explore the relationship 
between the intrinsic chemical reactivity and the enzyme inhibitory activity. 
 
 
3.1 Synthesis 
 
Earlier (Section 1.1.3), it was mentioned the preference of papain for bulky S-amino acids 
such as Phe. It is also known that papain favours ligands based on the N-Ac-S-Phe-Gly 
motif,30  and on the Leu-i-Am sequence (side chain of the successful inactivator E-64c, in 
Section 1.2.2). 
Thus, to probe the potential interaction between this enzyme and 1,4-naphthoquinone 
derivatives, the naphthoquinone core was attached to the Phe, Leu-i-Am and Gly moieties. 
This strategy involved the preparation of compounds 3.1-3.3 and the attempted synthesis of 
derivatives 3.4a (Figure 3.1). The non-specific methylamino (3.1 and 3.2, R = Me) and ethoxy 
(3.5) derivatives were also synthesised for comparison on enzyme inhibitory activity. 
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Figure 3.1 Generic structures of N-(1,4-naphthoquinon-2-yl)amino derivatives (3.1-3.3) and of N-[(1,4-
naphthoquinon-2-yl)methyl]amino derivatives (3.4a). Structure of 2-ethoxy-1,4-naphthoquinone (3.5). 
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The introduction of a methylene bridge in the 3.4a series was planned to tentatively find 
the best binding interaction of the inhibitors with papain. It was also expected that these 
derivatives could be more reactive toward thiols than 3.1 due to the presence of an inductively 
electron withdrawing methyleneamino group instead of an electron donating amino 
substituent.  
 
 
3.1.1 Reaction of 1,4-naphthoquinones with nitrogen and oxygen nucleophiles 
 
Previous investigations accomplished the synthesis of naphthoquinones through a 
Michael-type addition of amines to the quinone moiety.52,114-120  Alternatively, the amine may 
be reacted with the reduced form of 2-bromo-1,4-naphthoquinones (Scheme 3.1).121  
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Scheme 3.1 Reaction of amines with the reduced form of 2-bromo-1,4-naphthoquinone. 
 
 
In the present work, the first approach to the synthesis of 3.1-3.3 (Scheme 3.2) consisted 
in the reaction of 2-bromo-1,4-naphthoquinone 3.6 with S-phenylalanine ethyl ester 
hydrochloride (1 mol eq) and TEA (2 mol eq) in DCM, but after stirring for 3 h at rt, only 
starting material was recovered. Changing the solvent to abs ethanol, as previously 
described,115,119  allowed the reaction to proceed smoothly through conjugate addition 
chemistry.122  The process led to the formation, in a one-pot procedure, of two compounds: 
3.1a, obtained as the major product, and the bromo analogue 3.2a as a minor product. 
Thereafter, employing glycine ethyl ester hydrochloride and methylamine under the same 
conditions afforded the compounds 3.1b, 3.2b and 3.1c, 3.2c, respectively. These results are 
consistent to the one involving coupling between quinone 3.7 (Figure 3.2) and amines, which 
also gave the bromo derivative in low yield,123  but contrast with that recently described for 
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the reaction of 2-bromo-1,4-naphthoquinone 3.6 with S-amino acid methyl esters, in which 
the mono-substituted 1,4-naphthoquinones 3.1 were the only products isolated.117  
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Scheme 3.2 Synthesis of N-(1,4-naphthoquinon-2-yl)amino derivatives and of 2-ethoxy-1,4-
naphthoquinone. Reagents and conditions: (i) TEA, abs ethanol for 3.5 and TEA, Leu-i-Am, abs ethanol for 
3.1d; (ii) PheOEt or GlyOEt hydrochlorides, TEA, abs ethanol for 3.1a,b, 3.2a,b and 3.3a,b; (iii) R = NH2Me, 
abs ethanol for 3.1c and 3.2c. 
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Figure 3.2 Structure of 6-bromo-2-methylquinoline-5,8-dione. 
 
This method was also applied to 1,4-naphthoquinone 3.8 and to 2,3-dichloro-1,4-
naphthoquinone 3.9 to afford compounds 3.1d, 3.5 and 3.3a,b. The side-chain Leu-i-Am of 
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3.1d was prepared under standard peptide coupling conditions from N-Boc-S-leucine-N-
hydroxysuccinimide ester and iso-amylamine, followed by the removal of the N-Boc group 
with TFA.101,106  
During the time course of this work, Tandon et al.,114,117  afforded derivative 3.3b and the 
methyl esters analogues of compounds 3.1a,b. The followed procedure is rather similar to the 
one mentioned above, but the employment of reflux conditions during a short time (3-5 h) led 
to yields ranging from 60% to 96% and all products were obtained as crystalline solids.  
 
 
NMR spectral characterisation. All compounds gave NMR, ESI-MS and elemental 
analyses consistent with their structures. However, it is noteworthy that NMR analyses of 
derivatives 3.2/3.3 lacked the signals for carbons bearing the halo substituent, and in the case 
of 3.3a also for the carbon at C-2. 
The common feature in the 1H NMR spectra is the characteristic triple doublet splitting of 
protons H-6 and H-7 (Figure 3.3), consistent with two ortho and one meta couplings. Each of 
the remaining aromatic protons (H-5 and H-8) was expected to give a ddd signal due to the 
split with the ortho, meta and para neighbouring protons. Instead, the spectra generally 
exhibited two not well resolved brdd (Figure 3.4) or brd signals. Generally, these signals 
present a Jortho of 7.6 Hz, which reflects the H-5/H-6 and H-8/H-7 couplings and, for the brdd 
case, an additional small value constant which was ascribed to both meta and para split. 
In phenylalanine derivatives, the methylene protons CHCH2Ph are diastereotopic to one 
another, due to the stereocentre of S-phenylalanine ethyl ester. Excluding the cases where 
accidental overlap might occur, each of these protons consists of a dd signal due to the 
coupling with each other and with the methine proton CHCH2Ph. An analogous situation was 
found for the methylene protons of the ester moiety OCH2CH3, whose resonance frequencies 
coincided in an obscure signal classified as a multiplet. The non-equivalence of these two 
protons also provides a convenient explanation for the complex signal, i.e. a multiplet, 
showed by the neighbouring methyl protons OCH2CH3. In contrast, glycine derivatives, 
which lack a stereocentre, exhibited the characteristic quartet and triplet splitting patterns for 
the ethyl component.  
The S-Leu-i-Am derivative 3.1d has also a stereocentre. Thus, the isopropyl methyl 
groups CH(CH3)2 of the leucine and iso-amylamine components are diastereotopic. This 
situation is easily deduced for the leucine component, which exhibited a doublet for each 
methyl group protons and two separate carbon signals. In contrast, for iso-amylamine, the two 
3. 1,4-Naphthoquinone Derivatives 
89 
Jortho = 7.6 Hz
Jortho = 7.6 HzJortho = 7.6 Hz
 
methyl groups appear to be equivalent, by showing a single doublet in the 1H NMR spectrum 
and one carbon signal. This situation was ascribed to an accidental coincidence in the 
chemical shift. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Observed 1H NMR triple doublet signals 
and splitting pattern diagram for the aromatic 
protons H-6 and H-7 of compound 3.1c. 
Constant not shown is 1.2 Hz (meta coupling). 
 
 
 
O
O
NHMe
H
H
3.1c  
 
 
H-7H-6
3. 1,4-Naphthoquinone Derivatives 
90 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Observed 1H NMR not well resolved dd signals for the 
aromatic protons H-5 and H-8 of compound 3.2c. 
 
 
 
Mass spectrum. The ESI-MS of derivatives 3.2/3.3 showed the readily identifiable 
patterns indicative of the presence of bromine or chlorine in the molecule. Therefore, bromo 
derivatives exhibited a doublet at (MH+) and (MH++2), the two peaks showing nearly equal 
intensity. Similarly, chloro derivatives presented (MH+) ions two mass units apart, but in a 3:1 
intensity ratio. 
 
 
 
3.1.2 Aminomethyl derivatives 
 
A search of the literature has not revealed much information concerning derivatives 3.4a 
(Scheme 3.3). All reported compounds are substituted at the 3-position with electron donating 
or withdrawing groups (R = Me, Cl, Br, OH, OMe, OCOMe).124-127  Although no details of 
the reaction were given, Prezhdo et al.126  claim the preparation of these derivatives from the 
appropriate 2-chloroalkyl naphthoquinone 3.10a, and secondary aromatic amines in yields of 
50-85%. Other investigations afforded the 3-hydroxyl derivatives through a Mannich 
reaction.124,125   
The literature also reports derivatives 3.4b,c (Figure 3.5),128,129  along with the failure of 
the attempts to synthesise 3.4d from the corresponding chloroalkyl naphthoquinones.126,127  
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Scheme 3.3 Preparation of aminomethyl derivatives by Prezhdo et al.126  
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Figure 3.5 Generic structures of aminoalkyl derivatives. 
 
 
In the present investigation, attempted preparation of derivatives 3.4a (Scheme 3.4) 
proceeded via the bromination of 2-methyl-1,4-naphthoquinone 3.11,130  to afford 3.10b, 
whose structure was confirmed by its 1H NMR spectrum.  
The next step consisted in the reaction of 3.10b with methylamine or amino acid ethyl 
ester hydrochlorides, under several conditions (Table 3.1). In all cases dark brown mixtures 
were obtained, the TLC analyses of which showed intractable mixtures. 
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Scheme 3.4 Attempted synthesis of aminomethyl derivatives. Reagents and conditions: (i) N-Bromo-
succinimide, benzoyl peroxide, CCl4, reflux, 24 h; (ii) see Table 3.1. 
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Table 3.1 Conditions for the synthesis of aminomethyl derivatives. 
 
Amine or S-amino acid ethyl ester/1 mol eq Solvent/Basea/Temperature/Reaction time 
DCM/TEA/reflux/2.5 h 
DCM/pyridine/reflux/1.5 h S-phenylalanine ethyl ester hydrochloride 
EtOH/TEA/rt/immediate 
glycine ethyl ester hydrochloride toluene/TEA/rt/14 h 
EtOH/NH2Me/rt/immediate 
acetone/NH2Me/rt/5 h 
DMFc/NH2Me/rt/immediate 
NH2Meb 
toluene/NH2Me/rt/14 h 
a TEA and pyridine were used in a 2 mol eq molar ratio. b An excess of amine was used (1 mol eq) as indicated in the right column. c N,N-
Dimethylformamide. 
 
 
 
 
3.2 Kinetic study of the reaction with cysteine 
 
3.2.1 Introductory remarks 
 
As stated earlier (Section 1.4), the choice of the 1,4-naphthoquinone scaffold as a 
potential lead structure for the design of irreversible cysteine protease inhibitors laid in the 
known reactivity of thiols to quinones.  
In an attempt to get insight into the factors that could affect the chemical reactivity of such 
compounds, this work exploited the relationship between the LUMO energies and the 
reactivity of some derivatives toward cysteine. This thiol was chosen because it showed to be 
highly reactive with 2- and 6-methyl-1,4-naphthoquinone derivatives, comparatively to GSH 
and DTT.131  The reaction was followed spectrophotometrically at pH 7.1, at 25 ºC, under 
pseudo-first-order conditions. 
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3.2.2 Results and Discussion 
 
Kinetic studies 
 
The reactivity studies began with the selection of the wavelength to be used in the kinetic 
measurements. With this goal, the reaction of cysteine with each of the naphthoquinones 
(Table 3.2) was followed by repeated spectral scanning over the wavelength range of 700 to 
200 nm.  
An attempt to study the reactivity of 2-bromo-1,4-naphthoquinone 3.6 and 5-hydroxy-1,4-
naphthoquinone 3.12 was made, but, for each one, the first recorded scanning was not similar 
to the compounds spectra in buffer lacking cysteine. This situation is indicative that, due to 
their high reactivity, the compounds had reacted with cysteine during the initial period of 
mixing of the reactants. 
For the remaining compounds, the main difficulty in the selection of the wavelength arose 
from the complexity of the spectra (see Appendix III for an example). In general, on mixing 
the reactants, there was a progressive change in the absorbance, followed by a region with a 
minimal variation in this property (plateau). Subsequently, the reaction was characterised by 
continuous spectral changes. Some of the spectra did not present an isosbestic point. 
These observations are similar to previous reports regarding the reactivity of quinones,132  
which related this pattern to the occurrence of complex secondary reactions involving the 
hydroquinone product that results from the initial Michael addition (outlined in Scheme 1.7, 
Chapter 1). Because the present kinetic studies were performed without protection from air, 
the mentioned complexity may arise from the aerobic oxidation of those products.51,131  
In order to simplify the kinetic interpretation of the overall process, some of the reported 
investigations were performed with exclusion of oxygen. To the best of author’s knowledge, 
spectrophotometry has been used only once to investigate naphthoquinones, and then under 
anaerobic conditions.131  Nevertheless, it has been recognised that these conditions may 
compromise any application of the results to biological systems.131  
In the present investigation, the kinetic measurements were performed at the wavelength 
that showed a much well defined plateau region, along with a maximum absorbance variation 
during the reaction progress. 
Then, the kobs values (Appendix II) were determined by following the absorbance decrease 
or increase until the plateau region, and before any significant secondary reaction was 
observed. 
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For 1,4-naphthoquinone 3.8, the UV-visible spectrum was recorded in the presence of 
buffer lacking cysteine during 19 h. The similarity between scans excluded any background 
reaction. As this compound revealed to be the most reactive during the above-mentioned 
selection of the wavelength, stability in the phosphate buffer was assumed for the other 
derivatives. Later, this situation was confirmed when the plot of the pseudo first-order rate 
constants, kobs, versus the total cysteine concentration, [cys]t, showed an intercept at [cys]t = 0 
indistinguishable from zero (Figure 3.6). In addition, the second-order rate constants, kcat, 
were given by the slope of this graph. 
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Figure 3.6 Plot of the pseudo first-order rate constants, kobs, for the reaction of compound 3.13 with 
cysteine, against the total cysteine concentration at pH 7.12 (α = 8.8 × 10−2) at 25 ºC and ionic strength 0.5 
M. Points are experimental and line is theoretical for kcat 7.98 M−1 s−1. 
 
The pseudo first-order rate constants, kobs, also showed a linear increase with the thiolate 
concentration, [cys−], (Figure 3.7) giving a slope corresponding to the second-order rate 
constants for the reaction with the thiolate anion, kcys−, (Table 3.2). This correlation resulted in 
an intercept at [cys−] = 0 indistinguishable from zero, indicating that there is no detectable 
reaction for the undissociated thiol. This result is consistent with previous studies with 
quinones which claim thiolate anion as the reactive species.131,132  
Under these conditions, the second-order rate constants, kcat, are strictly dependent on the 
fraction of cysteine present as conjugate base, α (Equation 2.4, conveniently repeated in this 
section). This dependence was showed for compound 3.11 (Figure 3.8).  
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Figure 3.7 Plot of the pseudo first-order rate constants, kobs, for the reaction of compound 3.13 with 
cysteine, against the cysteine thiolate concentration at pH 7.12, at 25 ºC and ionic strength 0.5 M. Points 
are experimental and line is theoretical for kcys− 93.1 M−1 s−1. 
 
 
kcat = kcys−α                                                                                                                                          (2.4) 
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Figure 3.8 Plot of the catalytic rate constants, kcat, for the reaction of 3.11 with cysteine, against the 
fraction of conjugate base, α, at 25 ºC and ionic strength 0.5 M. The kcat values were determined at four 
different pH values (7.1, 7.9, 8.0 and 8.8). Points are experimental and line is from linear regression analysis of 
the data. 
 
According to Equation 2.4, the second-order rate constant, kcys−, could be determined from 
the intercept at α = 1. For the remaining compounds, kcys− values were given by kcys− = kcat/α 
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and showed to be in good agreement with the ones given by the slopes of kobs versus the 
thiolate concentration, [cys−]. 
1,4-Naphthoquinone 3.8, however, revealed a hyperbolic dependence of kobs on the total 
cysteine concentration (Figure 3.9). Such a dependence has been reported for the reaction of 
dopaminoquinone 3.14 with cysteine (Scheme 3.5) and has been ascribed to an initial 
formation of the reversible tetrahedral intermediate 3.15, resulting from cysteine conjugate 
addition to C-6 (dopaminoquinone numbering), which is then followed by the decomposition 
into the final product.133  
 
 
  
 
Figure 3.9 (a) Plot of the pseudo first-order rate constants, kobs, for the reaction of naphthoquinone 3.8 
with cysteine, against the total cysteine concentration at pH 7.08 (α = 7.08 × 10−2) at 25 ºC and ionic 
strength 0.5 M. Points are experimental and line is theoretical for 1/Kcys 9.26 × 10−6 ± 3.16 × 10−6 M and kcys 
2.64 × 10−2 ± 0.17 × 10−2 s−1; (b) Plot of the pseudo first-order rate constants, kobs, for the reaction of 
naphthoquinone 3.8 with cysteine, against the cysteine thiolate concentration at pH 7.08, at 25 ºC and 
ionic strength 0.5 M.  
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Scheme 3.5 The proposed reaction mechanism of cysteine with dopaminoquinone. Hydrogen bonds are in 
grey. 
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Assuming that reaction of 3.8 with cysteine thiolate also involves initial reversible 
formation of an adduct (e.g. 3.16, Figure 3.10), then kobs dependence on [cys]t follows 
Equation 3.1, 
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Figure 3.10 Possible adduct resulting from the reaction of cysteine thiolate with naphthoquinone 3.8. 
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where Kcys is the stability constant for the formation of the adduct, kcys is the first-order rate 
constant for the decomposition of the adduct and (Ka+[H+])/Ka is 1/α (this equation was 
solved in Appendix IV). 
Kinetic data were computer-fitted (Sigma Plot® software) to Equation 3.1 allowing the 
determination of Kcys (1.08×105 M−1), of kcys (2.64×10−2 s−1) and thus of the second-order rate-
constant for the reaction with the thiolate anion kcys− (= kcysKcys). 
Overall, the kcys− values varied by up to four orders of magnitude, with 1,4-
naphthoquinone 3.8 as the most effective acceptor for cysteine. 
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Table 3.2 LUMO energies and cysteine-catalysed second-order rate constants, kcys−, for naphthoquinones. 
 
O
O
R1
R2
R3
R4  
kcys− (M−1 s−1) Compound R1 R2 R3 R4 ELUMO/Hartree 
Method Aa Method Bb 
3.1a PheOEt H H H −0.1146 25.2 25.9 
3.1b GlyOEt H H H −0.1097 0.55 0.49 
3.1c NHMe H H H −0.1070 0.24 0.24 
3.5 OEt H H H −0.1114 11.1 10.9 
3.6 Br H H H    
3.8 H H H H −0.1245 2851.2c 
3.11 Me H H H −0.1193  114.3 
3.12 H H OH H    
3.13 Morpholinyl Cl H H −0.1161 93.1 93.1 
a From the slope of kobs versus [cys−]. b From kcys− = kcat/α. c From Equation 3.1. 
 
 
 
Relationship between LUMO energies and the reactivity toward cysteine 
 
Molecular orbital calculations were performed by Dr. Rita C. Guedes (from the Faculty of 
Pharmacy, University of Lisbon).  
The interest in LUMO energies arose from two reported correlations; first, between the 
reactivity of quinones and their LUMO energy,46,48,51  and second, between LUMO energies 
and electronic descriptors134  thereby providing an alternative approach to QSAR 
studies.132,134-136  In the context of this latter observation, the present study found a correlation 
between the LUMO energy of naphthoquinones and the corresponding Hammett σp constants 
for C-2 and C-3 substituents (Figure 3.11). 
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Figure 3.11 Linear correlation between the LUMO energy of naphthoquinones and the Hammett σp 
constants. For data see Appendix V. Line is from linear regression analysis of the data. 
 
 
Plotting log kcys− against the corresponding LUMO energies resulted in a linear correlation 
(Figure 3.12), which shows that the lower the LUMO energy the more reactive the molecule. 
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Figure 3.12 Linear correlation between the LUMO orbital energies and the second-order rate constants, 
kcys−, for the reaction of naphthoquinones with the thiolate anion. Line is from linear regression analysis of 
the data. 
 
 
Calculations of the LUMO density for the glycine derivative 3.1b (Figure 3.13), as well 
for other aminoacid derivatives, showed that for these compounds this orbital is largely 
centred on the double bond of the quinone ring.  
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Overall, these observations are consistent with the occurrence of a Michael-type addition, 
which is dependent on the electrophilicity of the naphthoquinone. 
 
 
 
 
 
 
 
LUMO HOMO 
 
Figure 3.13 Frontier molecular orbitals of a low-energy conformation of the glycine derivative 3.1b. 
 
 
 
3.3 Inhibitory activity against cysteine proteases 
 
This section presents the results obtained for naphthoquinones in the inactivation studies 
on papain, bovine spleen cathepsin B, falcipain-2 and Plasmodium falciparum W2. To 
investigate the selectivity of the compounds for cysteine proteases, they were also evaluated 
against porcine pancreatic elastase, a serine protease. In addition, the papain-inhibitory 
activity of two indolequinones is described. These compounds contain an isosteric 
replacement of the fused benzene moiety and thus can provide structural information for 
structure-activity relationships. 
All kinetic inhibition assays were performed by Kitz and Wilson’s pre-incubation 
method,137  following the protocols described in Appendix I. 
The inhibitory activity of the compounds is analysed in conjunction with the data from 
reactivity studies. 
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3.3.1 Papain inhibition studies 
 
Earlier (Section 1.3), it was mentioned that quinones can interact with biological 
molecules by two mechanisms: (i) their capacity to undergo redox cycling, generating reactive 
oxygen species and (ii) their capacity to act as electrophiles leading to covalent modifications. 
Whether a quinone acts as an electrophile, a redox cycler or as both is mainly dependent on its 
reduction potential. 
The redox cycle was illustrated in Scheme 1.6 (Chapter 1), which shows that the start of 
this mechanism requires the action of a reducing agent over quinones. Most of the inhibition 
assays for cysteine proteases, including the one used in this thesis, carry out the enzyme-
inhibitor incubation in the presence of a reducing agent, e.g. DTT, which may, therefore, 
trigger the redox process, leading to the enzyme inactivation through oxidation of thiol 
groups. This mechanism was found in the inhibition of glyceraldehyde-3-phosphate 
dehydrogenase by 3.17, which, under aerobic conditions, is able to transfer electrons from 
DTT to oxygen (Scheme 3.6). The inactivation process revealed to be more affected by the 
concentration of the thiol than by the quinone concentration, because the latter operates as a 
catalyst.138  
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Scheme 3.6 Proposed mechanism of glyceraldehyde-3-phosphate dehydrogenase by 9,10-
phenanthrenequinone under aerobic conditions. Adapted from Rodriguez et al.138  
 
 
Conversely, naphthoquinones (Table 3.3) and indolequinones (Figure 3.14) inactivated 
papain at a rate dependent on the concentration of the inhibitor as well as on the incubation 
time. This type of kinetic profile has been related recently to the quinone behaving as an 
electrophile.138  In addition, performing an inhibition assay with compound 3.5 (58 µM) under 
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N2 led to an inactivation degree similar to the one observed under aerobic conditions, 
excluding the existence of significant redox mechanism; kobs (3.13 ± 0.16) × 10−4 s−1 versus 
(3.49 ± 0.33) × 10−4 s−1, respectively. 
Therefore, the present results are consistent with covalent modification of papain. 
 
 
Table 3.3 LUMO energies and kinetic data for inactivation of papain by naphthoquinones. 
 
O
O
R1
R2
R3
R4  
Papain Compound R1 R2 R3 R4 ELUMO/Hartree 
k2 (M−1 s−1) kinact (10−3 s−1) KI (µM) 
3.1a*a PheOEt H H H −0.1146 NIb   
3.2a PheOEt Br H H −0.1214 1.92   
3.3a* PheOEt Cl H H −0.1216 0.67   
3.1b* GlyOEt H H H −0.1097 35.4 0.34 ± 0.05 9.57 ± 4.18 
3.2b* GlyOEt Br H H −0.1172 14.7 1.32 ± 0.03 89.6 ± 7.08 
3.3b* GlyOEt Cl H H −0.1174 5.35 1.42 ± 0.16 266 ± 68.4 
3.1c* NHMe H H H −0.1070 0.76   
3.2c* NHMe Br H H −0.1149 1.03   
3.1d* Leu-i-Am H H H  1.35 0.30 ± 0.04 222 ± 39.4 
3.5* OEt H H H −0.1114 11.6 1.34 ± 0.18 115 ± 43.7 
3.6* Br H H H −0.1320 33.3 2.20 ± 0.31 66.0 ± 20.0 
3.8 H H H H −0.1245 (49.5 ± 4.2)c   
3.9 Cl Cl H H −0.1370 6.39   
3.11* Me H H H −0.1193 4.90   
3.12 H H OH H  (60.4 ± 4.1)c   
3.13* Morpholinyl Cl H H −0.1161 9.29   
3.18 Me H Me Me −0.1133 NIb   
3.19 OH H H H −0.1170 (82.0 ± 4.4)d   
3.20 H H OAc H −0.1335 14.6   
a The derivatives with an asterisk were assayed for antimalarial activity (Section 3.3.3). Compounds 3.6, 3.8, 3.9, 3.11, 3.12, 3.13 and 3.19 were 
commercially available. Derivatives 3.18 and 3.20 were kindly provided by Dr. Mohammed Jaffar (University of Manchester). b No inhibition when tested up 
to their solubility limit (50 µM for 3.1a and 150 µM for 3.18). c Inhibition % at 65 µM after 30-min incubation; d Inhibition % at 1.3 mM after 20-min incubation. 
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Figure 3.14 Structure of the assayed indolequinones and kinetic data for inactivation of papain. These 
compounds were kindly provided by Dr. Mohammed Jaffar, from the University of Manchester. 
 
The time dependency of inhibition also suggested an irreversible process, which was 
confirmed by dialyses carried out after reaction of glycine derivative 3.1b with papain, from 
which no enzymatic activity could be recovered after 24 h. Independently, no loss of activity 
was found for the control enzyme. 
The simple reaction of an enzyme, E, with an irreversible inhibitor, I, (active-site directed) 
follows a model analogous to that of the Michaelis-Menten mechanism, i.e. there is an initial 
formation of a non-covalent enzyme-inhibitor complex, E•I, followed by covalent 
modification, E~I, and hence irreversible inhibition (Equation 3.2).139  
 
E + I
kinactKI E·I E~I                                                                                                       (3.2) 
 
Overall, the process is described by Equation 3.3, where KI represents the dissociation 
constant of the E•I complex and kinact is the first-order rate constant for the chemical 
inactivation step. According to this kinetic expression, the pseudo first-order inactivation rate 
constants, kobs, should display a hyperbolic dependence with inhibitor concentration, [I], 
indicative of saturation inhibition kinetics (kobs values are listed in Appendix VI). 
 
[ ]
[ ]I
I
I
inact
obs += K
kk                                                                                                                                        (3.3) 
 
KI = 48.3 ± 18.9 µM 
kinact = (1.70 ± 0.29) × 10−3 s−1 
k2 = 35.2 M−1 s−1 
 
k2 = 0.43 M−1 s−1 
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This behaviour was observed for compounds 3.1b, 3.1d, 3.2b, 3.3b, 3.5, 3.6 and 3.21, 
(Figure 3.15A), which suggests that the inactivation step is preceded by a specific non-
covalent interaction between enzyme and inhibitor in a Michaelis-type complex. 
In the case of derivatives 3.1c, 3.2a,c, 3.3a, 3.9, 3.11, 3.13, 3.20 and 3.22, kobs varied 
linearly with inhibitor concentration (Figure 3.15B), suggesting that KI >> [I]. In these 
conditions, Equation 3.3 simplifies to Equation 3.4, whose slope is the apparent second-order 
rate constant, k2 (=kinact/KI), for the enzyme inactivation process. 
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I
K
kk =                                                                                                                                        (3.4) 
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Figure 3.15 (a) Plot of the pseudo first-order inactivation rate constants, kobs, against inhibitor 
concentration for the inactivation of papain by derivative 3.2b, at pH 7.0 at 25 ºC; (b) plot of the pseudo 
first-order inactivation rate constants, kobs, for the inactivation of papain by derivative 3.2c against 
inhibitor concentration, at pH 7.0 at 25 ºC. 
a 
b 
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Naphthoquinone 3.8, juglone 3.12 and lawsone 3.19 showed a departure from the two 
above-mentioned patterns and their inhibitory activity is discussed in the following section. 
Overall, the compounds inhibited papain with the second-order rate constants for the 
inactivation process, k2, ranging from 0.67 to 35.4 M−1 s−1, which represents ∼50-fold 
variation in their inhibitory activity. 
Unfortunately, the Phe and Leu-i-Am fragments did not improve inhibitory potency as 
initially reasoned, although the observation of a hyperbolic dependence for the Leu-i-Am 
derivative 3.1d supports a specific inhibition process. The phenylalanine derivative 3.1a did 
not inactivate papain. The lack of papain-inhibitory activity of compounds bearing a Phe 
residue directly attached to the “warhead”, was already found by Hanzlik et al.28  (as 
mentioned in Section 2.3) and it was further observed for the synthesised vinyl sultams. 
The most potent inhibitors were the indolequinone 3.21, the glycine derivative 3.1b (k2 = 
35.4 M−1 s−1) and 2-bromo-1,4-naphthoquinone 3.6 (k2 = 33.3 M−1 s−1). The action of 3.21 
may, however, be due to the nucleophilic attack of Cys25 to aldehyde function, instead of 
involving Michael addition. 
Comparing the kinetic parameters of 3.1b and 3.6, it is clear that the first-order rate 
constant for the chemical inactivation step, kinact, plays an important role in the inhibitory 
activity of 3.6. In fact, this compound showed the highest kinact of all, consistent with the 
propensity of halo-quinones to undergo nucleophilic substitution, ascribed to the increased 
electron affinity provided by the substituent.122  The expected contribution of an electron-
withdrawing group to the increase of the activity is also clear in the Phe and NHMe series, 
particularly in the case of the brominated phenylalanine derivative 3.2a (1.92 M−1 s−1) 
compared to its inactive non-halo counterpart 3.1a. 
In contrast, the potency of the glycine derivative 3.1b is connected with its KI (9.57 µM), 
which is the lowest in the series. This suggests that the Gly residue is able to promote 
stabilization of the non-covalent enzyme-inhibitor complex, directing the naphthoquinone 
moiety to the active cysteine residue thereby enhancing the inhibitory potency, even at low 
alkylation rate constants. Modelling the interaction of this compound with papain revealed 
that all top 10 conformations presented hydrogen bonding interactions between the carbonyl 
oxygen atom at C-4 and NH of Gln19 (Figure 3.16). This orientation presents C-3 close (2.8-
2.9 Å) to the sulphur atom of Cys25, as would be expected for Michael addition chemistry. 
The ethyl glycinate moiety is pointing toward the S2 pocket, although it does not reach this 
binding site. 
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Figure 3.16 Gold-generated active site interaction of papain with 3.1b (magenta). Figure generated using 
Pymol software.26  The molecular modelling calculations were performed by Dr. Rita C. Guedes (from the 
Faculty of Pharmacy, University of Lisbon). 
 
 
The suggestion that the ability of the inhibitor to fit in the active site of papain may be 
much more important than the intrinsic electrophilicity of the naphthoquinone is further 
supported by the comparison of the kinetic parameters for the glycine derivatives, for which 
the halo compounds 3.2b and 3.3b are weaker inhibitors than the non-halo counterpart 3.1b 
(largely, though not exclusively, due to an increase in the KI value). These observations also 
suggest that substitution both at C-2 and C-3 positions of the naphthoquinone core may be 
detrimental to inhibitory activity. In fact, a similar situation seems to occur in the case of the 
methylamino bromo derivative 3.2c which, in contrast to 2-bromo-1,4-naphthoquinone 3.6, 
did not exhibit saturation kinetics. 
Analysing both inhibition kinetic parameters and LUMO energy values (Table 3.3) led to 
the interesting finding that for compounds 3.1b, 3.2b, 3.3b, 3.5 and 3.6 a trend exists in which 
kinact increase as the corresponding LUMO energies decrease, suggesting that the chemical 
inactivation step of papain might be a function of the LUMO energy of the inhibitor. Even so, 
as kinact values vary only 7-fold (3.6 versus 3.1d), whereas KI values vary ∼30-fold (3.1b 
versus 3.3b), it would seem that the overall activity of the compounds toward papain is 
governed to a large extent by the molecular recognition of the inhibitor prior to the 
irreversible reaction step. Indeed, it was not possible to establish any correlation between the 
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apparent second-order rate constants, k2, and LUMO energies, indicating that inhibitory 
activity does not parallel chemical reactivity. 
 
 
Papain-inhibitory activity of naphthoquinone, juglone and lawsone. Naphthoquinone 
3.8, juglone 3.12 and lawsone 3.19 were shown to be time-dependent inhibitors but, 
unfortunately, plotting the enzyme residual activity against incubation time presented a 
scattering of points which were poorly fitted to a pseudo-first-order kinetics (Figure 3.17), so 
their inhibitory activity was evaluated at fixed time and concentration of the inhibitor. 
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Figure 3.17 Time course of papain inactivation by juglone 3.12, at pH 7.0 at 25 ºC. The inhibitor 
concentration was 65 µM. The enzymatic activity is expressed as residual activity percentage (RA%). This 
inhibition pattern was observed for concentrations ranging from 50 to 130 µM, up to 80-min incubation. 
 
 
For compounds 3.8 and 3.12, this departure from the usual behaviour was though to be 
caused by the instability of the compounds in the reaction buffer with DTT. This hypothesis 
was formulated on the basis of two facts; first, that enzyme-inhibitor incubation mixture 
turned from pale yellow to brown, this colour change only occurring in the presence of DTT, 
and second, that these compounds have a high reactivity toward simple thiols, as reported by 
Öllinger et al.47  and further observed in the present work (Section 3.2). 
Thus, the possible interaction with DTT was further investigated by taking into account 
the contribution of the two properties used by quinones, redox versus electrophilicity. 
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As already mentioned, quinones may function as redox cyclers in the presence of DTT 
and oxygen, generating reactive oxygen species that inactivate cysteine proteases. When 
quinone is inhibiting the enzyme by this indirect mechanism, its action is prevented/reduced 
by performing the enzyme-inhibitor incubation in an antioxidant environment.138  Having this 
in mind, compound 3.12 (65 µM) was assayed keeping the incubation mixture under N2 or, 
alternatively, by adding ascorbic acid to the incubation buffer. Inhibition was not prevented or 
reduced in both experiments, excluding the possible existence of significant redox 
mechanism. 
On the other hand, when quinone is acting as an electrophile and is significantly reactive 
toward DTT, increasing the concentration of this agent should deplete the inhibitor, protecting 
the enzyme from inactivation.138  The enzyme-inhibitor incubation was therefore carried out 
in the presence of an excess of DTT (13.1 mM versus the original 1.7 mM). As expected, 
compound 3.12 (65 µM) failed to inhibit papain completely. 
These results showed that the atypical inactivation pattern found for derivatives 3.8 and 
3.12 may be ascribed to the presence of DTT that reacts with the compounds due to their 
excessively high electrophilicity. An accurate determination of inhibition kinetic parameters 
might be probably accomplished by performing the enzyme-inhibitor incubation in a medium 
free from DTT. However, this situation was not further investigated, as the efforts were 
focused on the detailed assessment of less chemical reactive compounds, such as glycine 
derivatives, more suitable for drug development. 
In the case of lawsone 3.19, the unusual pattern of inhibition was related to the instability 
of the compound in phosphate buffer pH 7.0, because the enzyme-inhibitor incubation 
mixture developed an intense orange coloration, even in the absence of DTT. Although this 
observation could result from the natural colour of the compound, it was suspicious that the 
coloration presented by the incubation mixture could be as intense as the stock solution of the 
inhibitor (almost ten times more concentrated). Taking into account the knowledge that 
lawsone and derivatives are indicators in solution (red in alkaline media and light yellow in 
acidic media),125  the colour enhancement was rationalised in terms of a change in the quinoid 
chromophore structure, due to the ionization of the hydroxyl function at C-2, whose pKa value 
is 4.10.140   
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3.3.2 Bovine spleen cathepsin B inhibition studies 
 
The naphthoquinones with highest papain-inhibitory activity were also evaluated against 
bovine spleen cathepsin B (kobs values are listed in Appendix VI). As shown in Table 3.4, 
compounds were found to be time-dependent inhibitors, with second-order rate constant k2 
values 3-20 times smaller than those for papain. The most potent inhibitor for papain, the 
glycine derivative 3.1b, was also the most active against cathepsin B. Its dissociation constant 
KI is also the lowest in the series, with a similar value to that with papain. In contrast, 2-
bromo-1,4-naphthoquinone 3.6 exhibited a linear dependence between kobs and [I] instead of 
the hyperbolic relationship observed for papain, suggesting a drastic increase in the KI value.  
The Leu-i-Am derivative 3.1d was also assayed. After 3-h incubation, it inhibited the 
enzyme by 50% at 156 µM (the maximal concentration tested against papain). The compound 
was not further investigated, as the kinetic results might be compromised by the instability of 
cathepsin after 4-h incubation (see Appendix I, Section AI.2.2). However, it should be noted 
that the same concentration of inhibitor inactivated papain ca. 3-fold times faster than 
inhibited cathepsin B. 
 
 
 
Table 3.4 LUMO energies and kinetic data for inactivation of bovine spleen cathepsin B by 
naphthoquinones. 
 
O
O
R1
R2
R3
R4  
Bovine spleen cathepsin B Compound R1 R2 R3 R4 
k2 (M−1 s−1) kinact (10−4 s−1) KI (µM) 
3.1b GlyOEt H H H 8.03 1.12 ± 0.06 14.0 ± 3.07 
3.2b GlyOEt Br H H 4.37 2.44 ± 0.24 55.9 ± 14.1 
3.5 OEt H H H 0.54 4.28 ± 0.63 797 ± 228 
3.6 Br H H H 5.65   
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3.3.3 Falcipain-2 and Plasmodium falciparum inhibition studies 
 
The indolequinone 3.22 and some of the naphthoquinones were evaluated against 
recombinant falcipain-2 and Plasmodium falciparum W2 (the tested compounds are indicated 
by an asterisk in Table 3.3). These studies were carried out by Dr. Philip J. Rosenthal’s group 
(University of California), following a reported protocol.16   
Derivative 3.3a exhibited the best IC50 value against Plasmodium falciparum (3.02 µM), 
but this effect was not associated with a favourable inactivation of falcipain-2 (IC50 >10 µM). 
Therefore, antimalarial activity is probably due to a different mechanism than inhibition of 
this enzyme, but this subject is beyond the scope of this thesis and it was not further 
investigated. 
For the remaining compounds, all IC50 values were over 10 µM (the accurate value was 
not determined beyond this concentration limit). This situation was not totally unexpected due 
to the simplicity of the 1,4-naphthoquinone derivatives and the lack of a specific sequence to 
probe the interaction with the active site of falcipain. 
It should be noted that Kapadia et al.141  reported the activity against Plasmodium 
falciparum W2 of compounds 3.8, 3.9, 3.12, 3.13 and 3.19, with IC50 values ranging from 
8.18 µM (3.8) to 72.9 µM (3.12). 
 
 
3.3.4 Porcine pancreatic elastase inhibition studies 
 
The group of derivatives assayed for activity against cathepsin B (Section 3.3.2) was also 
evaluated against porcine pancreatic elastase, a serine protease. They revealed to be inactive 
when incubated for 2 h over the same range of concentrations used against papain and 
cathepsin B. 
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4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
This thesis aimed the achievement of novel irreversible inhibitors of papain-like cysteine 
proteases. The design of the inhibitors involved the attachment of vinyl sultam or 1,4-
naphthoquinone cores to a peptide segment complementary to the target enzyme. 
Five dipeptide vinyl sultams were synthesised, but they all demonstrated weak activity 
against falcipain-2 (IC50 between 13.7 and 48.4 µM) and Plasmodium falciparum W2 (IC50 > 
7.8 µM), although selectivity for falcipain-2 over papain was demonstrated (compounds lack 
papain-inhibitory activity). Docking studies suggested that the binding mode of vinyl sultams 
to cysteine proteases (cruzain and papain) does not favour the inhibition reaction, i.e. the 
conjugate addition of Cys25 to the vinyl sultam system. 
Therefore, the vinyl sultam, i.e. γ- and δ- vinyl sultams, is not a good scaffold from which 
to obtain inhibition of papain-like enzymes. 
The 1,4-naphthoquinone derivatives have been evaluated against papain and bovine spleen 
cathepsin B, exhibiting an irreversible inhibitory action in both enzymes with second-order 
rate constants, k2, ranging from 0.67 to 35.4 M−1 s−1 for papain, and from 0.54 to 8.03 M−1 s−1 
for cathepsin B. Some compounds displayed a hyperbolic dependence of the first-order 
inactivation rate constant, kobs, with the inhibitor concentration, indicative of a specific 
interaction process between enzyme and inhibitor, with KI values between 9.57 and 266 µM 
for papain, and between 14.0 and 797 µM for cathepsin B. In addition, compounds failed the 
inhibition of porcine pancreatic elastase, a serine protease, suggesting selectivity for cysteine 
proteases. 
As stated before (Section 1.3), the intrinsic chemical reactivity of quinones may be cited 
as a potential limitation to their clinical use. On the other hand, it is recognised that the 
quinone system can be structurally modified in such a way that selective targeting can be 
achieved. Atovaquone 1.18, a drug approved and commercialised for human use, is a clear 
“proof of concept” within this context.  
In connection, the present investigation found that enzyme inhibitory activity of the 1,4-
naphthoquinone derivatives does not parallel chemical reactivity toward the model thiol 
cysteine. Instead, it appears to be mainly affected by how well these inhibitors fit into the 
enzyme active site. In fact, it must be stressed that glycine derivative 3.1b (structure is 
conveniently repeated in Figure 4.1), though being one of the least reactive compounds 
toward the thiol cysteine, is one of the best papain inactivators (k2 = 35.4 M−1 s−1). A 103-fold 
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ratio between the enzymatic and non-enzymatic reactivity of naphthoquinones can be 
estimated by inferring the second-order rate constant, kcat (0.033 M−1 s−1), for the reaction of 
3.1b with cysteine at pH 7.0 (the pH value of the papain inhibition studies). This selectivity 
points toward the fundamental role of enzyme binding in the inhibition process, as 3.1b has 
the lowest KI (9.57 µM) in the series, and it is quite important considering that, under 
biological conditions, thiol species are expected to occur at high concentrations, e.g., GSH, 
promoting unspecific undesirable conjugations. 
According to this preliminary information, the 1,4-naphthoquinone scaffold appears to be 
a promising lead structure in the design of papain-like cysteine protease inhibitors. However, 
the viability of this approach is dependent on the cytotoxicity of the compounds, which could 
not be investigated due to time limitations and that should be a primary subject in the 
following steps of the project.  
The present study found a linear correlation between the chemical reactivity toward 
cysteine and LUMO energies, used as a parameter of electrophilicity. This finding strongly 
suggests that the LUMO values can be useful predictors of the chemical reactivity of another 
1,4-naphthoquinone derivatives. It is imperative to investigate if a similar relationship exists 
in a cellular context. It would be very helpful if limiting LUMO energy values could be found 
as corresponding to a safe cytotoxic profile, because the energies could be calculated in the 
design of new derivatives, anticipating the citotoxicity of future generations of compounds 
and deciding about their feasibility before synthetic work. 
Another remaining subject is the unambiguously assess of the nature of the interaction 
between papain and the 1,4-naphthoquinone derivatives using mass spectrometry, namely 
MALDI-MS of tryptic digests. As discussed in Section 3.3.1, all evidences point out to a 
covalent bonding rather than oxidation, with Cys25 being the most likely site of modification. 
Nevertheless, this should be clarified. 
Further efforts should focus on (i) the adjustment of the inherent chemical reactivity to 
biological tolerable values and (ii) on the exploitation of the specific binding requirements to 
the target enzyme. In this latter context, the design of novel inhibitors must be necessarily 
based on computer-aided structure-based techniques. As described in Section 3.3.1, docking 
of 3.1b into papain revealed that the inhibitor is pointing toward the specificity site, i.e. P2, 
although not reaching it. Therefore, modelling studies may proceed from this compound, by 
manipulating the glycinyl substituent in order to find extra binding interactions with the P2 
pocket.  
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Another approach is suggested in Figure 4.2. The general structure 4.1 encompasses a 
recognition segment, which is also an electron-withdrawing and leaving group. This strategy 
was derived from the interesting inactivation of papain by 2-bromo-1,4-naphthoquinone 3.6, 
(k2 = 33.3 M−1 s−1), in which the chemical inactivation step, assessed by kinact, plays an 
important role (it was the highest kinact in the series). Thus, it is expected that derivatives 4.1 
might lead to stronger inhibitors by increasing specificity and chemical reactivity. Whether 
this latter property will be tolerable is, at this point, unknown. 
One of the best inhibitors for papain in this thesis was the indolequinone 3.21 (structure is 
conveniently repeated in Figure 4.1), with k2 = 35.2 M−1 s−1. This compound and its analogue 
3.22 can be easily processed by derivatisation of the hydroxyl/aldehyde group. 
As papain is a good model for its family of enzymes, it may be reasoned that 3.1b, 3.21 
and 4.1 might be also starting points for other papain-like proteases. Extending the 1,4-
naphthoquinone/indolequinone “warhead” to cysteine proteases that are potential therapeutic 
targets will be the ultimate and most important goal of the research line initiated in this thesis. 
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Figure 4.1 Inhibitors 3.1b, 3.21 and 3.22. 
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Figure 4.2 Proposed structure for inhibitor development. 
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5. EXPERIMENTAL SECTION 
 
5.1 Synthesis 
 
5.1.1 Reagents and Solvents 
 
Reagent grade chemicals were bought from Sigma-Aldrich and Merck (solvents). The 
amines were dried over potassium hydroxide and distilled under reduced pressure, with the 
exception of TEA and pyridine, which were distilled under atmospheric pressure. DMSO, 
DCM and MeOH were dried by distillation from calcium hydride. THF was dried by 
distillation from sodium-benzophenone. Isopropanol was dried by distillation from Mg/I2.108  
The remaining compounds were used without further purification.  
 
 
5.1.2 Chromatography 
 
Column chromatography was performed with silica gel (Merck, 230-400 mesh ASTM). 
Preparative TLC was performed on silica gel GF254 (Merck 1.07730). TLC was performed on 
pre-coated silica gel 60 F254 (Merck) and visualized under UV light or by exposure to iodine 
vapour. All the reactions were monitored by TLC unless otherwise stated.  
 
 
5.1.3 Equipment 
 
Melting points were determined using a Kofler camera Bock Monoscope M and are 
uncorrected. The IR spectra were determined using thin films on NaCl plates or preparing 
KBr pellets on a Nicolet Impact 400 FTIR spectrophotometer and only the most significant 
absorption bands are reported. Low-resolution mass spectra were recorded using a VG 
Quattro LCMS instruments. GC-MS spectra were performed on a Hewlett Packard 5890 
Series II with a 5970 Series mass detector. Optical rotations were obtained using a Perkin 
Elmer 241 polarimeter, using a 1 dm length cuvette (concentration is expressed in g/100 mL). 
Elemental analyses were performed using an EA 1110 CE Instruments automatic analyser. 
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HR-ESI-MS were recorded on an ESI-TOF spectrometer (Biotof II Model, Brucker). NMR 
spectra were recorded on a Bruker Avance 400 NMR spectrometer (1H 400 MHz; 13C 100.61 
MHz), on a Jeol JNM-300 (1H 300 MHz; 13C 75 MHz) or on a Jeol JNM-60 (1H 60 MHz). 1H 
and 13C chemical shifts, δ, are expressed in ppm (parts per million) and are relative to the 
corresponding resonance of tetramethylsilane. Coupling constants (J) are reported in hertz 
(Hz).  
 
 
5.1.4 Experimental procedures and product characterisation 
 
5.1.4.1 N-Phenyl-β-sultam 
 
N-Phenylethenesulfonamide (2.46a) and 2-chloro-N-phenylethanesulfonamide (2.48) 
2-Chloroethanesulfonyl chloride 2.20a (3.2 mL; 30.7 mmol) diluted with DCM (5 mL) was 
added slowly to a solution of aniline (2.8 mL; 30.7 mmol) in DCM (100 mL) with TEA (4.3 
mL; 30.7 mmol), at −10 ºC. The reaction mixture was vigorously shaken between the 
additions of 2-chloroethanesulfonyl chloride. At this point, the formation of a white 
precipitate (TEA salt) was observed. Stirring at −10 ºC was continued for a further 20 min, 
after which the reaction medium was extracted with 2M-sodium hydroxide (2×100 mL). The 
aqueous layer became turbid after acidification with conc. hydrochloric acid; it was then 
extracted with DCM (4×50 mL). The organic layer was washed with water (100 mL) and 
dried with anhydrous magnesium sulfate. The solvent was removed to afford 3.6 g (65%) of 
2.46a.  
Alternatively, a mixture of aniline (1.1 mL; 12.3 mmol) and 2-chloroethanesulfonyl chloride 
2.20a (0.64 mL; 6.1 mmol), in toluene (20 mL), was stirred for 24 h at rt. The reaction 
medium was washed with hydrochloric acid 5% (w/v) and water, then it was submitted to a 
column chromatography on silica gel (n-hexane/DCM 1:4→0:1) to afford compounds 2.46a 
(412 mg; 37%) and 2.48 (46 mg; 3%). 
2.46a; yellow oil; IR (film): νmax = 3265 (NH), 1598, 1495, 1411, 1340 (S=O), 1150 (S=O), 
925, 753, 695, 665 cm−1. δ 1H NMR (300 MHz, CDCl3): 5.94 (dd, 1H, J = 0.4, 9.7, Hb), 6.27 
(dd, 1H, J = 0.4, 16.5, Ha), 6.54 (dd, 1H, J = 9.7, 16.5, Hc), 7.21−7.41 (m, 6H, Ph and NH). δ 
13C NMR (75 MHz, CDCl3): 121.2 (CH), 125.6 (CH), 128.6 (CH2=), 129.6 (CH), 135.2 
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(=CH), 136.3 (C). Carbon signal assignments were made using HMQC and DEPT techniques. 
ESI-MS m/z (rel. int.) 201 (MNH4+) (56). 
2.48; yellow oil; IR (film): νmax = 3268 (NH), 1599, 1494, 1412, 1344 (S=O), 1153 (S=O), 
930, 753, 695, 663 cm−1. δ 1H NMR (300 MHz, CDCl3): 3.48 (t, 2H, J = 7.0, CH2SO2), 3.86 
(t, 2H, J = 7.0, CH2Cl), 7.20−7.37 (m, 6H, Ph and NH). δ 13C NMR (75 MHz, CDCl3): 36.7 
(CH2SO2), 52.7 (CH2Cl), 121.2 (CH), 125.9 (CH), 129.8 (CH), 135.9 (C). ESI-MS m/z (rel. 
int.) 242 (MNa+) (95).  
 
N-Phenyl-2-hydroxyethanesulfonamide (2.25a) 
Compound 2.46a (1.0 g; 5.4 mmol) was added to a solution of sodium hydroxide (1.3 g; 32.5 
mmol) in water (25 mL). The resultant yellow suspension was refluxed for 3 days, during 
which time the mixture turned white milky. Then, it was acidified with conc. hydrochloric 
acid and extracted with DCM (3×40 mL). The organic layer was washed (100 mL) with 
water, dried with anhydrous magnesium sulfate and evaporated to yield a yellow oil (487 mg), 
which gave 2.25a (422 mg) by column chromatography on silica gel (50 g) using a gradient 
of DCM/EtOAc (1:0→7:3). 
2.25a; yellow oil (39%); IR (film): νmax = 3505 (OH), 3263 (NH), 1598, 1493, 1416, 1334 
(S=O), 1143 (S=O), 926, 755, 695 cm−1. δ 1H NMR (300 MHz, CDCl3): 2.05 (brs, 1H, OH), 
3.26 (t, 2H, J = 5.2, CH2SO2), 4.07 (t, 2H, J = 5.2, CH2OH), 6.82 (brs, 1H, NH), 7.14−7.34 
(m, 6H, Ph e NH). δ 13C NMR (75 MHz, CDCl3): 52.4 (CH2SO2), 57.4 (CH2OH), 121.7 (CH), 
125.8 (CH), 129.7 (CH), 136.6 (C). The 1H NMR spectrum is consistent with the one 
published.67  Carbon signal assignments were based on the chemical shift and on DEPT 
techniques. ESI-MS m/z (rel. int.) 219 (MNH4+) (100). 
 
N-Phenyl-2-hydroxyethanesulfonamide Mesylate (2.8a) 
The reaction was carried out under N2. Mesyl chloride (0.58 mL; 7.5 mmol) was added to a 
solution of 2.25a (1.0 g; 5.0 mmol) in dry DCM (25 mL) with TEA (1.0 mL; 7.5 mmol), at 0 
ºC. After 30 min of stirring, at 0 ºC, the reaction mixture was washed with 20 mL of 
hydrochloric acid 5% (w/v), of saturated sodium chloride solution and of water. Then, it was 
dried with anhydrous magnesium sulfate and the solvent was evaporated to afford a yellowish 
solid (1.2 g). Compound 2.8a (644 mg) was purified by washing crude product with cold 
chloroform. 
2.8a; white crystals (46%); m.p. 101-103 ºC, lit.67  94-95 ºC; IR (film): νmax = 3274 (NH), 
1598, 1493, 1347 (S=O), 1173 and 1149 (S=O), 990, 964, 797, 756 cm−1. δ 1H NMR (300 
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MHz, CD3CN): 3.01 (s, 3H, CH3SO2O), 3.47 (t, 2H, J = 5.8, CH2SO2), 4.49 (t, 2H, J = 5.8, 
MsOCH2), 7.16−7.39 (m, 5H, Ph), 7.72 (brs, 1H, NH). δ 13C NMR (75 MHz, CD3CN): 37.9 
(CH3SO2O), 51.1 (CH2SO2), 65.2 (MsOCH2), 122.1 (CH), 126.3 (CH), 130.8 (CH), 138.4 
(C). The 1H NMR spectrum is consistent with the one published.67  Carbon signal assignments 
were based on the chemical shift and on DEPT techniques. ESI-MS m/z (rel. int.) 297 
(MNH4+) (100). 
 
2-Phenyl-1,2-thiazetidine 1,1-dioxide (2.5a) 
To a solution of 2.8a (122 mg; 0.4 mmol) in dry DMSO (20 mL) was added ground sodium 
carbonate (140 mg; 1.3 mmol). The mixture was stirred at 60 ºC for 1 h under N2, after which 
it was diluted with water and extracted with DCM (4×20 mL) and EtOAc (2×20 mL). The 
organic layers were washed with water (2×20 mL), combined, dried with anhydrous 
magnesium sulfate and evaporated to give an oil (30 mg), which crystallized in a mixture of 
EtOH/water to yield 2.5a (7 mg). 
2.5a; white crystals (9%); m.p. 133-135 ºC, lit. 132 ºC,65  128-129 ºC;67  IR (film): νmax = 
1590, 1498, 1317 (S=O), 1205 and 1180 (d, S=O), 1151 (S=O), 760, 694 cm−1. δ 1H NMR 
(300 MHz, CDCl3): 3.65 (t, 2H, J = 6.6, CH2N), 4.21 (t, 2H, J = 6.6, CH2SO2), 6.84−7.30 (m, 
5H, Ph). δ 13C NMR (75 MHz, CDCl3): 33.1 (CH2N), 57.3 (CH2SO2), 115.1 (CH), 123.4 
(CH), 129.6 (CH), 138.3 (C). The 1H NMR spectrum is consistent with the one published.67  
Carbon signal assignments were based on the chemical shift and on DEPT techniques. ESI-
MS m/z (rel. int.) 201 (MNH4+) (63). 
 
N-Phenylmethanesulfonamide (2.50) 
According to Page et al.,67  mesyl chloride (4.5 mL; 58.2 mmol) was added slowly to a 
solution of aniline (10.6 mL; 116.3 mmol) in toluene (50 mL), which led to the formation of a 
white precipitate. The mixture was refluxed for 2 h and the solvent was removed to give a 
brown solid (9.0 g), which was recrystallized from a mixture of EtOH/water to give 2.50 (5.7 
g). 
2.50; white crystals (57%); m.p. 102-104 ºC, lit.67  101-102 ºC; IR (film): νmax = 3257 (NH), 
1595, 1498, 1473, 1322 (S=O), 1158 (S=O), 760, 694 cm−1. δ 1H NMR (60 MHz, CDCl3): 
3.03 (s, 3H, CH3), 7.33 (m, 6H, Ph and NH). 
This compound was initially synthesised with lower yields following two further procedures 
(Table 5.1). 
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Table 5.1 Conditions for the synthesis of N-phenylmethanesulfonamide. 
 
NH2Ph (mol eq) NaOH (mol eq) TEA (mol eq) Procedure Temperature/Reaction time Yield% 
1.5 1.1   A rt/2 h 23 
1.5 1.1   A reflux/1 h  17 
1.5 1.1   A rt/12 h  13 
1.5  1.1  B rt/3 h  40 
 
 
Procedure A was based on the literature108  and consisted in the addition of aniline and mesyl 
chloride to an aqueous solution of sodium hydroxide. The mixture was vigorously stirred 
(except for the reflux conditions), then it was washed with ethyl ether and acidified with conc. 
hydrochloric acid to afford 2.50 as a white solid, which was collected by filtration in vacuo. 
The product was recrystallized from a mixture of EtOH/water. 
In procedure B, mesyl chloride was added dropwise to a solution of aniline in DCM. After 
stirring, extraction of the reaction medium with 2M-sodium hydroxide, followed by 
acidification with conc. hydrochoric acid induced the precipitation of 2.50. After being 
collected by filtration in vacuo, the product was recrystallized from a mixture of EtOH/water. 
 
N-(Chloromethyl)-N-phenylmethanesulfonamide (2.49a) 
A mixture of N-phenylmethanesulfonamide 2.50 (466 mg; 2.7 mmol), paraformaldehyde (150 
mg) and chlorotrimethylsilane (10.5 mL; 83.0 mmol) in DCM (5 mL) was refluxed for 21 h, 
after which the solution was no longer cloudy. DCM and chlorotrimethylsilane were 
evaporated to afford compounds 2.49a and 2.50 as a 4:1 mixture (584 mg). The reaction was 
monitored at 5 h and 21 h using aliquots (1 mL) from the reaction medium which were 
evaporated, analysed by 1H NMR and put back into the reaction mixture. 
2.49a; white amorphous solid (81%); δ 1H NMR (60 MHz, CDCl3): 3.02 (s, CH3 of 2.50), 
3.14 (s, 3H, CH3SO2), 5.74 (s, 2H, CH2Cl), 7.52−7.64 (m, 5H, Ph). 
 
Preparation of LDA (employed in the reactions described in Table 2.1, Chapter 2) 
Preparation of LDA was carried out under N2 at 0 ºC. In a typical experimental procedure, a 
1.6 M solution of n-BuLi in n-hexane (1.6 mmol) was added to a solution of diisopropylamine 
(0.2 mL; 1.6 mmol) in dry THF (3 mL) and stirred for 15 min.67  
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5.1.4.2 N-Benzyl-β-sultam 
 
N-Benzylethenesulfonamide (2.46b) 
2.46b (1.4 g) was prepared from benzylamine (1.3 mL; 12.3 mmol) using the method 
described earlier for 2.46a. 
2.46b; pale oil (58%); IR (film): νmax = 3287 (NH), 1496, 1454, 1425, 1327 (S=O), 1148 
(S=O), 971, 841, 739, 699 cm−1. δ 1H NMR (300 MHz, CDCl3): 4.16 (brd, 2H, J = 1.9, 
CH2Ph), 4.54 (brs, 1H, NH), 5.86 (brd, 1H, J = 9.7, Hb), 6.20 (dd, 1H, J = 0.9, 16.5, Ha), 6.42 
(dd, 1H, J = 9.7, 16.5, Hc), 7.24−7.29 (m, 5H, Ph). δ 13C NMR (75 MHz, CDCl3): 47.3 
(CH2Ph), 126.8 (CH2=), 127.9 (CH), 128.1 (CH), 128.8 (CH), 136.0 (=CH), 136.4 (C). ESI-
MS m/z (rel. int.) 215 (MNH4+) (98). 
 
N-Benzyl-2-hydroxyethanesulfonamide (2.25b) 
2.25b (115 mg) was prepared from 2.46b (293 mg; 1.5 mmol) using the method described 
earlier for 2.25a. Reaction time: 3 h. Purification by column chromatography on silica gel 
using a gradient of DCM/EtOAc (1:0→3:2). 
2.25b; white crystals (36%); m.p. 60-62 ºC; IR (film): νmax = 3452−3305 (br, OH and NH), 
1429, 1322 and 1298 (d, S=O), 1136 (S=O), 846, 736, 699 cm−1. δ 1H NMR (300 MHz, 
CDCl3): 2.37 (t, 1H, J = 5.7, OH), 3.11 (t, 2H, J = 5.3, CH2SO2), 3.96 (q, 2H, J = 5.5, 
CH2OH), 4.26 (d, 2H, J = 6.1, CH2Ph), 4.69 (brs, 1H, NH), 7.27−7.30 (m, 5H, Ph). δ 13C 
NMR (75 MHz, CDCl3): 47.4 (CH2SO2), 54.7 (CH2OH), 57.4 (CH2Ph), 128.1 (CH), 128.3 
(CH), 129.0 (CH), 136.6 (C). ESI-MS m/z (rel. int.) 233 (MNH4+) (100). 
 
N-Benzyl-2-hydroxyethanesulfonamide Mesylate (2.8b) 
2.8b was prepared from 2.25b (449 mg; 2.1 mmol) using the method described earlier for 
2.8a. Reaction time: 30 min. Crude product (548 mg) was washed with cold chloroform to 
give pure 2.8b (127 mg). 
2.8b; white crystals (21%); m.p. 88-89 ºC; IR (film): νmax = 3240 (NH), 1453, 1433, 1345 and 
1310 (d, S=O), 1170 and 1135 (d, S=O), 804, 732, 696 cm−1. δ 1H NMR (300 MHz, CD3CN): 
3.06 (s, 3H, CH3SO2O), 3.31 (t, 2H, J = 6.0, CH2SO2), 4.25 (d, 2H, J = 6.2, CH2Ph), 4.48 (t, 
2H, J = 6.0, MsOCH2), 5.83 (brs, 1H, NH), 7.37−7.38 (m, 5H, Ph). δ 13C NMR (75 MHz, 
CD3CN): 37.8 (CH3SO2O), 47.6 (CH2SO2), 52.2 (CH2Ph), 65.4 (MsOCH2), 128.7 (CH), 
129.0 (CH), 129.7 (CH), 138.9 (C). ESI-MS m/z (rel. int.) 311 (MNH4+) (100). 
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2-(Benzylamino)ethanesulfonic acid (2.15b) 
A mixture of finely ground sodium 2-chloroethanesulfonate 2.17a (1.0 g; 5.3 mmol) and 
benzylamine (2.3 mL; 20.0 mmol) was stirred at 100 ºC for 2 h. During this time, the 
sulfonate was gradually dissolved in benzylamine and a green color started to develop. The 
amine was removed under reduced pressure to afford a white solid (1.0 g), which was 
crystallized from a mixture of EtOH/water65  to give 2.15b (450 mg). 
2.15b; white solid (39%); m.p. 220-222 ºC, lit.65  225 ºC; IR (KBr): νmax = 3445 (NH), 1600, 
1450, 1420, 1251, 1130, 935, 870, 790, 755, 740 cm−1. 1H NMR (300 MHz, d6-DMSO): 2.81 
(t, 2H, J = 7.0, CH2N), 3.12 (t, 2H, J = 7.0, CH2SO3), 4.14 (s, 2H, CH2Ph), 7.36−7.49 (m, 5H, 
Ph). The 1H NMR spectrum is in agreement with that reported in the literature.65  
 
2-Chloroethanesulfonyl fluoride (2.20b) 
A solution of 2-chloroethanesulfonyl chloride 2.20a (0.9 mL; 8.6 mmol) in dioxane (8 mL) 
was added dropwise to a solution of potassium fluoride (1.0 g; 17.2 mmol) in water (10 mL). 
After stirring for 2 h, at rt, the reaction medium was diluted with water (25 mL) and extracted 
with ethyl ether (2×25 mL). The organic layer was washed with water, dried with anhydrous 
magnesium sulfate, evaporated and distilled under reduced pressure (39 mm Hg) to give 
2.20b (0.6 g). This product is eye irritant. 
2.20b; yellow liquid (48%); b.p. 100 ºC (39 mmHg), lit.79  93 ºC (52 mmHg), 72-73 ºC (18.5 
mmHg); IR (film): νmax = 1411 (S=O), 1197 (S=O) cm−1. δ 1H NMR (60 MHz, CDCl3): 3.62-
3.88 (m). GC-MS m/z (rel. int.) 146 (M+) (40), 63 (ClCH2CH2+) (70), 27 (CH2CH+) (100). 
 
 
5.1.4.3 γ-Sultams core 
 
2-Phenylisothiazolidine 1,1-dioxide (2.27a) 
A mixture of aniline (2.5 mL; 27.0 mmol), TEA (3.8 mL; 27.0 mmol) and 3-
chloropropanesulfonyl chloride 2.41a (3.4 mL; 27.0 mmol) in DCM (40 mL) was refluxed for 
1 h. Then, it was washed with 30 mL of hydrochloric acid 5% (w/v) and of saturated sodium 
chloride solution, dried with anhydrous magnesium sulfate and evaporated to afford 3-chloro-
N-phenylpropane-1-sulfonamide 2.39a (5.2 g; 22.4 mmol). This product was subsequently 
refluxed for 90 min with a solution of sodium hydroxide (0.9 g; 22.4 mmol) and TEA (3.1 
mL; 22.4 mmol) in MeOH (28 mL). The solvent was evaporated and the mixture was 
redissolved in DCM (150 mL), after which it was washed with 100 mL of hydrochloric acid 
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5% (w/v), of 2M-sodium hydroxide and of water. The organic solution was dried with 
anhydrous magnesium sulfate and evaporated to afford 2.27a (2.6 g) as a white amorphous 
solid which was purified by column chromatography on silica gel using ethyl ether and a 
mixture of ethyl ether/EtOAc (1:1) as eluents. Alternatively, purification was achieved by 
recrystallization from a mixture of MeOH/water.83  
2.39a; yellow oil; IR (film): νmax = 3266 (NH), 1599, 1494, 1341 (br, S=O), 1151 (S=O), 925, 
754, 695 cm−1. δ 1H NMR (300 MHz, CDCl3): 2.30 (tt, 2H, J = 6.1, 7.5, CH2CH2CH2), 3.29 
(t, 2H, J = 7.5, CH2SO2), 3.65 (t, 2H, J = 6.1, CH2Cl), 6.55 (brs, 1H, NH), 7.34−7.51 (m, 5H, 
Ph). δ 13C NMR (75 MHz, CDCl3): 26.8 (CH2CH2CH2), 42.6 (CH2SO2), 49.1 (CH2Cl), 120.9 
(CH), 125.6 (CH), 129.8 (CH), 136.4 (C). ESI-MS m/z (rel. int.) 251 (MNH4+) (46), 253 
(MNH4++2) (18). 
2.27a; white amorphous solid (49%, 2 steps) or white crystals (MeOH/water); m.p. 125-127 
ºC, lit. 119-120 ºC83  (MeOH/water), 120-121 ºC85  (acetone); IR (film): νmax = 1597, 1498, 
1452, 1310, 1291, 1138 (S=O), 908, 765, 736, 694 cm−1. δ 1H NMR (300 MHz, CDCl3): 2.52 
(tt, 2H, J = 6.6, 7.5, CH2CH2CH2), 3.37 (t, 2H, J = 7.5, CH2N), 3.77 (t, 2H, J = 6.6, CH2SO2), 
7.12−7.40 (m, 5H, Ph). δ 13C NMR (75 MHz, CDCl3): 18.8 (CH2CH2CH2), 46.7 (CH2N), 48.3 
(CH2SO2), 119.4 (CH), 124.5 (CH), 129.3 (CH), 137.6 (C). 1H and 13C NMR signal 
assignments were based on the chemical shift and on the splitting pattern. 1H NMR spectrum 
of 2.27a showed to be in agreement with the one reported.84  ESI-MS m/z (rel. int.) 215 
(MNH4+) (100). 
 
2-Benzylisothiazolidine 1,1-dioxide (2.27b) 
Benzylamine (7.9 mL; 72.6 mmol) was added slowly to a solution of 3-chloropropanesulfonyl 
chloride 2.41a (4.5 mL; 36.3 mmol) in DCM (150 mL), at −10 ºC. The reaction mixture was 
vigorously shaken between the additions of benzylamine. A white precipitate (benzylamine 
salt) was observed. The mixture was stirred for another 60 min, at −10 ºC, after which it was 
washed with 100 mL of hydrochloric acid 5% (w/v), of saturated sodium chloride solution 
and of water, dried with anhydrous magnesium sulfate and evaporated to give 3-chloro-N-
benzylpropane-1-sulfonamide 2.39b (8.1 g; 32.8 mmol). This product was subsequently 
treated as described for 2.39a (reaction time: 30 min) and submitted to the same extractive 
work-up to afford 2.27b (6.0 g). 
2.39b; white amorphous solid; IR (film): νmax = 3228 (NH), 1452, 1435, 1295 (br), 1131 
(S=O), 767, 731, 695 cm−1. δ 1H NMR (300 MHz, CDCl3): 2.23 (tt, 2H, J = 6.2, 7.4, 
CH2CH2CH2), 3.10 (t, 2H, J = 7.4, CH2SO2), 3.61 (t, 2H, J = 6.2, CH2Cl), 4.32 (d, 2H, J = 
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6.1, CH2Ph), 4.59 (brs, 1H, NH), 7.32−7.39 (m, 5H, Ph). δ 13C NMR (75 MHz, CDCl3): 27.0 
(CH2CH2CH2), 42.9 (CH2SO2), 47.4 (CH2Cl), 50.7 (CH2Ph), 128.1 (CH), 128.4 (CH), 129.1 
(CH), 136.7 (C). ESI-MS m/z (rel. int.) 266 (MNH4+) (46). 
2.27b; yellow oil (79%, 2 steps); IR (film): νmax = 1604, 1496, 1453, 1361, 1303 (br), 1139 
(S=O), 959, 770, 737, 706 cm−1. δ 1H NMR (300 MHz, CDCl3): 2.29 (tt, 2H, J = 6.8, 7.7, 
CH2CH2CH2), 3.10 (t, 2H, J = 6.8, CH2N), 3.19 (t, 2H, J = 7.7, CH2SO2), 4.16 (s, 2H, 
CH2Ph), 7.58−7.60 (m, 5H, Ph). δ 13C NMR (75 MHz, CDCl3): 18.5 (CH2CH2CH2), 45.9 
(CH2N), 46.5 (CH2SO2), 48.2 (CH2Ph), 128.1 (CH), 128.7 (CH), 128.8 (CH), 135.7 (C). 
Carbon signal assignments of 2.27b were confirmed by HMQC techniques. 1H and 13C NMR 
spectra of 2.27b showed to be in agreement with those reported.97  The ESI-MS m/z (rel. int.) 
229 (MNH4+) (100). 
 
 
5.1.4.4 δ-Sultams core 
 
2-Phenyl-1,2-thiazinane 1,1-dioxide (2.28b) 
1,4-Butane sultone 2.36 (3.0 mL; 29.4 mmol) and aniline (4.0 mL; 44.1 mmol) were heated at 
100 ºC, under agitation, until the formation of a glassy solid (approximately 30 min). This 
product was refluxed for 90 min with phosphorus oxychloride (74 mL; 793.8 mmol), 
whereupon it was gradually dissolved. The remaining phosphorus oxychloride was 
evaporated under reduced pressure to give a brown oil (12.9 g), which was suspended in 
EtOAc (300 mL). Sodium carbonate (11 g; 104 mmol) was added and the mixture was stirred 
at rt for 1 h, after which it was filtered and evaporated to afford 2.28b as a brown solid (8.0 
g). The compound (2.6 g) was purified by column chromatography on silica gel (80 g) using 
DCM (1 L) as eluent.  
In a separate run, the reaction mixture was filtered, washed with hydrochloric acid 5% (w/v) 
and water, dried and evaporated. Purification was achieved by recrystallization from 
MeOH,83  but the process required several charcoal treatments. 
2.28b; white amorphous solid (43%, 3 steps) or white crystals (MeOH); m.p. 115-116 ºC, 
lit.83  109-110 ºC; IR (film): νmax = 1595, 1492, 1449, 1325, 1294, 1138 (S=O), 884, 767, 743, 
697 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.91 (tt, 2H, J = 5.4, 6.4, CH2CH2N), 2.33 (tt, 2H, J 
= 5.4, 5.6, CH2CH2SO2), 3.21 (t, 2H, J = 6.4, CH2N), 3.74 (t, 2H, J = 5.6, CH2SO2), 
7.28−7.39 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 24.5 (CH2CH2N), 24.9 
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(CH2CH2SO2), 51.0 (CH2N), 53.8 (CH2SO2), 127.3 (CH), 127.7 (CH), 129.4 (CH), 140.8 (C). 
1H and 13C NMR signal assignments were based on the chemical shift and on the splitting 
pattern. ESI-MS m/z (rel. int.) 229 (MNH4+) (100). 
 
 
2-Benzyl-1,2-thiazinane 1,1-dioxide (2.28c) 
 
• By cyclisation of 4-(benzylamino)butanesulfonyl chloride hydrochloride 2.30b:  
2.28c (4.4 g) was prepared from benzylamine (7.2 mL; 66 mmol) using the method described 
erlier for 2.28b. Purification was carried out by column chromatography on silica gel using 
DCM as eluent. Alternatively, the compound was purified by recrystallization from MeOH. 
2.28c; yellow oil (44%, 3 steps) or white crystals (MeOH); m.p. 74-76 ºC, lit.89  74 ºC; IR 
(film): νmax = 1495, 1454, 1327, 1292, 1139 (S=O), 896, 767, 744, 704 cm−1. δ 1H NMR (400 
MHz, CDCl3): 1.59−1.64 (m, 2H, CH2CH2N), 2.22 (tt, 2H, J = 5.6, 6.4, CH2CH2SO2), 3.10 (t, 
2H, J = 6.4, CH2N), 3.22 (t, 2H, J = 5.6, CH2SO2), 4.31 (s, 2H, CH2Ph), 7.35−7.36 (m, 5H, 
Ph). δ 13C NMR (100.61 MHz, CDCl3): 22.0 (CH2CH2N), 24.3 (CH2CH2SO2), 48.6 (CH2N), 
49.1 (CH2SO2), 50.3 (CH2Ph), 128.1 (CH), 128.8 (CH), 128.9 (CH), 136.3 (C). 1H and 13C 
NMR signal assignments were based on the chemical shift and on the splitting pattern. 1H 
NMR spectrum was in agreement with the one reported.90  ESI-MS m/z (rel. int.) 226 (MH+) 
(85). 
 
• By cyclisation of 4-bromo-N-benzylbutanesulfonamide 2.40a:  
Step 1) To a solution of 1,4-butane sultone 2.36 (0.75 mL; 7.3 mmol) in MeOH (10 mL) was 
added potassium bromide (996 mg; 8.4 mmol). The resultant suspension was refluxed for 48 
h, after which time a precipitate was still present. The solvent was evaporated and the residue, 
4-bromobutane-1-sulfonate 2.38a (1.7 g), was washed with n-hexane to remove the remaining 
1,4-butane sultone 2.36. 
Step 2) 4-Bromobutane-1-sulfonate 2.38a (1.7 g; 6.8 mmol) was triturated (3-4 min) with 
finely ground phosphorus pentachloride (1.6 g; 7.8 mmol). During this process, bubbling was 
observed and an orange coloration developed. The mixture was diluted with chloroform (25 
mL) and it was triturated for a further 15 min. Ethyl ether (50 mL) was added to precipitate 
the remaining phosphorus pentachloride. The medium was filtrated and evaporated to give 4-
bromobutane-1-sulfonyl chloride 2.42a (1.0 g), which was immediately used in the following 
step. 
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Step 3) A solution of 4-bromobutane-1-sulfonyl chloride 2.42a freshly prepared (1.0 g; 4.6 
mmol) in DCM (5 mL) was slowly added to a solution of benzylamine (1.0 mL; 9.2 mmol) in 
DCM (40 mL), at −10 ºC. The reaction mixture was vigorously shaken between the additions 
of 2.42a, with formation of a white precipitate (benzylamine salt). Stirring at −10 ºC was 
continued for a further 60 min, after which the medium was washed with 50 mL of 
hydrochloric acid 5% (w/v) and of water, dried over anhydrous magnesium sulfate and 
evaporated to yield 4-bromo-N-benzylbutanesulfonamide 2.40a (609 mg). 
Step 4) 4-Bromo-N-benzylbutanesulfonamide 2.40a (609 mg; 2.0 mmol) was refluxed for 1 h 
with a solution of sodium hydroxide (80 mg; 2.0 mmol) and TEA (0.3 mL; 2.0 mmol) in 
MeOH (20 mL). The solvent was evaporated to give 2-benzyl-1,2-thiazinane 1,1-dioxide 
2.28c (288 mg). No further work-up was performed. 
2.38a; white amorphous solid; IR (KBr): νmax = 1351, 1198, 1172, 1058 cm−1. 
2.42a; yellow liquid; IR (film): νmax = 1380, 1170 cm−1. δ 1H NMR (60 MHz, CDCl3)
c: 1.73-2.10 (m), 2.13-2.50 (m), 3.17-3.63 (m).  
2.40a; yellow oil; IR (film): 3303 (NH), 1452, 1350 (S=O), 1168 and 1148 (S=O), 910, 828, 
782, 704 cm−1. δ 1H NMR (300 MHz, CDCl3)c: 1.40-1.90 (m), 1.93-2.43 (m), 2.80-3.23 (m), 
4.12 (d, J = 6.0, CH2Ph), 7.00-7.10 (m, Ph). ESI-MS m/z (rel. int.) 307 (MH+) (82), 309 
(MH++2) (100). 
2.28c; yellow oil (18%, crude yield, 4 steps); IR (film): νmax = 1454, 1329, 1293, 1139 (S=O), 
896, 766, 710 cm−1. δ 1H NMR (300 MHz, CDCl3)c: 1.63-1.97 (m), 2.07-2.50 (m), 3.10-3.33 
(m), 4.33 (s, CH2Ph), 7.33-7.35 (m, Ph). ESI-MS m/z (rel. int.) 226 (MH+) (100). 
 
 
5.1.4.5 Aminoacid and dipeptide aldehydes 
 
N-tert-Butoxycarbonyl-S-phenylalanylglycine ethyl ester (2.62a) 
To a solution of N-Boc-S-phenylalanine-N-hydroxysuccinimide ester (1.0 g; 2.8 mmol) in dry 
THF (14 mL) was added glycine ethyl ester hydrochloride (390 mg; 2.8 mmol) and TEA (0.4 
mL; 2.8 mmol). The resultant suspension was stirred at rt for 38 h, then it was filtered in 
vacuo and evaporated. The resultant residue (1.4 g) was submitted to column chromatography 
on silica gel (40 g), using EtOAc as eluent (0.15 mL), to afford 2.62a (860 mg). 
                                                 
c Impure compound. Signal integral ratio was inconsistent. 
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2.62a; white crystals (89%); m.p. 90-92 ºC; IR (film): νmax = 3319 (NH), 1747 (C=O of 
COOEt), 1664 (C=O of Boc), 1530 (br), 1204 and 1172 (d, C-O), 702 cm−1. 1H NMR (400 
MHz, CDCl3): 1.27 (t, 3H, J = 7.2, OCH2CH3), 1.40 (s, 9H, CH3-Boc), 3.05 (dd, 1H, J = 6.4, 
13.8, CHHPh), 3.12 (dd, 1H, J = 6.6, 13.8, CHHPh), 3.92 (dd, 1H, J = 4.8, 18.4, CHHgli), 4.03 
(dd, 1H, J = 5.6, 18.4, CHHgli), 4.19 (q, 2H, J = 7.2, OCH2CH3)d, 4.41−4.42 (m, 1H, 
CHCH2Ph), 5.02 (brs, 1H, Boc-NH), 6.45 (t, 1H, J = 4.4, NHgli), 7.20−7.32 (m, 5H, Ph). δ 13C 
NMR (100.61 MHz, CDCl3): 14.3 (OCH2CH3), 28.3 (CH3-Boc), 38.4 (CH2Ph), 41.4 (CH2gli), 
55.7 (CHCH2Ph), 61.6 (OCH2CH3), 80.3 (C-Boc), 127.0 (CH), 128.7 (CH), 129.3 (CH), 
136.6 (C), 155.5 (CO-Boc), 169.4 (CONH), 171.5 (COOEt). 1H and 13C NMR signal 
assignments were made by comparison with those reported for the analogous N-tert-
butoxycarbonyl-R-phenylalanylglycine ethyl ester.100  ESI-MS m/z (rel. int.) 724 (M2Na+) 
(100).  
 
N-tert-Butoxycarbonyl-S-phenylalanyl-S-phenylalanine ethyl ester (2.62b) 
2.62b (1.1 g) was prepared from S-phenylalanine ethyl ester hydrochloride (634 mg; 2.8 
mmol) using the method described for 2.62a. 
2.62b; white crystals (91%); m.p. 95-97 ºC; IR (film): νmax = 3321 (NH), 1745 (C=O of 
COOEt), 1660 (C=O of Boc), 1500, 1485, 1241 (C-O), 1170 (C-O), 750, 701 cm−1. 1H NMR 
(400 MHz, CDCl3): 1.20 (t, 3H, J = 7.0, OCH2CH3), 1.40 (s, 9H, CH3-Boc), 3.00−3.09 (m, 
4H, 2×CH2Ph), 4.05−4.15 (m, 2H, OCH2CH3), 4.33−4.34 (m, 1H, CHCH2Ph), 4.75 (dd, 1H, J 
= 6.0, 12.4, CHCH2Ph), 4.95 (brs, 1H, NH), 6.31 (d, 1H, J = 6.8, NH), 6.98−7.01 (m, 2H, Ph), 
7.18−7.31 (m, 8H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 14.1 (OCH2CH3), 28.3 (CH3-Boc), 
38.0 (CH2Ph), 38.3 (CH2Ph), 53.3 (CHCH2Ph), 55.7 (CHCH2Ph), 61.5 (OCH2CH3), 80.2 (C-
Boc), 127.0 (CH), 127.1 (CH), 128.5 (CH), 128.7 (CH), 129.3 (CH), 129.4 (CH), 135.7 (C), 
136.5 (C), 155.3 (CO-Boc), 170.7 (CONH), 170.9 (COOEt). 1H NMR signal assignments 
were based on chemical shift, relative integration and on the splitting pattern. Carbon signals 
assignments were based on chemical shift. ESI-MS m/z (rel. int.) 903 (M2Na+) (100).  
 
N-tert-Butoxycarbonyl-S-phenylalanylglycine (2.63a) 
A solution of 2.62a (860 mg; 2.5 mmol) in distilled THF (12 mL) and 1M-sodium hydroxide 
(2.5 mmol) was refluxed for 25 min. Then, THF was evaporated and the aqueous residue was 
                                                 
d Co-incident peak. 
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submitted to chromatography using an HCl-activated Amberlite IR 120H ion-exchange 
column, using as eluent a mixture of EtOH/water 1:1, to yield 2.63a (710 mg). 
2.63a; white amorphous solid (90%); IR (KBr): νmax = 3357 (NH), 3267 (NH), 1716 (C=O of 
acid), 1676 (C=O), 1635 (C=O), 1575, 1445, 1244 (C-O), 1168 (C-O), 740, 702 cm−1. 1H 
NMR (400 MHz, CDCl3 + MeOD): 1.24 (s, 9H, CH3-Boc), 2.79 (m, 1H), 3.04 (m, 1H), 3.78 
(brd, 1H, J = 18.0), 3.86 (brd, 1H, J = 18.0), 4.26 (m, 1H), 7.08−7.17 (m, 5H, Ph). δ 13C NMR 
(100.61 MHz, CDCl3 + MeOD): 27.9 (CH3-Boc), 38.3 (CH2Ph), 40.9 (CH2gli), 60.2 
(CHCH2Ph), 126.6 (CH), 128.3 (CH), 129.1 (CH), 171.3 (CO). ESI-MS m/z (rel. int.) 668 
(M2Na+) (100). 
 
N-tert-Butoxycarbonyl-S-phenylalanyl-S-phenylalanine (2.63b) 
2.63b (910 mg) was prepared from 2.62b (1.1 g; 2.5 mmol) using the method described for 
2.63a. 
2.63b; white amorphous solid (88%); IR (KBr): νmax = 3396 (NH), 3353 (NH), 1734 (C=O of 
acid), 1695 (C=O), 1664 (C=O), 1539 and 1515 (d), 1448, 1249 (C-O), 1166 (C-O), 747, 698 
cm−1. 1H NMR (400 MHz, CDCl3 + MeOD): 1.34 (s, 9H, CH3-Boc), 2.83−2.89 (m, 1H), 
2.99−3.04 (m, 2H), 3.12 (brdd, 1H, J = 5.0, 13.8), 4.27−4.34 (m, 1H), 4.67−4.72 (m, 1H), 
7.06 (brd, 1H, J = 6.4, Ph), 7.13 (brd, 1H, J = 6.8, Ph), 7.19−7.25 (m, 6H, Ph). 13C NMR 
(100.61 MHz, CDCl3 + MeOD): 28.1 (CH3-Boc), 37.5 (CH2Ph), 60.4 (CHCH2Ph), 126.9 
(2×CH), 128.4 (CH), 128.5 (CH), 129.3 (CH), 129.4 (CH), 136.1 (C), 136.5 (C), 156.1 (CO-
Boc), 172.9 (CO). ESI-MS m/z (rel. int.) 848 (M2Na+) (100).  
 
 
Synthesis of hydroxamates 
 
• Using isobutyl chloroformate as coupling reagent: 
TEA (6.5 mL; 46.2 mmol) was added to a solution of N-Boc-S-phenylalanine (6.0 g; 22.6 
mmol) in DCM (150 mL) and the mixture was cooled down to −10 ºC. Isobutyl chloroformate 
(3.0 mL; 22.4 mmol) was added dropwise, followed after 30 min by O, N-
dimethylhydroxylamine hydrochloride (2.3 g; 23.4 mmol). The resultant suspension became 
clear after an overnight at rt. The medium was worked up with 100 mL of 3M-hydrochloric 
acid, of saturated sodium hydrogen carbonate solution and of saturated sodium chloride 
solution, and then it was dried with anhydrous magnesium sulfate and evaporated. The 
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resultant oil (6.0 g) was submitted to a column chromatography on silica gel (150 g), using as 
eluent a mixture of n-hexane/EtOAc 1:1 (0.8 L), to afford 2.54 (4.2 g).  
 
• Using BOP as coupling reagent: 
BOP (1.4 g; 3.0 mmol) was added to a solution of N-Boc-S-phenylalanine (800 mg; 3.0 
mmol) in DCM (10 mL) with TEA (0.4 mL; 3.0 mmol). After 5 min of stirring at rt, O, N-
dimethylhydroxylamine hydrochloride (324 mg; 3.3 mmol) and TEA (0.5 mL; 3.3 mmol) 
were added and the resultant suspension was stirred for a further 1.5 h, during which time the 
medium became clear. The reaction was diluted with DCM (50 mL), washed with 30 mL of 
3M-hydrochloric acid, of saturated sodium hydrogen carbonate solution and of saturated 
sodium chloride solution, then it was dried with anhydrous magnesium sulfate. The solvent 
was evaporated to give an yellow oil (1.2 g), which was submitted to a column 
chromatography on silica gel (40 g), using as eluent a mixture of n-hexane/EtOAc 1:1 (0.2 L), 
to afford 2.54 (716 mg).  
 
• Using TBTU as coupling reagent: 
This technique followed the procedure described for BOP, with the exception that the addition 
of TBTU resulted in a suspension that was stirred until it became clear (≈ 30 min). Only then, 
O, N-dimethylhydroxylamine hydrochloride was added. 
 
N-Methoxy-N-methyl N′-tert-butoxycarbonyl-S-phenylalanyl amide (2.54); white oil 61% 
(isobutyl chloroformate), 77% (BOP), 83% (TBTU); IR (film): νmax = 3295 (NH), 1702 
(C=O), 1655 (C=O), 1498, 1389 and 1367 (d), 1170 (C-O), 856, 750, 698 cm−1. δ 1H NMR 
(400 MHz, CDCl3): 1.41 (s, 9H, CH3-Boc), 2.89 (m, 1H, CHHPh), 3.07 (dd, 1H, J = 6.0, 13.6, 
CHHPh), 3.19 (s, 3H, NCH3), 3.67 (s, 3H, OCH3), 4.96−4.98 (m, 1H, CHCH2Ph), 5.19 (brd, 
1H, J = 8.4, NH), 7.18−7.32 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 28.3 (CH3-Boc), 
32.1 (NCH3), 38.9 (CH2Ph), 51.5 (CHCH2Ph), 61.6 (OCH3), 79.6 (C-Boc), 126.8 (CH), 128.4 
(CH), 129.5 (CH), 136.6 (C), 155.2 (CO-Boc), 172.3 (CONCH3). 1H NMR spectrum signals 
were assigned according to the literature.99  Carbon signal assignments were made using 
HMQC and DEPT techniques. ESI-MS m/z (rel. int.) 347 (MK+) (100).  
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N-Methoxy-N-methyl (N′-tert-butoxycarbonyl-S-phenylalanylglycinyl)amide (2.61a) 
2.61a (255 mg) was prepared from 2.63a (400 mg; 1.2 mmol) using TBTU-mediated 
coupling. Reaction time: 13 h. Purification by column chromatography on silica gel using a 
gradient of n-hexane/EtOAc (1:1→1:3). 
2.61a; white oil (56%); IR (film): νmax = 3317 (br, NH), 1714−1661 (br, 3×C=O), 1519 (br), 
1451, 1250 (C-O), 1171 (C-O), 740, 701 cm−1. 1H NMR (400 MHz, CDCl3): 1.36 (s, 9H, 
CH3-Boc), 2.36 (m, 1H, CHHPh), 2.97−3.03 (m, 1H, CHHPh), 3.17 (NCH3), 3.69 (OCH3), 
4.07 (brd, 1H, J = 18.0, CHHgli)e, 4.21 (dd, 1H, J = 4.4, 18.4, CHHgli), 4.46−4.48 (m, 1H, 
CHCH2Ph), 5.24 (brs, 1H, Boc-NH), 6.90 (brs, 1H, NHgli), 7.18−7.27 (m, 5H, Ph). 1H NMR 
signals were assigned by comparison with the ester 2.62a and hydroxamate 2.54. ESI-MS m/z 
(rel. int.) 753 (M2Na+) (100).  
 
N-Methoxy-N-methyl (N′-tert-butoxycarbonyl-S-phenylalanyl-S-phenylalanyl)amide 
(2.61b) 
2.61b (166 mg) was prepared from 2.63b (200 mg; 0.5 mmol) using TBTU-mediated 
coupling. Reaction time: 13 h. Purification by column chromatography on silica gel using a 
mixture of n-hexane/EtOAc. 
2.61b; pale oil (75%); IR (film): νmax = 3306 (br, NH), 1715−1651 (br, 3×C=O), 1536−1498, 
1249 (C-O), 1166 (C-O), 740, 698 cm−1. 1H NMR (400 MHz, CDCl3): 1.41 (s, 9H, CH3-Boc), 
2.91 (brdd, 2H, J = 6.8, 13.6, CH2Ph)f, 3.06 (brdd, 2H, J = 6.4, 14.0, CH2Ph)f, 3.15 (s, 3H, 
NCH3), 3.62 (s, 3H, OCH3), 4.36−4.38 (m, 1H, CHCH2Ph), 4.93−4.94 (m, 1H), 5.20−5.21 (m, 
1H), 6.53 (d, 1H, J = 8.0, NH), 7.04−7.09 (m, 2H, Ph), 7.19−7.31 (m, 8H, Ph). δ 13C NMR 
(100.61 MHz, CDCl3): 28.2 (CH3-Boc), 32.0 (NCH3), 38.4 (CH2Ph), 38.6 (CH2Ph), 50.2 
(CHCH2Ph), 55.5 (CHCH2Ph), 61.5 (OCH3), 80.0 (C-Boc), 126.9 (CH), 128.4 (CH), 128.6 
(CH), 129.4 (2×CH), 136.0 (C), 136.6 (C), 155.2 (CO-Boc), 170.6 (CONH), 171.0 
(CONCH3). 1H and 13C NMR signals were assigned by comparison with the ester 2.62b and 
hydroxamate 2.54. ESI-MS m/z (rel. int.) 479 (MNa+) (84).  
 
N-tert-Butoxycarbonyl-S-phenylalaninal (2.53) 
Lithium aluminium hydride (41 mg; 1.0 mmol) was added to a solution of 2.54 (251 mg; 0.8 
mmol) in dry THF (8 mL), at 0 ºC. The reaction was stirred at 0 ºC for 30 min, after which it 
was quenched using a solution of potassium hydrogen sulfate (194 mg; 1.4 mmol) in water (2 
                                                 
e Not well resolved signal. 
f Co-incident peak. 
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mL). Then, it was diluted with water (40 mL) and extracted with ethyl ether (3×30 mL). The 
organic layer was washed with 30 mL of 3M-hydrochloric acid, of saturated sodium hydrogen 
carbonate solution and of saturated sodium chloride solution, dried with anhydrous 
magnesium sulfate and evaporated to afford 2.53 (168 mg), sufficiently pure for the next step. 
2.53; white amorphous solid (83%); IR (film): νmax = 3354 (NH), 2816 (H-CO), 2722 (H-
CO), 1695 (br), 1506, 1451, 1251 (C-O), 1168 (C-O), 849, 743, 701 cm−1. δ 1H NMR (400 
MHz, CDCl3): 1.45 (s, 9H, CH3-Boc), 3.14 (brd, 2H, J = 6.8, CH2Ph)g, 4.45 (brdd, 1H, J = 
6.2, 13.0, CHCH2Ph), 5.07 (brs, 1H, NH), 7.19 (d, 2H, J = 7.2, Ph), 7.28 (t, 1H, J = 3.6, Ph), 
7.34 (t, 2H, J = 7.2, Ph), 9.65 (s, 1H, COH). δ 13C NMR (100.61 MHz, CDCl3): 28.3 (CH3-
Boc), 35.5 (CH2Ph), 60.8 (CHCH2Ph), 80.2 (C-Boc), 127.1 (CH), 128.8 (CH), 129.3 (CH), 
135.8 (C), 155.2 (CO-Boc), 199.4 (COH). 1H NMR spectrum signals were assigned according 
to the literature.99  Carbon signal assignments were made using HMQC and DEPT techniques. 
ESI-MS m/z (rel. int.) 499 (M2H+) (100). 
 
N-tert-Butoxycarbonyl-S-phenylalanine ethyl ester (2.59) 
TEA (3.3 mL; 24.0 mmol) was added to a suspension of S-phenylalanine ethyl ester 
hydrochloride (500 mg; 2.2 mmol) in distilled THF (10 mL). The mixture was cooled to 0 ºC 
and stirred for 20 min, after which Boc anhydride (0.5 mL; 2.4 mmol) was added dropwise. 
The reaction was stirred for a further 30 min at 0 ºC and then for additional 2 h at rt, after 
which it was acidified with conc. hydrochloric acid and extracted with DCM (3×20 mL). The 
organic layer was washed with 2×40 mL of water, dried with anhydrous magnesium sulfate 
and evaporated to give 2.59 (418 mg).  
2.59; yellow oil; (65%); IR (film): νmax = 3370 (NH), 1715 (br, 2×C=O), 1500, 1251 (C-O), 
1169 (C-O), 748, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.14 (brt, 3H, J = 7.2, 
OCH2CH3)h, 1.34 (s, 9H, CH3-Boc), 2.95−3.05 (m, 2H, CH2Ph), 4.07 (brq, 2H, J = 7.2, 
OCH2CH3)g, 4.48 (m, 1H, CHCH2Ph), 4.96 (brd, 1H, J = 7.2, NH), 7.06 (d, 2H, J = 7.2, Ph), 
7.13−7.22 (m, 3H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 14.1 (OCH2CH3), 28.3 (CH3-Boc), 
38.4 (CH2Ph), 54.5 (CHCH2Ph), 61.3 (OCH2CH3), 80.3 (C-Boc), 127.0 (CH), 128.5 (CH), 
129.4 (CH), 136.1 (C), 155.1 (CO-Boc), 172.0 (COOEt). 1H NMR signal assignments were 
based on the relative integration and on the splitting pattern. Carbon signal assignments were 
made using HMQC technique. ESI-MS m/z (rel. int.) 332 (MK+) (100). 
 
                                                 
g Co-incident peak. 
h Not well resolved signal. 
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N-tert-Butoxycarbonyl-S-phenylalaninol (2.58) 
The reaction was carried out under N2. A 1.0 M solution of DIBAL in heptane (1.0 mmol) 
was added dropwise to a solution of 2.59 (77 mg; 0.3 mmol) in dry THF (2 mL) at −78 ºC. 
The mixture was stirred 1 h, after which MeOH (0.3 mL) was added slowly, followed by a 
solution of potassium sodium (+) tartrate (3.8 g; 13.4 mmol) in water (6 mL). After being 
vigorously stirred at rt for 1.5 h, it was extracted with EtOAc (3×20 mL). The organic layer 
was washed with 40 mL of saturated aqueous solution of sodium chloride, dried with 
anhydrous magnesium sulfate and evaporated to afford 2.58 (60 mg).  
2.58; white amorphous solid (91%); IR (film): νmax = 3355 (NH and OH), 1687 (C=O), 1527, 
1444, 1269 (C-O), 1170 (C-O), 752, 738 and 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.34 
(s, 9H, CH3-Boc), 2.58 (brs, 1H, OH), 2.77 (d, 2H, J = 7.2, CH2Ph)i, 3.47 (dd, 1H, J = 5.0, 
10.6, CHHOH), 3.57−3.59 (m, 1H, CHHOH), 3.80 (brs, 1H, CHCH2Ph), 4.75 (brs, 1H, NH), 
7.13−7.25 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 28.4 (CH3-Boc), 37.4 (CH2Ph), 
53.7 (CHCH2Ph), 64.3 (CH2OH), 79.7 (C-Boc), 126.5 (CH), 128.6 (CH), 129.3 (CH), 137.8 
(C), 156.2 (CO-Boc). 1H and 13C NMR signals were assigned by comparison with analogues 
2.53, 2.54 and 2.59. ESI-MS m/z (rel. int.) 252 (MH+) (100). 
 
 
5.1.4.6 Sultam phosphonates 
 
• Typical experimental procedure: 
The reaction was carried out under N2. A 1.6 M solution of n-BuLi in n-hexane (22.6 mmol) 
was added to a solution of diisopropylamine (3.0 mL; 21.6 mmol) in dry THF (38 mL) at 0 
ºC. After 15 min, the solution was cooled to −78 ºC, followed by the addition of a solution of 
N-benzyl-δ-sultam 2.28c (4.4 g; 19.4 mmol) in dry THF (40 mL). The mixture was stirred for 
10 min, and then a solution of diethyl chlorophosphate (1.6 mL; 11.0 mmol) in dry THF (8 
mL) was added dropwise. After 1 h, the reaction medium was quenched using a saturated 
aqueous solution of sodium chloride (100 mL) and extracted with DCM (3×30 mL) and 
EtOAc (30 mL). The organic layers were washed with water, combined and dried with 
anhydrous magnesium sulfate. The solvent was evaporated to yield a crude product (3.5 g), 
which was fractionated by column chromatography on silica gel (150 g) using a gradient of 
                                                 
i Co-incident peak. 
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DCM/EtOAc (1:0→0:1) to afford phosphonate 2.66b (1.3 g; 34%). Compounds 2.65a, 2.65b 
and 2.66a were prepared using the same method from 2.27a, 2.27b and 2.28b, respectively.  
 
2-Phenyl-5-diethylphosphoryl-isothiazolidine 1,1-dioxide (2.65a); yellow oil (65%); IR 
(film): νmax = 1596, 1496, 1323 (S=O), 1261 (P=O), 1148 (S=O), 1023 and 955 (d, P-O-C), 
833, 757, 695 cm−1. δ 1H and 13C NMR see Table 2.5 in Chapter 2. ESI-MS m/z (rel. int.) 684 
(M2NH4+) (100). 
 
2-Benzyl-5-diethylphosphoryl-isothiazolidine 1,1-dioxide (2.65b); yellow oil (43%); IR 
(film): νmax = 1449, 1316 (S=O), 1260 (P=O), 1158 (S=O), 1025 and 970 (d, P-O-C), 774, 
731, 700 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.36−1.41 (m, 6H, 2×OCH2CH3), 2.47−2.66 
(m, 2H, CHCH2), 3.10 (ddd, 1H, J = 2.0, 7.5, 14.4, CHHN), 3.20 (ddd, 1H, J = 5.2, 7.5, 9.7, 
CHHN), 3.62 (ddd, 1H, J = 8.7, 8.8 and JHP = 15.7, CH), 4.22 (m, CH2Ph)j, 4.25 (m, 
OCH2CH3)j, 4.32 (m, OCH2CH3)j, 7.34−7.36 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 
16.4−16.5 (m, 2×OCH2CH3), 22.0 (d, JCP = 3.0, CHCH2), 44.8 (d, JCP = 8.0, CH2N), 49.2 
(CH2Ph), 54.5 (d, JCP = 149.9, CH), 63.4 (d, JCP = 7.0, OCH2CH3), 64.3 (d, JCP = 6.0, 
OCH2CH3), 128.0 (CH), 128.5 (CH), 128.7 (CH), 135.4 (C). ESI-MS m/z (rel. int.) 347 (M+) 
(59). 
 
2-Phenyl-5-diethylphosphoryl-1,2-thiazinane 1,1-dioxide (2.66a); yellow oil (45%); IR 
(film): νmax = 1594, 1492, 1337 (S=O), 1257 (P=O), 1152 (S=O), 1026 and 972 (d, P-O-C), 
848, 801, 763, 697 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.34−1.38 (m, 6H, 2×OCH2CH3), 
1.92−2.05 (m, 2H, CH2CH2N), 2.51−2.65 (m, 2H, CHCH2), 3.61−3.62 (m, 2H, CHHN and 
CH), 4.03 (ddd, J = 4.4, 10.4, 14.0, CHHN), 4.22 (m, OCH2CH3)k, 4.28 (m, OCH2CH3)k, 
7.25−7.38 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 16.3−16.4 (m, 2×OCH2CH3), 24.2 
(d, JCP = 9.8, CH2CH2N), 27.1 (d, JCP = 3.7, CHCH2), 53.4 (CH2N), 58.6 (d, JCP = 136.9, 
CH), 63.4 (d, JCP = 6.6, OCH2CH3), 64.0 (d, JCP = 6.9, OCH2CH3), 126.9 (CH), 127.4 (CH), 
129.2 (CH), 140.7 (C). ESI-MS m/z (rel. int.) 712 (M2NH4+) (100). 
 
2-Benzyl-5-diethylphosphoryl-1,2-thiazinane 1,1-dioxide (2.66b); yellow oil (34%); IR 
(film): νmax = 1447, 1356 (S=O), 1257 (P=O), 1156 (S=O), 1025 and 974 (d, P-O-C), 808, 
772, 727, 702 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.36−1.45 (m, 6H, 2×OCH2CH3), 
                                                 
j Overlapped signals. δ Values from HMQC spectrum. 
k Overlapped signals. δ Values from HMQC spectrum. 
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1.58−1.73 (m, 2H, CH2CH2N), 2.37−2.51 (m, 2H, CHCH2), 3.16 (ddd, 1H, J = 4.0, 4.0, 14.4, 
CHHN), 3.47 (m, CH)l, 3.50 (m, CHHN)l, 4.22−4.32 (m, 5H, 2×OCH2CH3 and CHHPh), 4.49 
(d, 1H, J = 14.4, CHHPh), 7.28−7.35 (m, 5H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 
16.3−16.4 (m, 2×OCH2CH3), 20.2 (d, JCP = 8.0, CH2CH2N), 27.0 (d, JCP = 3.0, CHCH2), 47.9 
(CH2N), 51.5 (CH2Ph), 56.5 (d, JCP = 137.8, CH), 63.3 (d, JCP = 6.0, OCH2CH3), 63.9 (d, JCP 
= 7.0, OCH2CH3), 128.0 (CH), 128.4 (CH), 128.7 (CH), 136.0 (C). ESI-MS m/z (rel. int.) 740 
(M2NH4+) (70). 
 
 
5.1.4.7 Horner-Wadsworth-Emmons reaction 
 
• Typical experimental procedure: 
All manipulations were made under N2. A 1.6 M solution of n-BuLi in n-hexane (1.2 mmol) 
was added to a solution of phosphonate 2.66b (428 mg; 1.2 mmol) in dry THF (23 mL) at −78 
ºC. The mixture was stirred for 20 min, during which time the temperature was allowed to 
gradually warm up to rt. Then, N-Boc-S-phenylalaninal 2.53 (325 mg; 1.3 mmol) in dry THF 
(6 mL) was added dropwise. After 20 min, the solvent was evaporated to afford a mixture of 
isomers 2.70a,b (863 mg), which were separated by column chromatography on silica gel (30 
g) using as eluent a mixture of n-hexane/EtOAc 1:1 (0.15 L). Isomers 2.67a,b, 2.68a,b and 
2.69a,b were prepared using the same method from 2.65a, 2.65b and 2.66a, respectively. 1H 
and 13C NMR signal assignments were possible using DEPT and 2D NMR techniques (1H-1H 
COSY, HMQC and HMBC). 
 
(E)-2-Phenyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.67a); white crystals after crystallization with 
MeOH (60%); m.p. 166−169 ºC; IR (KBr): νmax = 3379 (NH), 1688 (C=O), 1597, 1499, 1366 
(S=O), 1252 (C-O), 1156 (br), 827, 746, 694 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.43 (s, 
9H, CH3-Boc), 2.33 (m, 1H, =CCHH), 2.83 (dd, 1H, J = 8.4, 13.2, CHHPh), 2.98 (m, 1H, 
=CCHH), 3.03 (dd, 1H, J = 5.6, 13.2, CHHPh), 3.45 (ddd, 1H, J = 5.6, 8.0, 9.0, CHHN), 3.59 
(ddd, 1H, J = 5.6, 8.0, 8.8, CHHN), 4.53 (brs, 1H, CHCH2Ph), 4.71 (brs, 1H, NH), 6.31 (brd, 
1H, J = 8.8, =CH), 7.18−7.39 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 21.7 
(=CCH2), 28.4 (CH3-Boc), 41.1 (CH2Ph), 44.1 (CH2N), 50.9 (CHCH2Ph), 80.2 (C-Boc), 
                                                 
l Overlapped signals. δ Values from HMQC spectrum. 
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121.0 (CH), 125.5 (CH), 127.1 (CH), 128.7 (CH), 129.4 (CH), 129.7 (CH), 131.3 (=CH), 
136.1 (C), 137.5 (=C), 138.6 (C), 154.9 (C=O). HR-ESI-MS calcd. for C23H32N3O4S 
(MNH4+) 446.5840, found 446.2105. 
 
(Z)-2-Phenyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.67b); white amorphous solid (16%); IR (film): 
νmax = 3373 (NH), 1702 (C=O), 1596, 1498, 1366 (S=O), 1263 (C-O), 1165 (br), 753, 723, 
697 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.40 (s, 9H, CH3-Boc), 3.02−3.11 (m, 4H, CHHN, 
CHHPh and =CCH2), 3.76 (m, 2H, CHHN and CHHPh), 4.91 (m, 2H, NH and CHCH2Ph), 
6.35 (brs, 1H, =CH), 7.20−7.42 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 25.8 
(=CCH2), 28.3 (CH3-Boc), 44.7 (CH2Ph and CH2N)m, 50.8 (CHCH2Ph), 79.8 (C-Boc), 121.3 
(CH), 125.7 (CH), 126.8 (CH), 128.6 (CH), 129.5 (CH), 129.6 (CH), 134.8 (C), 135.4 (=C), 
137.2 (C), 155.1 (C=O). HR-ESI-MS calcd. for C23H32N3O4S (MNH4+) 446.5840, found 
446.2103. 
 
(E)-2-Benzyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.68a); pale oil (58%); IR (film): νmax = 3364 
(NH), 1704 (C=O), 1505, 1451, 1366 (S=O), 1247 (C-O), 1159 (br), 780, 738, 702 cm−1. δ 1H 
NMR (400 MHz, CDCl3): 1.43 (s, 9H, CH3-Boc), 2.10-2.14 (m, 1H, =CCHH), 2.83 (m, 
=CCHH)n, 2.84 (m, CHCHHPh)n, 2.85 (m, CHHN)n, 2.97 (m, CHHN)o, 3.02 (m, 
CHCHHPh)o, 4.11 (brd, 1H, J = 14.0, NCHHPh), 4.17 (brd, 1H, J = 14.0, NCHHPh), 4.48 
(m, 1H, CHCH2Ph), 4.78 (brs, 1H, NH), 6.29 (brd, 1H, J = 9.2, =CH), 7.21−7.36 (m, 10H, 
Ph). δ 13C NMR (100.61 MHz, CDCl3): 21.7 (=CCH2), 28.4 (CH3-Boc), 41.1 (CHCH2Ph), 
43.2 (CH2N), 47.9 (NCH2Ph), 51.0 (CHCH2Ph), 80.1 (C-Boc), 127.0 (CH), 128.1 (CH), 128.7 
(2×CH), 129.7 (CH), 130.9 (=CH), 134.9 (C), 136.1 (C), 138.3 (=C), 154.9 (C=O). HR-ESI-
MS calcd. for C24H30N2NaO4S (MNa+) 465.5618, found 465.1818. 
 
(Z)-2-Benzyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.68b); white crystals (29%); m.p. 138−140 ºC; IR 
(film): νmax = 3365 (NH), 1707 (C=O), 1500, 1451, 1367 (S=O), 1250 (C-O), 1164 (br), 774, 
                                                 
m Signal assignment was effected using HMQC and HMBC techniques. 
n Overlapped signals. δ Values from HMQC spectrum. 
o Overlapped signals. δ Values from HMQC spectrum. 
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736, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.43 (s, 9H, CH3-Boc), 2.83 (m, =CCHH)p, 
2.84 (m, CHCHHPh)p, 3.07 (m, =CCHH)q, 3.10 (m, CHCHHPh and CH2N)q, 4.21 (s, 2H, 
NCH2Ph), 4.96 (m, 2H, CHCH2Ph and NH), 6.26 (brs, 1H, =CH), 7.18−7.39 (m, 10H, Ph). δ 
13C NMR (100.61 MHz, CDCl3): 25.7 (=CCH2), 28.3 (CH3-Boc), 43.7 (CHCH2Ph and 
CH2N)r, 47.8 (NCH2Ph), 50.8 (CHCH2Ph), 79.6 (C-Boc), 126.8 (CH), 128.1 (CH), 128.6 
(CH), 128.7 (CH), 128.8 (CH), 129.6 (CH), 134.7 (C), 135.0 (C), 155.1 (C=O). HR-ESI-MS 
calcd. for C24H30N2NaO4S (MNa+) 465.5618, found 465.1818. 
 
(E)-2-Phenyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-propylidene]-1,2-
thiazinane 1,1-dioxide (2.69a); pale oil (65%); IR (film): νmax = 3368 (NH), 1701 (C=O), 
1595, 1499, 1450, 1339 (S=O), 1247 (C-O), 1162 (br), 854, 738, 697 cm−1. δ 1H NMR (400 
MHz, CDCl3): 1.47 (s, 9H, CH3-Boc), 1.50 (m, 1H, =CCH2CHH), 1.92 (m, 1H, =CCH2CHH), 
2.59−2.66 (m, 1H, =CCHH), 2.77 (dd, 1H, J = 8.2, 13.4, CHHPh), 2.87−2.89 (m, 1H, 
=CCHH), 3.04 (dd, 1H, J = 5.0, 13.4, CHHPh), 3.77−3.80 (m, 2H, CH2N), 4.71 (m, 2H, 
CHCH2Ph and NH), 6.24 (brd, 1H, J = 8.8, =CH), 7.20−7.35 (m, 10H, Ph). δ 13C NMR 
(100.61 MHz, CDCl3): 26.2 (=CCH2CH2), 27.1 (=CCH2), 28.4 (CH3-Boc), 41.2 (CH2Ph), 
49.0 (CHCH2Ph), 53.4 (CH2N), 80.0 (C-Boc), 126.9 (CH), 127.0 (CH), 127.2 (CH), 128.7 
(CH), 129.1 (CH), 129.5 (CH), 131.3 (=CH), 136.2 (C), 140.0 (=C), 141.2 (C), 154.9 (C=O). 
HR-ESI-MS calcd. for C24H30N2NaO4S (MNa+) 465.5618, found 465.1818. 
 
(Z)-2-Phenyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-propylidene]-1,2-
thiazinane 1,1-dioxide (2.69b); white amorphous solid (7%); IR (film): νmax = 3365 (NH), 
1702 (C=O), 1498, 1453, 1337 (S=O), 1246 (C-O), 1162 (br), 855, 749, 693 cm−1. δ 1H NMR 
(400 MHz, CDCl3): 1.41 (s, 9H, CH3-Boc), 1.95−2.07 (m, 2H, =CCH2CH2), 2.90 (m, 
=CCH2)s, 2.95 (m, CH2Ph)s, 3.85−3.98 (m, 2H, CH2N), 4.71 (brs, 1H, NH), 5.10 (brs, 1H, 
CHCH2Ph), 6.12 (brs, 1H, =CH), 7.19−7.39 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 
26.3 (=CCH2CH2), 28.3 (CH3-Boc), 35.0 (=CCH2), 40.4 (CH2Ph), 50.0 (CHCH2Ph), 53.8 
(CH2N), 79.5 (C-Boc), 126.6 (CH), 127.3 (2×CH), 128.5 (CH), 129.2 (CH), 129.5 (CH), 
136.0 (=C), 136.5 (=CH), 137.3 (C), 141.3 (C), 155.2 (C=O). HR-ESI-MS calcd. for 
C24H31N2O4S (MH+) 443.5800, found 443.1999. 
                                                 
p Overlapped signals. δ Values from HMQC spectrum. 
q Overlapped signals. δ Values from HMQC spectrum. 
r Signal assignment was effected using HMQC, 1H-1H COSY and HMBC techniques. 
s Overlapped signals. δ Values from HMQC spectrum. 
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(E)-2-Benzyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-propylidene]-1,2-
thiazinane 1,1-dioxide (2.70a); pale oil (54%); IR (film): νmax = 3367 (NH), 1704 (C=O), 
1502, 1452, 1334 (S=O), 1247 (C-O), 1163 (br), 855, 769, 739, 701 cm−1. δ 1H NMR (400 
MHz, CDCl3): 1.48 (s, 9H, CH3-Boc), 1.64 (m, 2H, =CCH2CH2), 2.56-2.57 (m, 1H, =CCHH), 
2.73 (m, =CCHH)t, 2.74 (m, CHCHHPh)t, 3.13 (dd, 1H, J = 5.0, 13.4, CHCHHPh), 3.19-3.27 
(m, 2H, CH2N), 3.82 (brd, 1H, J = 14.2, NCHHPh), 4.07 (brd, 1H, J = 14.2, NCHHPh), 4.68-
4.74 (m, 2H, CHCH2Ph and NH), 6.21 (d, 1H, J = 9.6, =CH), 7.24-7.39 (m, 10H, Ph). δ 13C 
NMR (100.61 MHz, CDCl3): 23.0 (=CCH2CH2), 27.0 (=CCH2), 28.4 (CH3-Boc), 41.3 
(CHCH2Ph), 47.4 (CH2N), 49.1 (CHCH2Ph), 50.2 (NCH2Ph), 80.1 (C-Boc), 127.1 (CH), 
127.8 (CH), 128.4 (CH), 128.6 (CH), 128.8 (CH), 129.6 (CH), 132.4 (=CH), 136.0 (C), 136.5 
(C), 138.4 (=C), 154.9 (C=O). HR-ESI-MS calcd. for C25H32N2NaO4S (MNa+) 479.5884, 
found 479.1975. 
 
(Z)-2-Benzyl-5-[(2S)-N-tert-butoxycarbonyl-2-amino-3-phenyl-propylidene]-1,2-
thiazinane 1,1-dioxide (2.70b); white amorphous solid (9%); IR (film): νmax = 3409 (NH), 
1696 (C=O), 1512, 1335 (S=O), 1250 (C-O), 1156 (br), 856, 769, 732, 698 cm−1. δ 1H NMR 
(400 MHz, CDCl3): 1.34 (s, 9H, CH3-Boc), 1.65 (m, 2H, =CCH2CH2), 2.65-2.66 (m, 2H, 
=CCH2), 2.94 (brs, 2H, CHCH2Ph), 3.26 (m, 2H, CH2N), 4.06 (d, 1H, J = 14.0, NCHHPh), 
4.21 (brd, 1H, NCHHPh)u, 4.66 (brs, 1H, NH), 5.17 (brs, 1H, CHCH2Ph), 5.98 (brs, 1H, 
=CH), 7.13-7.30 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 23.6 (=CCH2CH2), 28.4 
(CH3-Boc), 34.8 (=CCH2), 41.0 (CHCH2Ph), 47.6 (CH2N), 49.8 (CHCH2Ph), 50.4 (NCH2Ph), 
77.8 (C-Boc), 126.8 (CH), 127.8 (CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 129.6 (CH), 
135.3 (=C), 136.0 (C), 136.7 (C and =CH)v, 155.1 (C=O). HR-ESI-MS calcd. for 
C25H32N2NaO4S (MNa+) 479.5884, found 479.1975. 
 
 
5.1.4.8 Deprotection (removal of Boc protecting group) 
 
Compound 2.69a (232 mg; 0.5 mmol) was dissolved in a solution (2.4 mL) of TFA 50% (w/v 
DCM solution). The mixture was stirred at rt for 20 min and then excess TFA was neutralized 
by dropwise addition of aqueous potassium carbonate at 30% (w/v) until pH 10. After dilution 
                                                 
t Overlapped signals. δ Values from HMQC spectrum. 
u Not well resolved signal. 
v Signal assignment was effected using HMQC and HMBC techniques. 
5. Experimental Section 
141 
with water (30 mL), the reaction medium was extracted with EtOAc (3×20 mL) and DCM 
(3×20 mL). The organic layers were washed with water, combined, dried with anhydrous 
magnesium sulfate and evaporated to give 2.73a (143 mg). Compounds 2.72a, 2.72b, 2.73b, 
2.74a and 2.74b were prepared using the same method from 2.68a, 2.68b, 2.69b, 2.70a and 
2.70b, respectively. 
 
(E)-2-Benzyl-5-[(2S)-2-amino-3-phenyl-propylidene]isothiazolidine 1,1-dioxide (2.72a); 
yellow oil (78%); IR (film): νmax = 3364 (NH), 3305 (NH), 1600, 1497, 1449, 1298, 1156 
(S=O), 784, 748, 696 cm−1. δ 1H NMR (400 MHz, CDCl3): 2.06−2.14 (m, 1H), 2.56−2.64 (m, 
1H), 2.75−2.89 (m, 3H), 2.92−2.97 (m, 1H), 3.67−3.72 (m, 1H), 4.09 (d, 1H, J = 14.0, 
NCHHPh), 4.16 (d, 1H, J = 14.0, NCHHPh), 6.36 (td, 1H, J = 2.8, 8.9, =CH), 7.18−7.37 (m, 
10H, Ph). ESI-MS m/z (rel. int.) 685 (M2H+) (100). 
 
(Z)-2-Benzyl-5-[(2S)-2-amino-3-phenyl-propylidene]isothiazolidine 1,1-dioxide (2.72b); 
yellow oil (73%); IR (film): νmax = 3364 (NH), 3296 (NH), 1600, 1498, 1459, 1288, 1151 
(S=O), 775, 733, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 2.61−2.67 (m, 1H), 2.78−2.81 (m, 
2H), 2.99−3.08 (m, 3H), 4.18 (brd, 2H, J = 2.4, NCH2Ph)w, 4.63 (brddd, 1H, J = 4.4, 9.0, 9.8, 
CHCH2Ph)x, 5.93 (td, 1H, J = 2.0, 9.8, =CH), 7.28−7.37 (m, 10H, Ph). ESI-MS m/z (rel. int.) 
685 (M2H+) (100). 
 
(E)-2-Phenyl-6-[(2S)-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-dioxide (2.73a); 
yellow oil (80%); IR (film): νmax = 3364 (NH), 3296 (NH), 1595, 1488, 1337 (S=O), 1156 
(S=O), 856, 831, 756, 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.31−1.41 (m, 1H), 
1.69−1.78 (m, 1H), 2.57−2.64 (m, 1H), 2.68−2.77 (m, 2H), 2.95 (dd, 1H, J = 6.0, 13.2, 
CHHPh), 3.60−3.65 (m, 1H), 3.80−3.93 (m, 2H), 6.35 (d, 1H, J = 9.6, =CH), 7.18−7.36 (m, 
10H, Ph). ESI-MS m/z (rel. int.) 685 (M2H+) (100). 
 
(Z)-2-Phenyl-6-[(2S)-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-dioxide (2.73b); 
yellow oil (83%); IR (film): νmax = 3374 (NH), 3286 (NH), 1595, 1488, 1342 (S=O), 1151 
(S=O), 836, 721, 699 cm−1. 1H NMR (400 MHz, CDCl3): 1.91−2.07 (m, 2H), 2.55 (dd, 1H, J 
= 9.0, 13.4, CHHPh), 2.83−2.96 (m, 3H), 3.79−3.85 (m, 1H), 3.89−3.95 (m, 1H), 4.67−4.73 
                                                 
w Co-incident peak. 
x Not well resolved signal. 
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(m, 1H), 5.80 (d, 1H, J = 8.8, =CH), 7.18−7.37 (m, 10H, Ph). ESI-MS m/z (rel. int.) 343 
(MH+) (100). 
 
(E)-2-Benzyl-6-[(2S)-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-dioxide (2.74a); 
yellowish amorphous solid (84%); IR (film): νmax = 3364 (NH), 3296 (NH), 1493, 1454, 1327 
(S=O), 1161 (S=O), 851, 768, 740, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.97−1.08 (m, 
1H), 1.34−1.44 (m, 1H), 2.45−2.51 (m, 1H), 2.55−2.62 (m, 1H), 2.66 (dd, 1H, J = 10.4, 13.2, 
CHCHHPh), 2.98 (dddd, 1H, J = 1.2, 4.2, 4.6, 14.5, =CCHH), 3.06 (dd, 1H, J = 5.8, 13.2, 
CHCHHPh), 3.37 (ddd, 1H, J = 3.0, 10.7, 14.4), 3.69 (d, 1H, J = 14.4, NCHHPh), 3.89−3.97 
(m, 1H), 4.16 (d, 1H, J = 14.4, NCHHPh), 6.32 (d, 1H, J = 9.6, =CH), 7.22−7.36 (m, 10H, 
Ph). ESI-MS m/z (rel. int.) 713 (M2H+) (100). 
 
(Z)-2-Benzyl-6-[(2S)-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-dioxide (2.74b); 
yellow oil (79%); IR (film): νmax = 3364 (NH), 3296 (NH), 1498, 1454, 1332 (S=O), 1151 
(S=O), 848, 765, 731, 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.68−1.74 (m, 2H), 
2.66−2.79 (m, 3H), 2.87 (dd, 1H, J = 5.6, 13.2, CHCHHPh), 3.23−3.29 (m, 1H), 3.34−3.41 
(m, 1H), 3.92 (d, 1H, J = 14.0, NCHHPh), 4.12 (d, 1H, J = 14.0, NCHHPh), 4.79−4.85 (m, 
1H), 5.81 (d, 1H, J = 9.2, =CH), 7.20−7.36 (m, Ph). ESI-MS m/z (rel. int.) 713 (M2H+) (100). 
 
(E)-2-Phenyl-5-[(2S)-2-amino-3-phenyl-propylidene]isothiazolidine 1,1-dioxide 
hydrochloride (2.75) 
Compound 2.67a (150 mg; 0.4 mmol) was dissolved in a solution (1.6 mL) of TFA 50% (w/v 
DCM solution). The mixture was stirred at rt for 20 min, then DCM was evaporated and the 
residue was washed with small portions of ethyl ether to afford 2.75 (100 mg). 
2.75; white amorphous solid (76%); IR (KBr): νmax = 3290 (br, NH), 2000 (br), 1585, 1496, 
1420 (br), 1317 (S=O), 1150 (S=O), 920, 753, 698 cm−1. δ 1H NMR (400 MHz, MeOD): 
1.85−2.00 (m, 1H), 2.72−2.79 (m, 1H), 2.85 (dd, 1H, J = 7.8, 13.0, CHHPh), 3.02 (dd, 1H, J 
= 7.6, 13.0, CHHPh), 3.04−3.06 (m, 1H), 3.55−3.60 (m, 1H), 4.02−4.05 (m, 1H), 6.24 (td, 1H, 
J = 2.5, 9.6, =CH), 7.20−7.25 (m, 5H, Ph). ESI-MS m/z (rel. int.) 329 (M+) (100). 
 
 
 
 
5. Experimental Section 
143 
5.1.4.9 Coupling with aminoacids and endcapping of the dipeptide moiety 
 
(E)-2-Phenyl-6-[(2S)-N-(N’-acetyl-S-phenylalanyl)-2-amino-3-phenyl-propylidene]-1,2-
thiazinane 1,1-dioxide (2.1) 
TEA (212 mg; 2.1 mmol) was added to a solution of 2.73a (169 mg; 0.5 mmol) in DCM (9 
mL), at 0 ºC. Then, N-Ac-S-phenylalanine (102 mg; 0.5 mmol) was added, followed by HOBt 
(81 mg; 0.6 mmol) and DCC (125 mg; 0.6 mmol). The reaction was stirred at rt for 3 days. 
The precipitate formed was removed by filtration and the filtrate was diluted with DCM (20 
mL), washed with 20 mL of hydrochloric acid 5% (w/v) and of water, and dried with 
anhydrous magnesium sulfate. The solvent was evaporated to afford a mixture (144 mg), 
which was subject to column chromatography on silica gel (14 g) using a gradient of 
DCM/EtOAc (1:0→0:1) to yield 2.1 (35 mg). 
2.1; white amorphous solid (13%); [ ]21Dα = +33º (CHCl3, c 0.82). IR (film): νmax = 3281 (br, 
NH), 1644 (br, C=O), 1498, 1339 (S=O), 1158 (S=O), 737, 698 cm−1. HR-ESI-MS calcd. for 
C30H34N3O4S (MH+) 532.6748, found 532.2265. 1H and 13C NMR see Table 2.9 in Chapter 2. 
 
Condensation with N-Boc-S-leucine-N-hydroxysuccinimide ester − synthesis of 
compounds 2.76a,b, 2.77 and 2.78a,b 
N-Boc-S-leucine-N-hydroxysuccinimide ester (127 mg; 0.4 mmol) was added to a solution of 
2.73a (132 mg; 0.4 mmol) in dry THF (2 mL) with TEA (39 mg; 0.4 mmol). The reaction 
mixture was stirred at rt for 14 h, then it was evaporated to leave a product, which was 
dissolved in DCM (40 mL) and washed with 40 mL of hydrochloric acid 5% (w/v) and of 
water. After being dried with anhydrous magnesium sulfate, the solvent was evaporated to 
yield 2.77 (173 mg), which was purified by column chromatography on silica gel (17 g) using 
EtOAc as eluent (50 mL). 1H and 13C NMR signal assignments were possible using DEPT 
and 2D NMR techniques (1H-1H COSY and HMQC). 
 
(E)-2-Benzyl-5-[(2S)-N-(N′-tert-butoxycarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.76a) 
2.76a was prepared from 2.72a (reaction time: 48 h); yellow oil (54%); IR (film): νmax = 3331 
(NH), 3280 (NH), 1689 (C=O), 1651 (C=O), 1523, 1453, 1306, 1166, 779, 704 cm−1. δ 1H 
NMR (400 MHz, CDCl3): 0.87−0.93 [m, 6H, 2×CH3 (Leu)], 1.44 (s, 9H, CH3-Boc), 
1.55−1.63 [m, 3H, CH2 and CH(CH3)2 (Leu)], 2.17 (m, 1H, =CCHH), 2.82−2.89 [m, 3H, 
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=CCHH, CHHPh (Phe) and CHHN], 2.91−3.01 [m, 2H, CHHPhe (Phe) and CHHN], 4.03 [m, 
1H, CHCO (Leu)], 4.08 (d, 1H, J = 14.2, NCHHPh), 4.14 (d, 1H, J = 14.2, NCHHPh), 
4.66−4.78 [m, 2H, CHCH2Ph (Phe) and NH (Leu)], 6.26 (brd, 1H, J = 9.2, =CH), 6.51 [brs, 
1H, NH (Phe)], 7.18−7.34 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 21.8 [CH3 (Leu) 
and =CCH2], 23.0 [CH3 (Leu)], 24.7 [CH(CH3)2 (Leu)], 28.3 (CH3-Boc), 40.6 [CH2Ph 
(Phe)]y, 40.7 [CH2 (Leu)]y, 43.2 (CH2N), 47.9 (NCH2Ph), 49.4 [CHCH2Ph (Phe)], 53.1 
[CHCO (Leu)], 127.1 (CH), 128.0 (CH), 128.7 (3×CH), 129.6 (CH)z, 129.8 (=CH)z, 134.9 
(C), 136.0 (C)aa, 139.2 (=C)aa, 155.9 (CO-Boc), 172.1 [CO (Leu)]. ESI-MS m/z (rel. int.) 579 
(MNa+) (100). 
 
(Z)-2-Benzyl-5-[(2S)-N-(N′-tert-butoxycarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.76b) 
2.76b was prepared from 2.72b (reaction time: 18 h); white amorphous solid (62%); IR 
(film): νmax = 3344 (NH), 3280 (NH), 1683 (C=O), 1659 (C=O), 1517, 1453, 1294, 1160, 
772, 734, 702 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.89 [brd, 6H, J = 5.6, 2×CH3 (Leu)], 
1.42 (s, 9H, CH3-Boc), 1.55−1.62 (m, 2H), 2.78−2.81 (m, 2H), 3.05−3.23 (m, 4H), 4.05 (m, 
1H), 4.18 (brd, 2H, J = 2.0), 4.76 (brd, 1H, J = 7.2), 5.02−5.10 (m, 1H), 6.23 (brd, 1H, J = 
8.0), 6.50 (brd, 1H, J= 6.8), 7.23−7.37 (m, 10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 21.8 
[CH3 (Leu)], 23.0 [CH3 (Leu)], 24.7 [CH(CH3)2 (Leu)], 25.7 (=CCH2), 28.3 (CH3-Boc), 39.4 
[CH2Ph (Phe)], 41.2 [CH2 (Leu)], 43.6 (CH2N), 47.9 (NCH2Ph), 50.2 [CHCH2Ph (Phe)], 53.0 
[CHCO (Leu)], 126.8 (CH), 128.1 (CH), 128.6 (CH), 128.7 (CH), 128.8 (CH), 129.5 (CH), 
133.7, 134.9, 137.1, 172.5 [CO (Leu)]. ESI-MS m/z (rel. int.) 579 (MNa+) (100). 
 
(E)-2-Phenyl-6-[(2S)-N-(N′-tert-butoxycarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.77); yellowish amorphous solid (70%); IR 
(film): νmax = 3342 (NH), 3282 (NH), 1687 (C=O), 1651 (C=O), 1520, 1295, 1165, 777, 735, 
702 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.89−0.94 [m, 6H, 2×CH3 (Leu)], 1.44 (s, 9H, CH3-
Boc), 1.56−1.65 (m, 2H), 1.83−2.00 (m, 1H), 2.61 (m, 1H), 2.75−2.88 (m, 2H), 2.96−3.04 (m, 
1H), 3.68−3.84 (m, 2H), 4.05 (m, 1H), 4.73−4.78 (m, 1H), 4.94 (ddd, 1H, J = 5.6, 8.8, 17.6), 
                                                 
y δ Values are interchangeable. 
z δ Values are interchangeable. 
aa δ Values are interchangeable. 
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6.23 (d, 1H, J = 9.6, =CH), 6.50 [brs, 1H, NH (Phe)], 7.18−7.34 (m, 10H, Ph). ESI-MS m/z 
(rel. int.) 579 (MNa+) (100). 
 
(E)-2-Benzyl-6-[(2S)-N-(N′-tert-butoxycarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.78a) 
2.78a was prepared from 2.74a (reaction time: 19h); yellowish amorphous solid (67%); IR 
(film): νmax = 3293 (br, NH), 1683 (C=O), 1651 (C=O), 1529, 1453, 1338 (S=O), 1166, 772, 
740, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.91−0.94 [m, 6H, 2×CH3 (Leu)], 1.10−1.20 
(m, 1H), 1.45 (s, 9H, CH3-Boc), 1.58−1.68 (m, 3H), 2.57 (m, 1H), 2.65−2.81 (m, 2H), 3.10 
[dd, 1H, J = 5.2, 13.2, CHHPh (Phe)]bb, 3.07−3.15 (m, 1H)bb, 3.24−3.29 (m 1H), 3.76−3.81 
(m, 1H), 4.02 (brs, 1H, NCHHPh), 4.06 (brs, 1H, NCHHPh), 4.78−4.85 (m, 1H), 4.95 (ddd, 
1H, J = 5.2, 9.4, 17.8), 6.21 (d, 1H, J = 9.6, =CH), 6.59 [brs, 1H, NH (Phe)], 7.22−7.34 (m, 
10H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 22.0 [CH3 (Leu)], 23.0 [CH3 (Leu)]cc, 23.1 
(=CCH2CH2)cc, 24.8 [CH(CH3)2 (Leu)], 27.0 (=CCH2), 28.3 (CH3-Boc), 40.9 [CH2Ph (Phe)], 
41.0 [CH2 (Leu)], 47.4 (CH2N), 47.7 [CHCH2Ph (Phe)], 50.2 (NCH2Ph), 127.1 (CH), 127.8 
(CH), 128.5 (CH), 128.6 (CH), 128.8 (CH), 129.5 (CH), 131.4 (=CH), 135.9 (C), 136.4 (C), 
139.2 (=C), 155.0 (CO-Boc), 172.0 [CO (Leu)]. ESI-MS m/z (rel. int.) 593 (MNa+) (100). 
 
(Z)-2-Benzyl-6-[(2S)-N-(N′-tert-butoxycarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.78b) 
2.78b was prepared from 2.74b (reaction time: 19h); yellowish amorphous solid (64%); IR 
(film): νmax = 3293 (br, NH), 1689 (C=O), 1651 (C=O), 1523, 1447, 1338 (S=O), 1160, 766, 
730, 695 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.87−0.89 [m, 6H, 2×CH3 (Leu)], 1.43 (s, 9H, 
CH3-Boc), 1.56−1.59 (m, 2H), 1.76−1.86 (m, 2H), 2.63−2.69 (m, 1H), 2.76−2.82 (m, 1H), 
3.26−3.30 (m, 1H), 3.33 (brd, 2H, J = 7.2), 3.40−3.46 (m, 1H), 4.01 (m, 1H), 4.10 (d, 1H, J = 
14.4, NCHHPh), 4.25 (d, 1H, J = 14.4, NCHHPh), 4.69 (m, 1H), 5.43−5.50 (m, 1H), 5.98 (d, 
1H, J = 8.4, =CH), 6.36 [brd, 1H, J = 6.0, NH (Phe)], 7.22−7.34 (m, 10H, Ph). δ 13C NMR 
(100.61 MHz, CDCl3): 21.8 [CH3 (Leu)], 23.0 [CH3 (Leu)], 23.5 (=CCH2CH2), 24.7 
[CH(CH3)2 (Leu)], 28.3 (CH3-Boc), 34.8 (=CCH2), 40.7 [CH2Ph (Phe)], 41.0 [CH2 (Leu)], 
47.6 (CH2N), 49.1 [CHCH2Ph (Phe)], 50.5 (NCH2Ph), 80.1 (C-Boc), 126.9 (CH), 127.8 (CH), 
                                                 
bb Overlapped signals. 
cc δ Values are interchangeable. 
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128.5 (2×CH), 128.6 (CH), 129.4 (CH), 129.5 (CH), 136.1, 137.0, 172.3 [CO (Leu)]. ESI-MS 
m/z (rel. int.) 593 (MNa+) (81). 
 
N-Boc group deprotection of dipeptide vinyl sultams − synthesis of compounds 2.79a,b, 
2.80 and 2.81a,b 
2.79a,b, 2.80 and 2.81a,b were respectively prepared from 2.76a,b, 2.77 and 2.78a,b using 
the method described earlier for 2.72-2.74. 
 
(E)-2-Benzyl-5-[(2S)-N-S-leucinyl-2-amino-3-phenyl-propylidene]isothiazolidine 1,1-
dioxide (2.79a); yellow oil (73%); IR (film): νmax = 3315 (br, NH), 1654 (C=O), 1498, 1366, 
1293, 1166 (S=O), 782, 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.88−0.93 [m, 6H, 2×CH3 
(Leu)], 1.15−1.25 (m, 2H), 1.58−1.67 (m)dd, 2.18−2.35 (m, 1H), 2.79−3.02 (m, 5H), 
3.32−3.35 (m, 1H), 4.10 (d, 1H, J = 14.0, NCHHPh), 4.16 (d, 1H, J = 14.0, NCHHPh), 
4.71−4.79 (m, 1H), 6.28 (td, 1H, J = 2.4, 9.6, =CH), 7.19−7.36 (m, 10H, Ph), 7.69 (d, 1H, J = 
8.4, NH). ESI-MS m/z (rel. int.) 456 (MH+) (100). 
 
(Z)-2-Benzyl-5-[(2S)-N-S-leucinyl-2-amino-3-phenyl-propylidene]isothiazolidine 1,1-
dioxide (2.79b); yellow oil (56%); IR (film): νmax = 3315 (br, NH), 1654 (C=O), 1454, 1293, 
1156 (S=O), 777, 736, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.88 [d, 3H, J = 6.4, CH3 
(Leu)], 0.90 [d, 3H, J = 6.4, CH3 (Leu)], 1.17−1.28 (m, 3H), 2.78−2.81 (m, 2H), 3.04−3.20 
(m, 4H), 3.36 (dd, 1H, J = 4.0, 9.6), 4.14 (d, 1H, J = 14.0, NCHHPh), 4.21 (d, 1H, J = 14.0, 
NCHHPh), 4.99−5.07 (m, 1H), 6.24 (td, 1H, J = 2.0, 7.7, =CH), 7.23−7.37 (m, 10H, Ph), 7.72 
(d, 1H, J = 7.2, NH). ESI-MS m/z (rel. int.) 911 (M2+) (100). 
 
(E)-2-Phenyl-6-[(2S)-N-S-leucinyl-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-
dioxide (2.80); yellow oil (88%); IR (film): νmax = 3325 (br, NH), 1654 (C=O), 1595, 1488, 
1341 (S=O), 1161 (S=O), 856, 833, 736, 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.91−0.97 
[m, 6H, 2×CH3 (Leu)], 1.60−1.72 (m)dd, 1.89−1.97 (m, 1H), 2.67−2.73 (m, 1H), 2.82 [dd, 1H, 
J = 8.4, 13.2, CHHPh (Phe)], 2.88−2.95 (m, 1H), 2.99 [dd, 1H, J = 6.2, 13.2, CHHPh (Phe)], 
3.33−3.37 (m, 1H), 3.69−3.85 (m, 2H), 4.92−5.00 (m, 1H), 6.25 (d, 1H, J = 9.6, =CH), 
7.19−7.33 (m, 10H, Ph), 7.66 (brd, 1H, J = 8.4, NH). ESI-MS m/z (rel. int.) 911 (M2+) (100). 
 
                                                 
dd Obscured under water resonance. 
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(E)-2-Benzyl-6-[(2S)-N-S-leucinyl-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-
dioxide (2.81a); yellow oil (73%); IR (film): νmax = 3315 (br, NH), 1654 (C=O), 1498, 1337 
(S=O), 1161 (S=O), 770, 735, 701 cm−1. δ 1H NMR (400 MHz, CDCl3): 0.93 [d, 3H, J = 6.2, 
CH3 (Leu)], 0.96 [d, 3H, J = 6.2, CH3 (Leu)], 1.14−1.32 (m, 3H), 1.60−1.71 (m, 2H), 
2.59−2.81 (m, 3H), 3.07−3.13 (m, 2H), 3.26−3.33 (m, 1H), 3.38 [dd, 1H, J = 3.2, 13.2, 
CHHPh (Phe)], 3.75 (d, 1H, J = 14.2, NCHHPh), 4.06 (d, 1H, J = 14.2, NCHHPh), 4.96 (ddd, 
1H, J = 5.6, 9.2, 18.4), 6.24 (d, 1H, J = 10.0, =CH), 7.24−7.36 (m, 10H, Ph), 7.70 (m, 1H, 
NH). ESI-MS m/z (rel. int.) 471 (MH+) (100). 
 
(Z)-2-Benzyl-6-[(2S)-N-S-leucinyl-2-amino-3-phenyl-propylidene]-1,2-thiazinane 1,1-
dioxide (2.81b); yellowish amorphous solid (86%); δ 1H NMR (400 MHz, CDCl3): 0.86−0.90 
[m, 6H, 2×CH3 (Leu)], 1.24−1.28 (m), 1.43 (s, CH3-Boc of 2.78b), 1.77−1.86 (m), 2.63−2.70 
(m), 2.77−2.84 (m), 3.02−3.12 (m), 3.25−3.33 (m), 3.41−3.49 (m), 4.09−4.17 (m), 4.20−4.31 
(m), 5.35−5.49 (m), 6.04 (d, J = 8.4, =CH), 6.34−6.35 (m), 7.21−7.34 (m, Ph), 7.52−7.54 (m). 
ESI-MS m/z (rel. int.) 471 (MH+) (100). 
 
Condensation with 4-morpholinecarbonyl chloride − synthesis of compounds 2.2, 2.3 
and 2.4a,b 
4-Morpholinecarbonyl chloride (44 mg; 0.2 mmol) diluted with dry THF (0.5 mL) was added 
to a solution of 2.80 (93 mg; 0.2 mmol) in dry THF (1.5 mL) with TEA (21 mg; 0.2 mmol). 
The reaction was stirred at rt for 16 h, during which the formation of a precipitate was 
observed. The solvent was evaporated, then the residue was dissolved in DCM (40 mL) and 
washed with 40 mL of hydrochloric acid 5% (w/v) and of water. After being dried with 
anhydrous magnesium sulfate, the solvent was evaporated to give a mixture (96 mg), which 
was subject to column chromatography on silica gel (15 g) using EtOAc as eluent (0.1 L) to 
give 2.3 (18 mg). 
 
(E)-2-Benzyl-5-[(2S)-N-(N′-4-morpholinylcarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]isothiazolidine 1,1-dioxide (2.2) 
2.2 (44 mg) was prepared from 2.79a (reaction time: 14 h); white amorphous solid (50%); 
[ ]21Dα = −14º (CHCl3, c 0.17). IR (film): νmax = 3269 (br, NH), 1623 (br, C=O), 1456, 1300, 
1155 (S=O), 738, 701 cm−1. HR-ESI-MS calcd. for C30H41N4O5S (MH+) 569.7365, found 
569.2792. 1H and 13C NMR see Table 2.10 in Chapter 2. 
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(E)-2-Phenyl-6-[(2S)-N-(N′-4-morpholinylcarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.3); white amorphous solid (15%); [ ]21Dα = −26º 
(CHCl3, c 0.67). IR (film): νmax = 3264 (br, NH), 1622 (br, C=O), 1455, 1342 (S=O), 1158 
(S=O), 736, 695 cm−1. HR-ESI-MS calcd. for C30H41N4O5S (MH+) 569.7365, found 
569.2792. 1H and 13C NMR see Table 2.11 in Chapter 2. 
 
(E)-2-Benzyl-6-[(2S)-N-(N′-4-morpholinylcarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.4a) 
2.4a (68 mg) was prepared from 2.81a (reaction time: 15 h); white amorphous solid (39%); 
[ ]21Dα = −20º (CHCl3, c 0.13). IR (film): νmax = 3318 (br, NH), 1621 (br, C=O), 1457, 1336 
(S=O), 1157 (S=O), 737, 699 cm−1. HR-ESI-MS calcd. for C31H42N4NaO5S (MNa+) 
605.7449, found 605.2768. 1H and 13C NMR see Table 2.12 in Chapter 2. 
 
(Z)-2-Benzyl-6-[(2S)-N-(N′-4-morpholinylcarbonyl-S-leucinyl)-2-amino-3-phenyl-
propylidene]-1,2-thiazinane 1,1-dioxide (2.4b) 
2.4b (14 mg) was prepared from 2.81b (reaction time: 15 h); white amorphous solid (28%); 
[ ]21Dα = −14º (CHCl3, c 0.16). IR (film): νmax = 3368 (NH), 1621 (br, C=O), 1455, 1331 (S=O), 
1155 (S=O), 756, 699 cm−1. HR-ESI-MS calcd. for C31H42N4NaO5S (MNa+) 605.7449, found 
605.2768. 1H and 13C NMR see Table 2.13 in Chapter 2. 
 
N-(4-Morpholinylcarbonyl)-S-phenylalanine (2.82) 
TEA (1.0 mL; 6.9 mmol) and 4-morpholinecarbonyl chloride (0.8 mL; 6.9 mmol) were added 
to a suspension of S-phenylalanine (1.0 g; 6.0 mmol) in THF (20 mL). The mixture was 
refluxed for 4 h. Then, it was acidified with conc. hydrochloric acid, diluted with water (80 
mL) and extracted with DCM (2×20 mL) and EtOAc (2×20 mL). The organic layers were 
washed with water, combined and dried with magnesium sulfate. The solvent was evaporated 
to yield 2.82 (0.9 g). 
2.82; yellow oil (54%); IR (film): νmax = 3331 (br, NH and OH), 1721 (C=O of acid), 1632 
(C=O of amide), 1530 (br), 1460, 1268 (br, C-O), 1115 (br, C-O), 878, 737, 702 cm−1. δ 1H 
NMR (400 MHz, CDCl3): 3.13 (dd, 1H, J = 7.2, 13.8, CHHPh), 3.23 (dd, 1H, J = 5.6, 13.8, 
CHHPh), 3.27−3.33 (m, 4H, CH2N), 3.57−3.73 (m, 4H, CH2O), 4.62−4.71 (m, 1H, 
CHCH2Ph), 4.96 (d, 1H, J = 7.2, NH), 7.17−7.32 (m, 5H, Ph). δ 13C NMR (100.61 MHz, 
CDCl3): 43.9 (CH2Ph), 47.2 (CH2N), 54.8 (CHCH2Ph), 66.3 (CH2O), 127.2 (CH), 128.7 
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(CH), 129.3 (CH), 136.2 (C), 174.2 (COOH). 1H NMR signal assignments were based on 
chemical shift, on relative integration and on the splitting pattern. Carbon signals assignments 
were made using HMQC and DEPT techniques. ESI-MS m/z (rel. int.) 279 (MH+) (100). 
This compound was initially synthesised with lower yields following an adapted 
procedure.142  4-Morpholinecarbonyl chloride (0.8 mL; 6.9 mmol) was added to a solution of 
S-phenylalanine (1.0 g; 6.0 mmol) in 6M-sodium hydroxide (1.3 mL; 7.8 mmol). When the 
mixture was shaken, it became warm and a precipitate was observed. Initially, the solid was 
collected by filtration in vacuo and washed with cold water, but according to the 1H NMR 
spectrum (400 MHz, D2O) it revealed to be S-phenylalanine. In the following attempts, an 
excess of 1M-sodium hydroxide was added until the medium became clear and alkaline. 
Then, the solution was acidified with conc. hydrochloric acid and extracted with EtOAc (2×40 
mL). The organic layer was washed with water, dried with magnesium sulfate and evaporated 
to give 2.82 (134 mg, 8%).  
 
 
5.1.4.10 Synthesis of vinyl sulfonamides 
 
N-Methyl-N-phenylmethanesulfonamide (2.85) 
Mesyl chloride (3.6 mL; 45.5 mmol) was added slowly to a solution of N-methylaniline (10.0 
mL; 91.0 mmol) in DCM (40 mL). The mixture was stirred at rt for 2 h. Then, it was washed 
with 40 mL of hydrochloric acid 5% (w/v) and of water, it was dried with anhydrous 
magnesium sulfate and the solvent was evaporated to afford 2.85 (6.8 g). 
2.85; white crystals (81%); mp 75-77 ºC; IR (KBr): νmax = 1590, 1493, 1332 (S=O), 1146 
(S=O), 767, 634 cm−1. δ 1H NMR (400 MHz, CDCl3): 2.86 (s, 3H, CH3SO2), 3.35 (s, 3H, 
CH3N), 7.30−7.34 (m, 1H, Ph), 7.39−7.44 (m, 4H, Ph). ESI-MS m/z (rel. int.) 208 (MNa+) 
(100). 
Alternatively, 2.85 was obtained from N-phenylmethanesulfonamide 2.50 by the following 
procedure: to a solution of 2.50 (1.0 g; 5.8 mmol) in DCM (10 mL) was added 
tetrabutylammonium hydroxide 30-hydrate (47 mg; 58.5 µmol), followed by a solution of 
sodium hydroxide (610 mg; 15.0 mmol) in water (1.5 mL). The formation of a white 
precipitate was observed. Then, iodomethane (1.0 g; 5.8 mmol) was added dropwise. After 
stirring at rt for 30 min, the precipitate still remained. The reaction was refluxed for 45 min, 
during which time the medium became clear. The mixture was diluted with 30 mL of DCM 
and saturated aqueous solution of sodium chloride. The organic layer was washed with water 
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(30 mL), dried with anhydrous magnesium sulfate and evaporated to yield 2.85 (448 mg; 
41%). 
 
N-Methyl-N-phenyl diethylphosphorylmethanesulfonamide (2.86) 
The reaction was carried out under N2 at rt. A 1.6 M solution of n-BuLi in n-hexane (18.0 
mmol) was added to 2.85 (3.0 g; 16.2 mmol) in dry THF (50 mL), which turned the solution 
yellow. TMEDA (2.7 mL; 18.0 mmol) was added, followed after 10 min by a solution of 
diethyl chlorophosphate (1.3 mL; 9.0 mmol) in dry THF (6 mL). The mixture was stirred for 
1 h (development of an orange coloration), after which it was quenched using a saturated 
aqueous solution of sodium chloride (100 mL) and extracted with DCM (3×100 mL) and 
EtOAc (100 mL). The organic layers were washed with water, combined and dried with 
anhydrous magnesium sulfate. The solvent was evaporated to yield a crude product (3.4 g), 
which was subjected twice to column chromatography on silica gel using ethyl ether as eluent 
to afford 2.86 (324 mg). The process also gave 81 mg of impure 2.86, which was no further 
purified. 
2.86; yellow oil (11%); IR (film): νmax = 1595, 1493, 1354 (S=O), 1261 (P=O), 1153 (S=O), 
1026 and 973 (d, P-O-C), 879, 796, 699 cm−1. ESI-MS m/z (rel. int.) 344 (MNa+) (100). 1H 
and 13C NMR see Table 2.14 in Chapter 2. 
 
(E) N-Methyl-N-phenyl (3S)-N-tert-butoxycarbonyl-3-amino-4-phenyl-but-1-enyl 
sulfonamide (2.84a) and its (Z) Isomer (2.84b) 
Compounds 2.84a (61 mg) and 2.84b (14 mg) were prepared from 2.86 (296 mg; 0.9 mmol) 
and N-Boc-S-phenylalaninal (2.53) according to the typical experimental procedure for the 
Horner-Wadsworth-Emmons reaction (Section 5.1.4.7). 
2.84a; white amorphous solid (16%); IR (film): νmax = 3369 (NH), 1707 (C=O), 1497, 1349 
(S=O), 1251 (C-O), 1167 (br), 870, 765, 742, 699 cm−1. δ 1H NMR (400 MHz, CDCl3): 1.44 
(s, 9H, CH3-Boc), 2.86−2.98 (m, 2H, CH2Ph), 3.15 (s, 3H, NCH3), 4.59 (m, 2H, NH and 
CHCH2Ph), 6.17 (d, 1H, J = 14.8, CHSO2), 6.62 (dd, 1H, J = 5.2, 14.8, CH=CHSO2), 
7.16−7.20 (m, 2H, Ph), 7.24−7.36 (m, 8H, Ph). δ 13C NMR (100.61 MHz, CDCl3): 28.3 (CH3-
Boc), 38.1 (NCH3), 40.3 (CH2Ph), 52.2 (CHCH2Ph), 80.2 (C-Boc), 124.7 (CHSO2), 127.0 
(CH), 127.2 (CH), 127.5 (CH), 128.8 (CH), 129.1 (CH), 129.3 (CH), 135.8 (C), 141.3 (C), 
145.7 (CH=CHSO2), 154.8 (CO-Boc). 1H NMR signal assignments were based on the 
chemical shift and on the splitting pattern. Carbon signal assignments were made using 
HMQC and DEPT techniques. ESI-MS m/z (rel. int.) 439 (MNa+) (100). Anal. Calcd 
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(C22H28N2O4S): C, 63.44; H, 6.78; N, 6.73; S, 7.70. Found: C, 63.96; H, 7.12; N, 6.64; S, 
7.61. 
2.84b; white amorphous solid; δ 1H NMR (400 MHz, CDCl3): 1.40 (s, 9H, CH3-Boc), 
2.88−2.95 (m, 2H, CH2Ph), 3.34 (s, 3H, NCH3), 4.55 (brs, 1H), 5.02 (brs, 1H), 6.09 (d, 1H, J 
= 10.8), 6.41 (brs, 1H), 7.16−7.18 (m, 2H, Ph), 7.23−7.40 (m, 8H, Ph). ESI-MS m/z (rel. int.) 
439 (MNa+) (100). This compound was obtained with the presence of small amounts of the E 
isomer. 
 
 
5.1.4.11 1,4-Naphthoquinone derivatives 
 
For nomenclature and NMR assignment purposes, carbon atoms and protons were numbered 
as follows:143,144  
 
7
6
5
8
4 3
21
O
O
R1
R2
R3
R4
4a
8a
 
 
Reaction of 1,4-naphthoquinones with amino acid ethyl esters 
S-Phenylalanine ethyl ester hydrochloride (97 mg; 0.4 mmol) and TEA (85 mg; 0.8 mmol) 
were added to a solution of 2-bromo-1,4-naphthoquinone 3.6 (102 mg; 0.4 mmol) in abs 
EtOH (15 mL). After stirring at rt for 1 h, the solvent was evaporated to yield crude product 
(300 mg). Compounds 3.1a (61 mg) and 3.2a (16 mg) were separated by column 
chromatography on silica gel (30 g) using DCM as eluent (0.5 L). Compounds 3.1b, 3.2b and 
3.3a,b were prepared using the same method from the appropriate naphthoquinone and amino 
acid ethyl ester.  
 
N-(1,4-Naphthoquinon-2-yl)-S-phenylalanine ethyl ester (3.1a); light orange gummy solid 
(42%); IR (film): νmax = 3374 (NH), 1737 (C=O of COOEt), 1673 and 1571 (C=O of 
quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 1.24−1.27 (m, 3H, CH2CH3), 3.19 (dd, 1H, J = 
6.6, 14.0, CHHPh), 3.28 (dd, 1H, J = 5.6, 14.0, CHHPh), 4.19−4.24 (m, 2H, CH2CH3), 4.32 
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(brddd, 1H, J = 5.6, 6.6, 7.6, CH)ee, 5.71 (s, 1H, H-3), 6.33 (d, 1H, J = 7.6, NH), 7.16−7.18 
(m, 2H, Ph), 7.25−7.34 (m, 3H, Ph), 7.64 (dt, 1H, J = 1.2, 7.6, H-7), 7.74 (dt, 1H, J = 1.2, 7.6, 
H-6), 8.06 (brdd, 1H, J = 0.8; 7.6, H-8)ee, 8.09 (brdd, 1H, J = 0.4, 7.6, H-5)ee. δ 13C NMR 
(100.61 MHz, CDCl3): 14.1 (CH2CH3), 37.5 (CH2Ph), 56.1 (CHCH2Ph), 62.0 (CH2CH3), 
102.1 (C-3), 126.2 (C-8), 126.4 (C-5), 127.5 (CH), 128.8 (CH), 129.2 (CH), 130.5 (C-8a), 
132.2 (C-7), 133.2 (C-4a), 134.8 (C-6), 135.1 (C), 146.6 (C-2), 170.3 (CO), 181.2 (C-1), 
183.2 (C-4). 1H and 13C NMR signal assignments were possible using DEPT and 2D NMR 
techniques (HMQC and HMBC). ESI-MS m/z (rel. int.) 350 (MH+) (100). Anal. Calcd 
(C21H19NO4): C, 72.19; H, 5.48; N, 4.01. Found: C, 72.45; H, 5.61; N, 4.13.  
 
N-(3-Bromo-1,4-naphthoquinon-2-yl)-S-phenylalanine ethyl ester (3.2a); orange oil (9%); 
IR (film): νmax = 3317 (NH), 1737 (C=O of COOEt), 1673 and 1571 (C=O of quinone) cm−1. 
δ 1H NMR (400 MHz, CDCl3): 1.26−1.30 (m, 3H, CH2CH3), 3.20−3.31 (m, 2H, CH2Ph), 
4.21−4.27 (m, 2H, CH2CH3), 5.58 (m, 1H, CH), 6.28 (brs, 1H, NH), 7.20−7.22 (m, 2H, Ph), 
7.24−7.34 (m, 3H, Ph), 7.65 (dt, 1H, J = 1.2, 7.6, H-7), 7.72 (dt, 1H, J = 1.2, 7.6, H-6), 8.00 
(brd, 1H, J = 7.6, H-8)ee, 8.14 (brd, 1H, J = 6.8, H-5)ee. δ 13C NMR (100.61 MHz, CDCl3): 
14.1 (CH2CH3), 40.0 (CH2Ph), 57.6 (CHCH2Ph), 61.9 (CH2CH3), 126.9 (C-5 and C-8), 127.5 
(CH), 128.8 (CH), 129.4 (CH), 131.9 (C-4a), 132.6 (C-7), 134.7 (C-6), 135.0 (C), 171.2 (CO), 
176.4 (C-4), 179.8 (C-1); the following 1H and 13C signal assignments are interchangeable: C-
1 with C-4, C-4a with C-8a, H-5 with H-8 and H-6/C-6 with H-7/C-7. Proton-carbon 
correlations were assigned from the HMQC spectrum. ESI-MS m/z (rel. int.) 428 (MH+) (83), 
430 (MH++2) (100). Anal. Calcd (C21H18BrNO4): C, 58.89; H, 4.24; N, 3.27. Found: C, 
58.77; H, 4.44; N, 3.42. 
 
N-(3-Chloro-1,4-naphthoquinon-2-yl)-S-phenylalanine ethyl ester (3.3a) 
Compound 3.3a (18 mg) was prepared from 2,3-dichloro-1,4-naphthoquinone 3.9 (102 mg; 
0.4 mmol) and S-phenylalanine ethyl ester hydrochloride (101 mg; 0.4 mmol). 
3.3a; orange oil (11%); IR (film): νmax = 3315 (NH), 1737 (C=O of COOEt), 1673 and 1571 
(C=O of quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 1.27 (t, 3H, J = 7.2, CH2CH3), 
3.24−3.27 (m, 2H, CH2Ph), 4.20−4.28 (m, 2H, CH2CH3), 5.51 (ddd, 1H, J = 2.0, 6.0; 12.2, 
CH), 6.34 (brs, 1H, NH), 7.19−7.21 (m, 2H, Ph), 7.27−7.34 (m, 3H, Ph), 7.66 (dt, 1H, J = 1.2, 
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7.6, H-7), 7.74 (dt, 1H, J = 1.2, 7.6, H-6), 8.03 (brd, 1H, J = 7.6, H-8)ff, 8.15 (brd, 1H, J = 7.6, 
H-5)ff. δ 13C NMR (100.61 MHz, CDCl3): 14.2 (CH2CH3), 40.2 (CH2Ph), 57.3 (CHCH2Ph), 
61.9 (CH2CH3), 126.8 (C-8), 126.9 (C-5), 127.6 (CH), 128.9 (CH), 129.4 (CH), 130.0 (C-8a), 
132.3 (C-4a), 132.7 (C-7), 134.9 (C-6), 135.1 (C), 171.3 (CO), 176.8 (C-4), 180.1 (C-1); the 
following 1H and 13C signal assignments are interchangeable: C-1 with C-4, C-4a with C-8a, 
H-5/C-5 with H-8/C-8, and H-6/C-6 with H-7/C-7. Proton-carbon correlations were assigned 
from the HMQC spectrum. ESI-MS m/z (rel. int.) 384 (MH+) (100), 386 (MH++2) (30). Anal. 
Calcd (C21H18ClNO4): C, 65.71; H, 4.73; N, 3.65. Found: C, 65.73; H, 4.45; N, 3.66. 
 
N-(1,4-Naphthoquinon-2-yl)glycine ethyl ester (3.1b) 
Compound 3.1b (19 mg) was prepared from 2-bromo-1,4-naphthoquinone 3.6 (201 mg; 0.8 
mmol) and glycine ethyl ester hydrochloride (116 mg; 0.8 mmol). The process also gave 65 
mg of impure 3.1b which was no further purified. 
3.1b; orange amorphous solid (9%); IR (film): νmax = 3373 (NH), 1743 (C=O of COOEt), 
1677 and 1573 (C=O of quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 1.34 (t, 3H, J = 7.2, 
CH2CH3), 3.94 (d, 2H, J = 5.2, NCH2), 4.31 (q, 2H, J = 7.2, CH2CH3), 5.66 (s, 1H, H-3), 6.41 
(brs, 1H, NH), 7.64 (brt, 1H, J = 7.6, H-7)ff, 7.73 (brt, 1H, J = 7.6, H-6)ff, 8.05−8.10 (m, 2H, 
H-5 and H-8). δ 13C NMR (100.61 MHz, CDCl3): 14.2 (CH2CH3), 43.9 (NCH2), 62.1 
(CH2CH3), 102.1 (C-3), 126.2 (C-8), 126.4 (C-5), 130.5 (C-8a), 132.3 (C-7), 133.3 (C-4a), 
134.8 (C-6), 147.2 (C-2), 168.3 (CO), 181.2 (C-1), 183.2 (C-4). NMR signals for aromatic 
protons and quaternary carbons were assigned by comparison with analogue 3.1a. The 
remaining carbon signal assignments were made using HMQC and DEPT techniques. ESI-
MS m/z (rel. int.) 260 (MH+) (50). Anal. Calcd (C14H13NO4): C, 64.86; H, 5.05; N, 5.40. 
Found: C, 64.59; H, 5.01; N, 5.60. 
 
N-(3-Bromo-1,4-naphthoquinon-2-yl)glycine ethyl ester (3.2b) 
Compound 3.2b (18 mg) was obtained together with compound 3.1b. 
3.2b; orange amorphous solid (6%); IR (film): νmax = 3317 (NH), 1741 (C=O of COOEt), 
1677 and 1569 (C=O of quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 1.34 (t, 3H, J = 7.2, 
CH2CH3), 4.31 (q, 2H, J = 7.2, CH2CH3), 4.62 (d, 2H, J = 5.6, NCH2), 6.54 (brs, 1H, NH), 
7.66 (dt, 1H, J = 1.0; 7.6, H-7), 7.73 (dt, 1H, J = 1.2; 7.6, H-6), 8.05 (brd, 1H, J = 7.6, H-8)ff, 
8.15 (brd, 1H, J = 7.6, H-5)ff. δ 13C NMR (100.61 MHz, CDCl3): 14.2 (CH2CH3), 46.7 
(NCH2), 62.1 (CH2CH3), 127.0 (C-5 and C-8), 129.9 (C-8a), 132.0 (C-4a), 132.6 (C-7), 134.8 
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(C-6), 146.2 (C-2), 169.5 (CO), 176.5 (C-4), 179.8 (C-1); the following 1H and 13C signal 
assignments are interchangeable: C-1 with C-4, C-4a with C-8a, H-5 with H-8 and H-6/C-6 
with H-7/C-7. Proton-carbon correlations were assigned from the HMQC spectrum. Carbon at 
C-2 was assigned on the basis of a HMBC experiment. ESI-MS m/z (rel. int.) 338 (MH+) 
(78), 340 (MH++2) (100). Anal. Calcd (C14H12BrNO4): C, 49.73; H, 3.58; N, 4.14. Found: C, 
50.30; H, 3.60; N, 4.15.  
 
N-(3-Chloro-1,4-naphthoquinon-2-yl)glycine ethyl ester (3.3b) 
Compound 3.3b (11 mg) was prepared from 2,3-dichloro-1,4-naphthoquinone 3.9 (121 mg; 
0.5 mmol) and glycine ethyl ester hydrochloride (73 mg; 0.5 mmol). 
3.3b; orange amorphous solid (7%); IR (film): νmax = 3315 (NH), 1737 (C=O of COOEt), 
1673 and 1571 (C=O of quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 1.34 (t, 3H, J = 7.2, 
CH2CH3), 4.31 (q, 2H, J = 7.2, CH2CH3), 4.61 (d, 2H, J = 6.0, NCH2), 6.53 (brs, 1H, NH), 
7.66 (dt, 1H, J = 0.8; 7.6, H-7), 7.75 (dt, 1H, J = 0.8; 7.6, H-6), 8.06 (brd, 1H, J = 7.6, H-8)gg, 
8.16 (brd, 1H, J = 7.6, H-5)gg. δ 13C NMR (100.61 MHz, CDCl3): 14.2 (CH2CH3), 46.3 
(NCH2), 62.1 (CH2CH3), 126.8 (C-8), 126.9 (C-5), 129.9 (C-8a), 132.3 (C-4a), 132.7 (C-7), 
134.9 (C-6), 143.9 (C-2), 169.5 (CO), 176.9 (C-4), 180.1 (C-1); the following 1H and 13C 
signal assignments are interchangeable: C-1 with C-4, C-4a with C-8a, H-5/C-5 with H-8/C-8 
and H-6/C-6 with H-7/C-7. Proton-carbon correlations were assigned from the HMQC 
spectrum. Carbon at C-2 was assigned on the basis of a HMBC experiment. The 1H NMR 
spectrum is in agreement with that reported in the literature.114  ESI-MS m/z (rel. int.) 294 
(MH+) (100), 296 (MH++2) (37). Anal. Calcd (C14H12ClNO4): C, 57.25; H, 4.12; N, 4.77. 
Found: C, 57.30; H, 4.30; N, 4.60.  
 
2-(Methylamino)-1,4-naphthoquinone (3.1c) and 2-(methylamino)-3-bromo-1,4-
naphthoquinone (3.2c) 
To a solution of 2-bromo-1,4-naphthoquinone 3.6 (283 mg; 1.2 mmol) in abs EtOH (40 mL) 
was added an excess of 40% aqueous methylamine solution (182 mg; 2.3 mmol). The mixture 
instantly turned orange. After vigorous stirring at rt for 40 min, the solvent was evaporated to 
yield crude product (330 mg). Compounds 3.1c (170 mg) and 3.2c (19 mg) were separated by 
column chromatography on silica gel (40 g) using as eluents DCM (0.2 L) and a mixture of 
DCM:EtOAc 3:1 (0.2 L).  
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3.1c; red amorphous solid (78%); IR (film): νmax = 3335 (NH), 1678 and 1566 (C=O of 
quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 2.96 (d, 3H, J = 5.6, CH3), 5.74 (s, 1H, H-3), 
5.97 (brs, 1H, NH), 7.64 (dt, 1H, J = 1.2, 7.6, H-7), 7.75 (dt, 1H, J = 1.2, 7.6, H-6), 8.06 
(brdd, 1H, J = 0.8; 7.6, H-8)hh, 8.12 (brdd, 1H, J = 0.8, 7.6, H-5)hh. δ 13C NMR (100.61 MHz, 
CDCl3): 29.2 (CH3), 100.7 (C-3), 126.3 (C-5 and C-8), 130.5 (C-8a), 132.0 (C-7), 133.7 (C-
4a), 134.8 (C-6), 149.0 (C-2), 181.9 (C-1), 182.9 (C-4). NMR signals for aromatic protons 
were assigned by comparison with analogue 3.1a. Carbon signal assignments were made 
using DEPT and 2D NMR techniques (HMQC and HMBC). ESI-MS m/z (rel. int.) 188 
(MH+) (100). Anal. Calcd (C11H9NO2): C, 70.58; H, 4.85; N, 7.48. Found: C, 70.96; H, 4.88; 
N, 7.43. 
3.2c; red amorphous solid (6%); IR (film): νmax = 3315 (NH), 1678 and 1571 (C=O of 
quinone) cm−1. δ 1H NMR (400 MHz, CDCl3): 3.47 (d, 3H, J = 5.6, CH3), 6.17 (brs, 1H, NH), 
7.64 (dt, 1H, J = 1.2, 7.6, H-7), 7.73 (dt, 1H, J = 1.2, 7.6, H-6), 8.04 (brdd, 1H, J = 0.8; 7.6, 
H-8)hh, 8.17 (brdd, 1H, J = 0.8, 7.6, H-5)hh. δ 13C NMR (100.61 MHz, CDCl3): 33.1 (CH3), 
126.9 (C-8), 127.1 (C-5), 129.8 (C-8a), 132.4 (C-4a), 132.5 (C-7), 134.9 (C-6), 147.0 (C-2), 
176.5 (C-4), 180.2 (C-1); the following 1H and 13C signal assignments are interchangeable: C-
1 with C-4, C-4a with C-8a, H-5/C-5 with H-8/C-8 and H-6/C-6 with H-7/C-7. Proton-carbon 
correlations were assigned from the HMQC spectrum. Carbon at C-2 was assigned on the 
basis of a HMBC experiment. ESI-MS m/z (rel. int.) 266 (MH+) (86), 268 (MH++2) (100). 
Anal. Calcd (C11H8BrNO2): C, 49.65; H, 3.03; N, 5.26. Found: C, 49.87; H, 2.98; N, 5.21. 
 
1-[(1,4-Naphthoquinon-2-yl)-S-leucylamido]-3-methylbutane (3.1d) 
The process began with the synthesis of N-Boc-S-leucinyl-isopentylamine 3.23 (180 mg) from 
N-Boc-S-leucine-N-hydroxysuccinimide ester (60 mg; 0.7 mmol) and iso-amylamine (60 mg; 
0.7 mmol) using the method described for 2.77 (Section 5.1.4.9), but with no need of 
chromatographic purification. The N-Boc group of 3.23 (173 mg; 0.6 mmol) was easily 
cleaved (see experimental for 2.73a, Section 5.1.4.8) to afford S-leucinyl-isopentylamine 3.24 
(135 mg). This compound (131 mg; 0.7 mmol) was added to a solution of 1,4-naphthoquinone 
3.8 (110 mg; 0.7 mmol) in abs EtOH (10 mL) with TEA (66 mg; 0.7 mmol). The reaction 
mixture was vigorously stirred at rt for 1 h and then the solvent was evaporated. Compound 
3.1d (42 mg) was purified by column chromatography on silica gel (40 g) using as eluents 
DCM (0.2 L) and a mixture of DCM:EtOAc 19:1 (0.5 L). 
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3.23; white amorphous solid (88%); IR (film): νmax = 3305 (br, NH), 1683 and 1649 (d, 
2×C=O), 1244 (C-O) cm−1. δ 1H NMR (400 MHz, CDCl3): 0.91−0.96 (m, 12H), 1.40−1.45 
(m, 4H), 1.45 (s, 9H, CH3-Boc), 1.57−1.69 (m, 2H), 3.25−3.30 (m, 2H), 4.06 (m, 1H), 4.96 
(brd, 1H, J = 7.6), 6.21 (m, 1H). ESI-MS m/z (rel. int.) 601 (M2+) (86). 
3.24; yellow oil (93%); IR (film): νmax = 3295 (br, NH), 1654 (C=O) cm−1. δ 1H NMR (400 
MHz, CDCl3): 0.81−0.97 (m, 9H), 1.28−1.45 (m, 3H), 1.54−1.70 (m, 3H), 3.15−3.20 (m, 1H), 
3.28−3.37 (m, 2H), 5.15 (brs, 1H), 7.35−7.45 (m, 1H), 8.12 (m, 1H). ESI-MS m/z (rel. int.) 
401 (M2+) (100). 
3.1d; brown oil (18%); IR (film): νmax = 3335 (NH), 1675 and 1572 (C=O of quinone), 1640 
(C=O of amide) cm-1. δ 1H NMR (400 MHz, CDCl3): 0.90 [d, 6H, J = 6.8, 2×CH3 (i-Am)]ii, 
0.95 [d, 3H, J = 6.4, CH3 (Leu)], 1.02 [d, 3H, J = 6.0, CH3 (Leu)], 1.37−1.42 [m, 2H, CH2CH 
(i-Am)], 1.55−1.63 [m, 1H, CH (i-Am)], 1.70−1.79 [m, 2H, CHH and CH(CH3)2 (Leu)], 
1.88−1.92 [m, 1H, CHH (Leu)], 3.28−3.33 [m, 2H, NHCH2 (i-Am)], 3.89−3.92 [m, 1H, 
CHNH (Leu)], 5.82 (s, 1H, H-3), 6.13 [d, 1H, J = 6.8, NH (Leu)], 6.28 [m, 1H, NH (i-Am)], 
7.66 (dt, 1H, J = 1.2, 7.6, H-7), 7.76 (dt, 1H, J = 1.2, 7.6, H-6), 8.07−8.10 (m, 2H, H-5 and H-
8). δ 13C NMR (100.61 MHz, CDCl3): 21.9 [CH3 (Leu)], 22.4 [2×CH3 (i-Am)]ii, 22.9 [CH3 
(Leu)], 25.1 [CH(CH3)2 (Leu)], 25.9 [CH (i-Am)], 38.0 [NHCH2 (i-Am)], 38.3 [CH2CH (i-
Am)], 41.8 [CH2 (Leu)], 55.9 [CHNH (Leu)], 102.4 (C-3), 126.3 (C-8), 126.5 (C-5), 130.4 
(C-8a), 132.4 (C-7), 133.2 (C-4a), 135.0 (C-6), 147.4 (C-2), 170.3 [CO (Leu)], 181.2 (C-1), 
183.2 (C-4). 1H and 13C NMR signal assignments were possible using DEPT and 2D NMR 
techniques (HMQC and HMBC). ESI-MS m/z (rel. int.) 357 (MH+) (100). Anal. Calcd 
(C21H28N2O3): C, 70.76; H, 7.92; N, 7.86. Found: C, 70.95; H, 7.45; N, 7.53. 
 
2-Ethoxy-1,4-naphthoquinone (3.5) 
A solution of 1,4-naphthoquinone 3.8 (311 mg; 1.9 mmol) in abs EtOH (40 mL) with TEA 
(192 mg; 1.9 mmol) was vigorously stirred at rt for 1 h, during which time a red color was 
found to develop. After stirring for another 12 h, the solvent was evaporated to yield crude 
product (529 mg), which was fractionated by column chromatography on silica gel (40 g) 
using DCM (0.45 L) as eluent to afford 110 mg of 3.5. 
3.5; yellow amorphous solid (29%); IR (film): νmax = 1682, 1656, 1610 cm−1. δ 1H NMR (400 
MHz, CDCl3): 1.55 (t, 3H, J = 6.8, CH2CH3), 4.12 (q, 2H, J = 6.8, CH2CH3), 6.17 (s, 1H, H-
3), 7.73 (dt, 1H, J = 1.6, 7.6, H-7), 7.77 (dt, 1H, J = 1.6, 7.6, H-6), 8.10 (brdd, 1H, J = 1.6; 
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7.4, H-8)jj, 8.15 (brdd, 1H, J = 1.6, 6.8, H-5)jj. δ 13C NMR (100.61 MHz, CDCl3): 13.9 
(CH2CH3), 65.4 (CH2CH3), 110.2 (C-3), 126.1 (C-8), 126.7 (C-5), 131.2 (C-8a), 132.0 (C-7), 
133.3 (C-4a), 134.3 (C-6), 159.7 (C-2), 180.2 (C-1), 185.1 (C-4). NMR signals for aromatic 
protons and quaternary carbons were assigned by comparison with analogue 3.1a. The 
remaining carbon signal assignments were made using HMQC and DEPT techniques. ESI-
MS m/z (rel. int.) 422 (M2NH4+) (82). Anal. Calcd (C12H10O3): C, 71.28; H, 4.98. Found: C, 
71.30; H, 4.58.  
 
2-(Bromomethyl)-1,4-naphthoquinone (3.10b) 
N-Bromo-succinimide (431 mg; 2.4 mmol) was added to a solution of 2-methyl-1,4-
naphthoquinone 3.11 (405 mg; 2.3 mmol) in CCl4 (20 mL). To this suspension, benzoyl 
peroxide (56 mg; 0.2 mmol) was added and the mixture was refluxed for 17 h. A second 
addition of N-bromo-succinimide (431 mg) was made and the reaction was refluxed for a 
further 7 h. The solvent was evaporated to give a product (1.3 g) which was subjected twice to 
column chromatography on silica gel using DCM as eluent to afford 3.10b (208 mg). 
3.10b; yellow amorphous solid (36%). 1H NMR (400 MHz, CDCl3): 4.42 (brs, 2H, CH2Br), 
7.12 (brs, 1H, =CH), 7.78−7.81 (m, 2H, Ph), 8.09−8.12 (m, 1H, Ph), 8.15−8.17 (m, 1H, Ph). δ 
13C NMR (100.61 MHz, CDCl3): 25.4 (CH2Br), 126.4 (CH), 126.9 (CH), 131.8 (C), 132.2 
(C), 134.1 (CH), 134.2 (CH), 136.8 (=CH), 146.1 (C), 183.2 (C=O), 184.7 (C=O). Carbon 
signal assignments were made using HMQC techniques.  
 
 
5.2 Kinetic study of the reaction with cysteine 
 
5.2.1 Reagents and Solvents 
 
DMSO and buffer materials for kinetic measurements were of analytical grade and were 
purchased from Merck (Germany). Ellman’s reagent was from Sigma-Aldrich. Freshly 
deionised water was used throughout. 
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5.2.2 Equipment 
 
Measurement of pH values was carried out at 25.0 ± 0.1 ºC, using a digital microprocessor 
pH meter (model micro pH 2002, Crisson Instruments S.A.), calibrated with standard buffers 
(Merck). Kinetic measurements were carried out using either Shimadzu UV-2100 or 
Shimadzu UV-1603 spectrophotometers, equipped with a temperature controller (CPS). 
 
 
5.2.3 Buffers and substrate solutions 
 
The stock solutions of vinyl sultams, vinyl sulfonamide and naphthoquinones were 
prepared in DMSO. 
For vinyl sultams/vinyl sulfonamide, thiol solutions were prepared by dissolution of 
cysteine in 50 mM K2HPO4/KH2PO4 buffer, pH 6.9, containing KCl to maintain ionic 
strength at 0.5 M and 30% (v/v) acetonitrile (due to vinyl sultams solubility problems). For 
naphthoquinones, thiol solutions were prepared by dissolution of cysteine in 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.1, containing KCl to maintain ionic strength at 0.5 M. In the 
case of 2-methyl-1,4-naphthoquinone, 3.11, the rates were measured at three additional pH 
values using thiol solutions prepared in sodium borate/HCl buffer (pH 7.9, 8.0 and 8.8).145  In 
all cases, thiol solutions with a change in the final pH value greater than 0.05 comparatively 
to the one of the employed buffer were rejected. 
Cysteine concentration ranged between ca. 1 and 4 mM for vinyl sultams/vinyl 
sulfonamide and between ca. 0.5 and 5 mM for naphthoquinones, except in the kinetics of 
naphthoquinone 3.8, in which the range was 0.06−5 mM. 
Because thiols are prone to oxidation, cysteine solutions were prepared immediately 
before use and the concentration of thiol in solution was measured just before use by Ellman’s 
method (Section 5.2.4).146   
 
 
5.2.4 Determination of free thiol content 
 
The free thiol content was assayed using Ellman’s reagent 5.1, i.e. DTNB = 5,5’-
dithiobis(2-nitrobenzoic acid).146  The reaction of a thiol with DTNB gives a mole equivalent 
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of the yellow 5-thio-2-nitrobenzoic acid anion 5.2 (Scheme 5.1), which can be measured by 
UV spectrophotometry (molar extinction coefficient of 14.15 × 103 M−1 cm−1).146  
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Scheme 5.1 Reaction of Ellman’s reagent with thiols.147  
 
In general, aliquots of the cysteine solutions (≤ 50 µL) were added to a preincubated 
quartz cuvette at 25.0 ± 0.1 ºC, containing a 0.1 mM solution of DTNBkk in 0.1 M 
K2HPO4/KH2PO4 buffer, pH 7.4, to give a total volume of 1 mL. Under these conditions, thiol 
concentrations in the cuvette ranged between 20 and 120 µM (absorbance values between 0.3 
and 1.7), where Lambert-Beer’s law is valid (see Figure 5.1). 
The absorbance at 412 nm was read after 5 min,ll against a blank solution lacking thiol. A 
new blank was prepared for every sample containing cysteine (this is recommended by the 
literature146  due to the possible degradation of DTNB during the time of the experiment). 
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Figure 5.1 Thiol titration curve for a cysteine solution using Ellman’s reagent. The assay was performed by 
adding 5, 10, 20 and 30 µL of a cysteine solution (5 mM in 4 mM K2HPO4/KH2PO4 buffer, pH 7.5) into a quartz 
cuvette with Ellman’s reagent (0.1 mM solution in 0.1 M K2HPO4/KH2PO4 buffer, pH 7.4), to complete a total 
volume of 1 mL. Points are experimental and line is from linear regression analysis of the data. 
                                                 
kkCaution: DTNB and its solutions must be protected from light during storage to prevent formation of yellow 
photodegradation products.146  
ll It was observed that absorbance values became reproducible after this period of time. Albeck et al.148  also 
indicate a 5 min incubation period before the determination of absorbance. 
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5.2.5 UV Spectrophotometry 
 
The kinetic measurements were carried out at 25.0 ± 0.1 ºC. 
Reactions were initiated by addition of an aliquot of vinyl sultam/vinyl 
sulfonamide/naphthoquinone stock solution (50, 100 or 150 µL) to a quartz cuvette containing 
DMSO (100, 50 and 0 µL, respectively) and 2.85 mL of a cysteine solution (Section 5.2.3). 
The absorbance was recorded against a blank of cysteine solution (2.85 mL) and DMSO (150 
µL). 
The initial concentration of the vinyl sultam/vinyl sulfonamide/naphthoquinone in the 
cuvette and the wavelengths used to monitor the kinetic reactions were as follows: 2.67a (50 
µM; decrease at 260 nm), 2.67b (50 µM; decrease at 260 nm), 2.68a (75 µM, decrease at 260 
nm), 2.69b (25 µM; decrease at 260 nm), 2.84a (75 µM, decrease at 255 nm), 3.1a (32 µM; 
decrease at 265 nm), 3.1b (50 µM; increase at 277.3 nm), 3.1c (50 µM; increase at 300 nm), 
3.5 (50 µM; decrease at 282 nm), 3.8 (50 µM; increase at 360 nm), 3.11 (50 µM; increase at 
279.8 nm), 3.13 (10 µM; decrease at 500 nm).The absorbance was recorded until a plateau 
region had been reached (see Figure 5.2 for a typical example).  
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Figure 5.2 Progress curve for the reaction of vinyl sultam 2.68a with cysteine (895 µM), at pH 6.93 at 25 
ºC and ionic strength 0.5 M. 
 
 
 
5. Experimental Section 
161 
5.2.6 Determination of kobs 
 
The pseudo first-order rate constants, kobs, were obtained from the slopes of the plots of ln 
(δA) versus time, where δA represents the difference in absorbance between each time t and 
time infinity (plateau region). 
 
 
5.3 Molecular modelling 
 
Molecular docking enzyme–inhibitor studies were performed with the flexible GOLD 3.0 
(Genetic Optimisation for Ligand Docking)  package.149  GOLD program uses a genetic 
algorithm (which mimics the process of evolution by applying genetic operators) to explore 
the full range of ligand conformational and rotational flexibility, and has been fully validated 
against 305 diverse and extensively checked protein-ligand complexes from the PDB 
database. The docking results were ranked based on the goldscore scoring function (fitness 
function).150  Goldscore function is defined as the sum of four components (protein-ligand 
hydrogen bond energy, protein-ligand Van der Waals, energy ligand internal Van der Waals 
energy, and ligand torsional strain energy) and is specially featured to predict ligand-binding 
positions. Each run of Gold generated a file with the atomic coordinates in the conformation 
that best fitted the enzyme active site and computed a fitness score. 
The papain structure used in the calculations (PDB code 1PPN) was obtained by deletion 
of one oxygen and the methanol present in the crystal structure. The structure was energy-
minimized.  
The cruzain structure used in the calculations (PDB code 1F2A) was obtained by deletion 
from the active site of the ligand 1.2d present in the crystal structure. To confirm the 
reliability of the final cruzain structure we have performed some docking calculations with the 
known covalent complex and confirmed that the final enzyme-complex structures are very 
close to the corresponding x-ray structures obtained from the literature.  
For each ligand (previously energy-minimized with density functional theory) 50 docking 
runs were performed (100,000 genetic algorithm operations, 5 islands).  
 
 
 
5. Experimental Section 
162 
5.4 Molecular orbital calculations 
 
LUMO energies were calculated using density functional theory (DFT). DFT151  
calculations were carried out with the Gaussian 03 suite of programs.152  1,4-Naphthoquinone 
structures were optimised without symmetry constraints using the hybrid B3LYP functional, 
which is a combination of the Becke’s three-parameter (B3) exchange functional153  with the 
Lee, Yang, and Parr (LYP) correlation functional,154  in conjunction with 6-311G(d,p)155  
basis set. All geometries were found to be minima on the respective potential energy surfaces. 
LUMO energies were calculated at this level of theory. 
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APPENDIX I. Protocols for enzymatic assays 
 
This appendix concerns itself with the development of procedures to evaluate the activity 
of potential inhibitors against papain and bovine spleen cathepsin B. In addition, it describes 
the inhibition assay for porcine pancreatic elastase. 
 
 
AI.1 Papain 
 
This section is divided in three parts; firstly, the establishment of the inhibition assay; 
secondly, a gel-filtration chromatography procedure for the purification of the activated 
enzyme, and finally, a dialysis experiment. 
 
 
AI.1.1 Development of papain inhibition assay 
 
AI.1.1.1 Introductory remarks 
 
Papain has been extensively investigated since the earlier twentieth century. Thus, several 
methods exist for the measurement of its activity.156  Nevertheless, not all are simple enough 
to be used in inhibition studies. For example, the Sigma quality control test procedure157  for 
papain (Sigma P4762) consists in a titrimetric determination of the acid produced during the 
hydrolysis of the benzoyl-S-arginine ethyl ester (BAEE). On the other hand, a search for 
papers describing new inhibitors revealed more convenient methods, i.e. spectrophotometric, 
although some have been reported lacking important experimental details, such as the enzyme 
or the substrate concentration.158-160   
In general, papain requires an optimum pH conditions, a reducing environment and a good 
substrate. 
The pH optima of papain vary from 6.0 to 7.0,157  what is related to the existence of a 
thiolate/imidazolium ion pair, crucial for the catalytic activity. Thereby, at neutral pH, the 
percentage of papain presents as its ion-pair form has been determined and is in the range of 
at least 50% to almost 100% of the total enzyme.23  
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A reducing agent, such as a thiol reagent or sodium borohydride, is required for the 
maximum hydrolytic activity of papain.156  This situation is due to the fact that the enzyme is 
isolated from Carica papaya as an inactive form, in which Cys25 is blocked by a disulfide 
bond. Thus, the reducing reagent is used to deblock it (activation of papain). In connection, 
the free Cys25 thiol group must be protected from oxidation in the reaction medium. The 
presence of a chelating agent, such as EDTA, is therefore required to remove traces of metal 
ions impurities, which are known oxidants.156  
Concerning substrates, papain is a fairly good catalyst in the hydrolysis of N-benzoyl and 
N-carbobenzoxy derivatives of single amino acids. This situation is ascribed to the binding of 
the N-acyl aromatic groups to the S2 subsite, which is the most important element of substrate 
specificity, as mentioned in Section 1.1.3). Among amino acids, papain hydrolyses the 
derivatives of Gln, His, Gly, Tyr, Arg and Lys. The two latter are considered the most 
susceptible.161  
In order to develop the papain inhibition assay, the present work focused on two reported 
procedures with different substrates, one involving Cbz-Gly-ONp and another involving 
BAPA.  
 
 
AI.1.1.2 Determination of the papain activity in the presence of Cbz-Gly-ONp 
 
The compound Cbz-Gly-ONp I.1 (Scheme AI.1) is considered to be a convenient 
substrate for papain due to its Km (9.3 µM)mm and fair solubility. In addition, the reaction is 
spectrophotometric because it generates the yellow product p-nitrophenol I.2.162  
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Scheme AI.1 Determination of the papain activity using Cbz-Gly-ONp as substrate.  
                                                 
mm At pH 6.8 at 25 ºC. 
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Briefly, the present work used papain freshly activated by sodium cyanoborohydride and 
carried out the reaction in K2HPO4/KH2PO4 buffer, pH 7.0, containing EDTA. The employed 
buffer and reducing agent were reported by Guo et al.158   
Papain activation followed the commonly reported incubation conditions of 1 h at 25 ºC.  
Substrate stock solutions were prepared in DMSO and 100 µL aliquots were transferred to 
the 1 mL cuvette, such that the organic solvent did not exceed 10% of the total volume.160  
Initially, the enzyme concentration was arbitrarily established in 100 µg/mL and the 
substrate was employed in a saturating amount (300 µM).  
These conditions resulted in a clear burst (Figure AI.1a). Such behaviour has already been 
reported for the papain-catalysed hydrolysis of similar Cbz-amino acid esters,163  and it is a 
quite general phenomenon, as it has been observed for other enzymes and substrates.139  This 
type of situation occurs in a two-step mechanism, in which the substrate rapidly reacts with 
the enzyme to form a covalent enzyme-bound intermediate, but then the turnover into the 
products is slow (although not negligible).139  In Cbz-Gly-ONp hydrolysis, deacylation of the 
enzyme is the slow step. Thus, there is an initial accumulation of the acyl-enzyme 
intermediate I.3 (Scheme AI.1) associated with a rapid release of p-nitrophenol, which causes 
the burst, but then the reaction proceeds slowly because it depends on the slow breakdown of 
I.3 to restore free papain.139   
It is known that burst may be overcome by decreasing the substrate concentration.139  The 
papain activity was therefore measured in the presence of two lower concentrations of Cbz-
Gly-ONp (30 µM and 3 µM), that led to a better linear region, particularly the 3 µM 
concentration (Figures AI.1b and AI.1c). However, this situation resulted in smaller 
absorbance values with higher associated error. In addition, the enzyme activity was 
reasonably low (ca. 6 × 10−5 AU/s for Figure AI.1c). As this assay was planned to be used in 
inhibition studies, a high reaction rate (good slope) was required in order to assess its decay in 
the presence of the inhibitor. Thus, the conditions remained unsuitable and an alternative 
spectrophotometric assay was exploited (following section). 
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Figure AI.1 Progression curves for the papain-catalysed hydrolysis of Cbz-Gly-ONp. The experiment was 
carried out at pH 7.0 at 25 ºC, using Cbz-Gly-ONp in the following concentrations: (a) 300 µM, (b) 30 µM and 
(c) 3 µM. For experiment (c), points are experimental and line is from linear regression analysis of the data. 
 
 
AI.1.1.3 Determination of the papain activity in the presence of BAPA 
 
In order to use BAPA I.4 as substrate (Figure AI.2), the present study focused on the 
method used by Zhao et al.164  Thus, papain activity was determined under the following 
conditions. 
 
 
 
 
 
 
 
 
 
 
Papain (1 mg/mL) was activated by incubation at 25 ºC, for 1 h, in 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 15 mM DTT. The reaction 
was started by the addition of papain (30 µL of the stock solution 1 mg/mL) into a cuvette 
containing 100 µL of BAPA stock solution (10 mM in DMSO) and 870 µL of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 15 mM DTT. Enzymatic 
activity was determined by following the release of p-nitroaniline from BAPA at 25.0 ± 0.1 
ºC at 410 nm during 4 min, against a blank of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, 
containing 2.5 mM EDTA and 15 mM DTT. According to Zhao et al., under these 
conditions, the papain concentration in the reaction medium is ca. 30 µg/mL. 
a b 
c 
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Figure AI.2 Benzoyl-S-arginine-4-nitroanilide (BAPA). 
 
 
 
It should be noted that the buffer composition was reported, but no pH value was given. 
Thus, it was established to work under optimum conditions for papain, i.e. at neutral pH. 
The report also lacked information on the solvent of BAPA stock solution. The substrate 
was therefore dissolved in DMSO, which did not exceed the already mentioned (Section 
AI.1.1.2) maximum of 10% in the reaction medium. 
Another important issue concerns papain concentration. In the published procedure,164  it 
was determined from the protein absorption at ca. 280 nm.nn However, it is known that 
activation does not lead to an enzyme containing 1.0 free thiol group per molecule of papain, 
what is tentatively ascribed to the further oxidation of thiol function to sulfinic and sulfonic 
acids.156  Thus, the accurate amount of active papain can only be determinated by sulfhydryl 
titration with the inactivator E-64 (Section 1.2.2) or using Ellman’s reagent (Section 5.2.4). 
The present investigation did not assess the concentration of active enzyme in the several 
employed papain solutions. Instead, it was assumed that the assays were being performed 
under similar conditions because equivalent enzyme activities were obtained, ca. 2.5 × 10−4 
AU/s, corresponding to a fairly good slope of the plot of absorbance versus BAPA hydrolysis 
reaction time. 
 
 
                                                 
nn Proteins absorb at 280 nm due to the presence of Trp, Tyr, Phe and cystine bonds.165  
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Investigation on reducing agent. As mentioned earlier (Section AI.1.1.1), papain must 
be activated in the presence of a reducing agent. The present investigation found that this 
reagent must also be present in the cuvette buffer, because performing the reaction between 
activated papain and BAPA in buffer lacking DTT led to a reasonable decrease in the initial 
velocity v (70% of the original enzymatic activity). This situation is consistent with the one 
reported by Sanner et al.,166  who observed that papain activity in the absence of cysteine 
varied from 30% to 60% of that determined in its presence. The fact was associated with the 
evidence that thiols increase kcat value, suggesting that these agents not only activate papain 
by reducing disulfide bonds, but they also contribute to papain activity by another 
mechanism, which could not be disclosed by Sanner et al.166  
The need for DTT in the assay buffer led to a concern with the stability of BAPA. 
Because this substrate reacts with a cysteine protease, it was considered that it might be also 
susceptible to DTT. Thus, two cuvettes with BAPA (100 µL) were prepared, one containing 
buffer with DTT (900 µL) and another with buffer lacking this agent. The absorbance was 
monitored during the established 4 min at 410 nm, against a blank of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 2.0 mM DTT (the thiol was 
included in the blank only when BAPA was assayed in its presence). There was no 
absorbance increase, independently of the presence or absence of DTT, and BAPA was 
therefore considered stable under the assay conditions. 
By searching the literature it was found that most of the assays reported for cysteine 
protease inhibitors perform the enzyme-inhibitor incubation in the presence of the reducing 
agent. This is clearly a tricky situation, because the search for a suitable inhibitor involves 
several compounds and some of them may be sufficiently chemical reactive to form adducts 
with irrelevant nucleophiles, namely thiols. Thus, the presence of such agent in the assay 
buffer may result in the inhibitor depletion leading to loss of a significant part of its activity. 
Considering that in vivo other thiol species are expected to occur at high concentrations, the in 
vitro results may therefore provide an insight into the behaviour under biological conditions. 
On the other hand, this situation may underestimate the inhibitor efficiency and should always 
be kept in mind when performing structure-activity studies and planning future compounds. 
In this context and as a reasonable compromise, it was decided to bring DTT in the buffer 
into the minimal effective concentration. Table AI.1 lists the papain activity for different DTT 
concentrations. The 1.7 mM solution was the lowest concentration whose activity was 
comparable to the one presented by the original 13.1 mM solution, and it was therefore 
employed in the following assays. 
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Table AI.1 Papain activity in the presence of different DTT concentrations. 
 
[DTT] stock solution (mM) [DTT] reaction medium (mM) Papain activity (10−4 AU/s)a 
15 13.1 2.66 ± 0.07 
10 8.7 2.64 ± 0.32 
5 4.4 2.57 ± 0.21 
2 1.7 2.65 ± 0.24 
1 0.87 2.25 ± 0.24 
0.5 0.44 1.78 ± 0.25 
a Values are the mean of three determinations. 
 
 
The DTT efficiency was compared to the one of sodium cyanoborohydride by carrying 
out parallel experiments with each of these reducing agents in the same concentration (2 mM 
stock solution). No activity was observed with sodium cyanoborohydride. 
Finally, the inhibition assay was planned by adding an incubation phase, in such a way 
that the employed concentration of enzyme and substrate in the reaction medium were the 
originally reported. To investigate if papain required the presence of DTT in the incubation 
buffer, two experiments were made (see Experiments A and B in Scheme AI.2). As shown, 
the enzyme reaction rates were similar, indicating that the DTT from the activation buffer is 
sufficient to maintain the active form of papain in the incubation mixture. 
The conditions of Experiment B appeared as more suitable for the inhibition studies, on 
the basis that a lower DTT concentration in the incubation medium leads to a smaller 
depletion of highly chemical reactive inhibitors. In addition, it was found that, under 
conditions B, the enzyme retains ca. 90% of its activity after 5 h in the incubation medium. 
Thus, the assay could be employed in inhibition studies, bearing in mind that beyond this 
period of time the kinetic results could be compromised. 
A positive control inhibition assay was carried out by employing the successful papain 
inhibitor, E-64 (Section 1.2.2), in a 50 µM concentration. As expected, it led to an enzyme 
residual activity of ca. 10%, after 1 min of incubation. 
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Scheme AI.2 Possible procedures to be used for the inhibition assay. In order to achieve an enzyme 
inactivation curve with nine experimental points, the volume of the samples, from the 1 mL incubation medium, 
was established in 100 µL. It was also decided to use the papain concentration (reaction medium) reported by 
Zhao et al., i.e., ca. 30 µg/mL.164  Taking together, these conditions resulted in a 300 µg/mL concentration for 
papain in the incubation medium. 
 
100 µL 
 
50 mM K2HPO4/KH2PO4 buffer, pH 7.0, 2.5 mM EDTA, 2.0 mM DTT (800 µL) 
10 mM BAPA in DMSO (100 µL) 
reaction medium 
Papain solution (1 mg/mL)
50 mM K2HPO4/KH2PO4 buffer, pH 7.0, 2.5 mM EDTA, 2.0 mM DTT 
Activation at 25 ºC for 30 min 
300 µL 
incubation medium 
A B 
50 mM K2HPO4/KH2PO4 buffer 
pH 7.0 
2.5 mM EDTA 
2.0 mM DTT 
 
DMSO (50 µL) 
650 µL 
50 mM K2HPO4/KH2PO4 buffer
pH 7.0 
2.5 mM EDTA 
no DTT 
 
DMSO (50 µL) 
650 µL 
(2.09 ± 0.10) × 10−4 AU/s (1.91 ± 0.14) × 10−4 AU/s 
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Investigation on activation time. The original procedure activated papain for 1 h. This 
period of time was investigated (Table AI.2) and it was found that, under the adapted 
conditions, the maximum enzymatic activity is reached after 30 min of incubation. The 
activation time was therefore established in 30 min. 
 
Table AI.2 Papain activity for several activation time periods.a 
 
Activation times (min) Relative papain activity (%)b 
1 63 
15 95 
30 100 
60 100 
a These experiments were performed by Luisa Martins (from the Faculty of Pharmacy, University of Lisbon). b The results are expressed comparatively to 
the activity detected after 60 min activation. The assays were performed using the 2 mM DTT stock solution. 
 
Papain was immediately used after activation or kept at −20 ºC between assays. In 
general, no significant loss of enzymatic activity was detected after 24 h storage (conserved 
ca. 90% of its original value). 
 
 
Determination of Km. It is known that any change in enzymatic assay conditions may 
compromise the obedience to Michaelis-Menten equation.167  As the present work established 
a modified procedure for the assessment of papain activity, it was necessary to check the 
equation’s validity under the new conditions. 
Thus, the enzyme reaction rate, v, was measured in the presence of different BAPA 
amounts to reveal the expected hyperbolic dependence of velocity on substrate concentration 
(Figure AI.3). The range of BAPA concentrations included the one employed in the 
enzymatic assay, i.e. 1 mM. It was therefore demonstrated that, under the established 
conditions, the enzymatic reaction obeys Michaelis-Menten kinetics.  
The data were computer-fitted (Sigma Plot® software) to Michaelis-Menten equation, 
allowing the determination of Km (4.63 ± 0.94) × 10−3 M and Vmax (1.35 ± 0.15) × 10−3 AU/s. 
The value found for Km is consistent with the ones revealed by the literature, i.e. 4.4 × 
10−3 M (in presence of 30 mM cysteine at 35 ºC and pH 7.2),168  and (3.00 ± 0.35) × 10−3 M 
(in presence of 5.0 mM β-mercaptoethanol at 25 ºC and pH 7.01).169  
An interesting result obtained with a BAPA analogue, benzoyl-S-arginine amide, is that 
Km for the hydrolysis of this substrate by papain is dependent on the reducing agent used as 
well as on its concentration, with an appreciably enhancement in Km value with increasing 
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cysteine concentration.166  It was reasoned that this effect might occur for other thiol-
activating enzymes.166  
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Figure AI.3 Reaction rate, v, plotted against the BAPA concentration, [BAPA], for the papain-catalysed 
hydrolysis of this compound, at pH 7.0 at 25 ºC. Points are experimental and line is theoretical for Km (4.63 ± 
0.94) × 10−3 M and Vmax (1.35 ± 0.15) × 10−3 AU/s. 
 
 
AI.1.2 Purification of papain by gel-filtration chromatography 
 
As described in the previous sections, this work established a papain inhibition assay 
involving an enzyme-inhibitor incubation mixture, whose buffer contains DTT (provided by 
the enzyme stock solution). The thiol presence may, however, become a limitation when 
testing inhibitors with sufficiently chemical reactivity to be depleted by DTT, a situation that 
leads to a decrease or abolition of the inhibitory activity of the compounds. To overcome this 
problem it would be necessary to employ papain free from DTT. 
Activated papain is easily purified from the reducing agent by gel-filtration 
chromatography on Sephadex columns.148,158,170  The present investigation used a PD-10 
desalting column, which efficiently separates molecules of high (Mr > 5000)oo from low 
molecular weight substances (Mr < 1000).171  
After gel-chromatography, the eluted fractions were assayed for papain content by 
measuring their A280. This yielded a chromatogram, exemplified by the one in Figure AI.4, 
which reveals a bell-shape elution profile for papain (in blue). The absorbance, however, did 
                                                 
oo Papain is a 23406-molecular weight (Mr) protein.157  
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not return to the baseline level, what was thought to be caused by the later elution of DTT, as 
this thiol also absorbs at 280 nm, although weakly than papain.157  This situation was 
confirmed by recording the A412 of the latter fractions, after reaction with Ellman’s reagent 
(Section 5.2.4). As no significant amounts of papain are expected to occur at this stage, the 
increase in the A412, i.e. the increase in free thiol content, could be essentially ascribed to 
DTT. 
The slight increase in the absorbance, seen around fraction 11, was also detected in other 
experiments and may be due to the remaining elution of the protein along with the starting 
elution of DTT. Thus, to ensure the complete separation of papain from the thiol agent, only 
fractions 2 to 8 were combined. 
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Figure AI.4 Elution profile (absorbance versus collected fractions) for papain purification by gel-filtration 
chromatography using a PD-10 desalting column. The buffer used was 50 mM K2HPO4/KH2PO4 buffer, pH 
7.0, 2.5 mM EDTA. 
 
 
The resultant papain stock solution could be easily assayed for effective active enzyme 
concentration using Ellman’s reagent, without interference from DTT. Nevertheless, this 
parameter was not assessed in the procedure lacking gel-filtration chromatography, in which 
the concentration of papain was calculated by weighing an accurate amount of enzyme. Thus, 
in order to equal the concentration employed in both protocols, it was decided to assay the 
purified enzyme solution for total protein concentration by measuring the A280. Calculations 
were done by using an extinction coefficient of 57.6 mM−1 cm−1 and a 23406-molecular 
weight.157  When required, the purified papain was diluted with 50 mM K2HPO4/KH2PO4 
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buffer, pH 7.0, 2.5 mM EDTA. By working in this way, comparable enzyme activities were 
obtained (purified versus non-purified). 
It is known that the linear relationship between enzyme amount and enzyme reaction rate, 
v, is a reliable test for the validity of the Michaelis-Menten equation.167  For purified papain, 
investigation on such dependence resulted in the expected correlation (Figure AI.5), which 
means that no departure from Michaelis-Menten kinetics exists when the enzyme is employed 
up to 60 µg/mL in the reaction medium (the established assay uses a concentration of ca. 30 
µg/mL). 
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Figure AI.5 Reaction rate, v, plotted against the papain concentration, [papain], for the papain-catalysed 
hydrolysis of BAPA, at pH 7.0 at 25 ºC. Points are experimental and line is from linear regression analysis of 
the data. 
 
 
A positive control inhibition assay was performed with the 2-bromo-1,4-naphthoquinone 
derivative 3.6, which was found to be one of the most potent papain inhibitors in this work 
(Section 3.3.1). Interestingly, the enzyme was inactivated to an extent similar to the one 
observed when employing non-purified papain (Figure AI.6). This situation suggests that this 
inhibitor is not significantly affected by the thiol presence. 
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Figure AI.6 Time course of papain inactivation by 2-bromo-1,4-naphthoquinone derivative 3.6, at pH 7.0 
at 25 ºC. The inhibitor concentration was 50 µM. The enzymatic activity is expressed as residual activity 
percentage (RA%). The inset presents a semi-logarithmic plot of RA versus time. Points are experimental and 
line is theoretical for kobs (8.05 ± 0.52) × 10−4 s−1 (purified papain) and (8.54 ± 0.67) × 10−4 s−1 (non-purified 
papain). 
 
Overall, it was demonstrated that purified papain, provided by gel-filtration 
chromatography (PD-10 desalting column), can be applied to the inhibition assay adapted in 
the present thesis. This alternative procedure may be carried out for the accurate evaluation of 
highly chemical reactive compounds.  
Although not investigated, a probability exists that purification leads to a less stable 
enzyme due to the absence of a reducing environment. Therefore, careful attention should be 
taken with the durability of the inhibition study. As usual, the reliability of the results would 
be assessed by a blank control, which must be assayed throughout the experiment. 
 
 
AI.1.3 Dialysis experiment 
 
A dialysis experiment was performed to check the irreversibility of papain inactivation by 
the naphthoquinone derivatives presented in Section 3.3.1. The enzyme-inhibitor complex 
was dialysed against phosphate buffer, containing DTT. This thiol is required to maintain the 
reducing conditions essential for papain activity. In fact, when the experiment was carried out 
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in buffer without DTT, the control enzyme lost ca. 40% of its activity after 2 h of dialysis, ca. 
60% after 10 h and ca. 80% after 24 h. 
The change in the enzymatic activity, during dialysis, was evaluated by taking periodical 
aliquots from the papain solution. However, differences in protease activity may be caused by 
the dilution of papain solution throughout dialysis, as the water from the buffer tends to cross 
the membrane (osmosis). Thus, for comparison purposes between assays, the enzymatic 
activity was expressed as AU/s/µg papain, where AU/s represents the increase in A410 during 
4 min, due to the cleavage of BAPA into p-nitroaniline. Finally, the enzymatic activity was 
converted to a percentage of the value found immediately before the dialysis.  
Concerning papain concentration, it was stated before (Section AI.1.1.3) that the 
concentration of a protein may be determined from its UV absorption (280 nm), using 
Lambert-Beer’s law. However, the method could not be used due to the interference from the 
inhibitor, which also absorbs at this wavelength (see the spectrum in Appendix III). The 
Bradford assay provided, therefore, a suitable alternative. It is also a spectrophometric 
method, whose absorbance results were converted to the approximate protein concentration 
according to the equation 
 
A595 = 32.4 × 10−3 × [protein concentration] + 4.4 × 10−3                                                                (AI.1) 
 
where the protein concentration is given in µg/mL. This equation showed to be valid up to 15 
µg/mL (r2 = 0.983).pp 
 
 
 
AI.2 Bovine spleen cathepsin B 
 
AI.2.1 Introductory remarks 
 
Cathepsin B is one of the best characterised mammalian cysteine proteases, whose role in 
human pathological processes was mentioned in Section 1.1.2.  
                                                 
pp This equation was previously obtained by Luisa Martins (from the Faculty of Pharmacy, University of 
Lisbon), by assaying six solutions of bovine serum albumin of different concentrations, using a procedure similar 
to the one employed in this work (the Bradford assay is described in Section AI.4.5). 
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Bovine spleen cathepsin B shares about 80% amino acid sequence homology with the 
human liver variety.172  Thus, it provided a suitable model for the human protease, at a lower 
price. 
The search for a convenient enzymatic assay was a straightforward task as the Sigma 
quality control test procedure157  for cathepsin B (Sigma C6286) consists in a convenient 
spectrophotometric method, which was first described by Bajkowski et al.173  Similarly to 
papain, cathepsin B requires a reducing environment and the presence of a chelating agent for 
full hydrolytic activity. However, while papain has a neutral pH optimum, cathepsin B is most 
active in an acidic medium (pH values from 4.0 to 6.5), which is in accordance with its 
activity within lysosomes.11,161  
 
 
AI.2.2 Development of cathepsin B inhibition assay 
 
According to Sigma, the bovine spleen cathepsin B stock solution is prepared in 20 mM 
sodium acetate buffer, pH 5.0, containing 1.0 mM EDTA and 5.0 mM cysteine. Proteolytic 
activity is measured in the same buffer by following the release of p-nitrophenol from Cbz-S-
Lys-ONp at 326 nm for approximately 3 min at 25 ºC. In the reaction mixture, the substrate 
concentration is 80 µM and the enzyme concentration is between 8.2 × 10−3 and 16.3 × 10−3 
units/mL. 
In the present work, the enzyme concentration was arbitrarily established in 10.0 × 10−3 
units/mL for the reaction with the substrate, which was employed in the concentration 
reported by Sigma, i.e. 80 µM. 
The main concern in adapting this procedure was the type of reducing agent used as well 
as its concentration because the potential inhibitors may react more or less significantly with 
the thiol present in the buffer. Thus, it was thought that comparative studies on the 
compounds efficiency against several cysteine proteases would give more reliable results if 
the inhibitor was exposed to the same thiol (type and concentration), independently of the 
target enzyme. It was therefore decided to employ the conditions previously established for 
papain, i.e., 0.6 mM DTT in the incubation medium and ca. 2 mM in the reaction cuvette. 
Interestingly, this latter concentration was used by Bajkowski et al.173  to carry out the 
cathepsin B-catalysed hydrolysis of the substrate used in this thesis. 
It is known that cathepsin B requires thiol activation.161  The Sigma protocol does not 
indicate an activation time period before the reaction with the substrate, but Bajkowski et 
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al.173  described a 15-min incubation phase at 25 ºC, which was adapted in the present 
investigation.qq Because the enzyme is supplied in sealed ampoules, it was dissolved in the 
activation buffer, then it was activated and kept within the sealed ampoule, at −20 ºC, between 
assays. No loss of enzymatic activity was detected during approximately two weeks. 
Under these conditions, plotting the Cbz-S-Lys-ONp hydrolysis reaction time against the 
increase in the absorbance resulted in a slope sufficiently high (ca. 1 × 10−3 AU/s) to assess its 
decay in the presence of the inhibitor. 
Another important subject was the stability of Cbz-S-Lys-ONp in the assay buffer. This 
was investigated by preparing a cuvette with substrate (100 µL of the stock solution 0.8 mM) 
and 900 µL of 20 mM sodium acetate buffer, pH 5.0, containing 1.0 mM EDTA and 2.0 mM 
DTT. The absorbance was recorded during the reported 3 min at 326 nm, against a blank of 
20 mM sodium acetate buffer, pH 5.0, containing 1.0 mM EDTA and 2.0 mM DTT. There 
was an absorbance increase of ca. 0.1 × 10−3 AU/s, corresponding to ca. 10% of the one 
above-mentioned, in the presence of the enzyme. These data indicated a slight degree of 
spontaneous chemical hydrolysis of the substrate, but this interference could be easily 
removed by adding substrate to the blank cuvette. Later, it was found that the kinetic results 
were not compromised by the substrate stability, because comparable results for Km value 
(39.4 ± 7.11 µM versus 47.4 ± 9.00 µM) were obtained in two independent experiments, one 
with substrate in the blank cuvette and another lacking this component. The presence of the 
substrate in the blank was therefore excluded in the inhibition studies. 
Figure AI.7 shows the hyperbolic dependence of reaction rate on substrate concentration. 
The value found for Km is slightly different from the one reported by Bajkowski et al.,173  
which is 2.7 ± 0.30 µM. This inconsistency is not easy to explain as both investigations 
assayed the enzyme in equal conditions, i.e. sodium acetate buffer (20 mM in this thesis and 
25 mM in the Bajkowski’s work), pH 5, containing 1 mM EDTA and DTT ca. 2 mM. 
On the other hand, the calculation of Km value followed a different approach from the one 
described by Bajkowski et al.173  These authors followed the reactions to completion and 
converted the absorbance data to rate data using the molar extinction coefficient of Cbz-S-
Lys-ONp, whereas the present work measured the initial rates, v. The calculation method was 
therefore considered as the most probable reason for discrepancy.  
The most important, however, is the evidence that the hydrolysis of Cbz-S-Lys-ONp by 
cathepsin B obeys Michaelis-Menten kinetics, under the established conditions. 
                                                 
qq The present work and Bajkowski et al. activated the enzyme under equal conditions, i.e. in the presence of 30 
mM DTT. 
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Figure AI.7 Reaction rate, v, plotted against the Cbz-S-Lys-ONp concentration, [Cbz-S-Lys-ONp], for the 
bovine spleen cathepsin B-catalysed hydrolysis of this compound, at pH 5.0 at 25 ºC. Points are 
experimental and line is theoretical for Km (39.4 ± 7.11) × 10−6 M and Vmax (1.71 ± 0.14) × 10−3 AU/s. 
 
 
A positive control inhibition assay was carried out by employing the successful papain 
inhibitor, E-64 (Section 1.2.2), in a 50 µM concentration. As expected, it led to an enzyme 
residual activity of ca. 10%, after 1 min of incubation. 
Concerning the enzyme stability in the incubation mixture, it was found that cathepsin B 
retains ca. 80% of its activity after 4 h and ca. 60% after 7 h. This should be kept in mind 
when evaluating the reliability of the kinetic results, provided by the inhibition studies. 
 
 
AI.3 Inhibition assay for porcine pancreatic elastase 
 
The protocol for porcine pancreatic elastase was already established in the host laboratory, 
and it was adapted from a procedure described by Hinchliffe et al.174  
A positive control inhibition assay was carried out by employing an in-house inhibitor, 
I.5175  (Figure AI.8), which totally inactivated the enzyme. 
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Figure AI.8 Structure of I.5, an inhibitor of porcine pancreatic elastase. 
 
 
 
AI.4 Experimental Section 
 
AI.4.1 Reagents and Solvents 
 
Papain (Sigma P4762), bovine spleen cathepsin B (Sigma C6286, 10 U), porcine 
pancreatic elastase (Sigma E0258), BAPA, Cbz-S-Lys-ONp, Suc-Ala-Ala-Ala-4-nitroanilide, 
DTT and 0.1 M Hepes buffer (H9897) were obtained from Sigma-Aldrich. Cbz-Gly-ONp was 
from Bachem. Bradford Reagent was from Bio-Rad (500-0006 Bio-Rad Protein Assay Dye 
Reagent Concentrate). DMSO and buffer materials for kinetic measurements were of 
analytical grade and were purchased from Merck (Germany). Freshly deionised water was 
used throughout. 
 
 
AI.4.2 Gel-filtration chromatography 
 
PD-10 Desalting columns were from GE Healthcare (Amersham Biosciences) and were 
kindly provided by Prof. K. Douglas, at the University of Manchester. 
 
 
AI.4.3 Dialysis experiments 
 
Dialysis experiments were carried out with Spectra/Por 4 dialysis membranes, 12000-
14000 MW (Spectrum Laboratories Inc. 132697). 
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AI.4.4 Equipment 
 
Measurement of pH values was carried out at 25.0 ± 0.1 ºC, using a digital microprocessor 
pH meter (model micro pH 2002, Crisson Instruments S.A.), calibrated with standard buffers 
(Merck).  
Activation of papain/cathepsin B was carried out at 25.0 ± 0.1 ºC using a thermostatic 
bath. 
Incubation of potential inhibitors with papain/cathepsin B/porcine pancreatic elastase was 
carried out at 25.0 ± 0.1 ºC using a thermostatic bath. 
Kinetic measurements were carried out at 25.0 ± 0.1 ºC using a Shimadzu UV-2100 
spectrophotometer, equipped with a temperature controller (CPS). 
 
 
AI.4.5 Procedures for papain 
 
Determination of the papain activity in the presence of Cbz-Gly-ONp. Papain (1 
mg/mL) was activated for 1 h in 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 1.0 mM 
EDTA and 10 mM sodium cyanoborohydride. The reaction was started by the addition of 
papain (100 µL of the stock solution 1 mg/mL) into a cuvette containing 100 µL of Cbz-Gly-
ONp stock solution (3 mM in DMSO) and 800 µL of 50 mM K2HPO4/KH2PO4 buffer, pH 
7.0, containing 1.0 mM EDTA. Enzymatic activity was determined at 410 nm during 4 min, 
against a blank of 900 µL of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 1.0 mM 
EDTA and 100 µL of Cbz-Gly-ONp stock solution. Under these conditions, the initial 
concentration of Cbz-Gly-ONp was 300 µM. 
The experiment was also performed using two different concentrations of Cbz-Gly-ONp, 
30 µM (100 µL of a stock solution 0.3 mM in DMSO) and 3 µM (100 µL of a stock solution 
0.03 mM in DMSO). 
 
 
Papain inhibition assay. Papain (1 mg/mL) was activated for 30 min by incubation in 50 
mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 2.0 mM DTT. Reactions 
were started by the addition of the inhibitor stock solution in DMSO (50 µL) to the incubation 
solution containing papain (300 µL of the stock solution 1 mg/mL) and 650 µL of 50 mM 
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K2HPO4/KH2PO4 buffer, pH 7.0, containing only 2.5 mM EDTA. At different times, aliquots 
(100 µL) from the incubation mixture were withdrawn and transferred to a quartz cuvette 
containing 100 µL of BAPA stock solution (10 mM in DMSO) and 800 µL of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 2.0 mM DTT.  
Enzymatic activity was determined at 410 nm during 4 min, against a blank of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 2.0 mM DTT.  
A blank incubation mixture, replacing the inhibitor solution by DMSO, was run and 
assayed in parallel. 
The assays in the presence of ascorbic acid were carried out as described above, except 
that the incubation buffer included ascorbic acid (2 and 30 mM). 
For assays with an excess of DTT, the concentration of this agent in the incubation buffer 
was increased to 15 mM. 
 
 
Determination of Km for the hydrolysis of BAPA by papain. Experiments for 
determination of Km were carried out as described above, except that the inhibitor solution in 
the incubation mixture was replaced by DMSO (50 µL). Substrate final concentrations in the 
cuvette ranged from 0.2 to 6.0 mM. Each concentration was assayed at least two times. 
 
 
Gel-filtration chromatography. Gel-filtration chromatography was carried out on PD-10 
desalting pre-packed columns (bed volume 8.3 mL and bed height 5 cm). These columns are 
composed of Sephadex G-25, with a particle size range from 85 to 260 µm. The columns are 
supplied in distilled water containing 0.15% KathonTM CG/ICP biocide and must be 
equilibrated with ca. 25 mL elution buffer.171  In this case, degassed 50 mM K2HPO4/KH2PO4 
buffer, pH 7.0, 2.5 mM EDTA. 
Papain (3 mg/1 mL) was activated as described above. The purification proceeded 
according to the supplier instructions,171  i.e. the 1 mL papain solution was diluted with 
elution buffer until a total volume of 2.5 mL, and then it was applied to the column, which 
was subsequently eluted with 3.5 mL buffer. It was decided to collect fractions of 10 drops 
each. 
The gel-filtration chromatography was carried out under N2 and the fractions were kept 
sealed to prevent oxidation of the free Cys25 thiol group. 
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To assess the papain content, aliquots (50 µL) from each fraction or from the final stock 
solution were withdrawn and transferred to a quartz cuvette containing 950 µL of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, 2.5 mM EDTA. The A280 of these solutions was recorded 
against a blank of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, 2.5 mM EDTA. 
The free thiol content was determined by Ellman’s method (Section 5.2.4), using 50 µL 
aliquots from each fraction. 
 
 
Dialysis experiments 
 
• Dialysis membrane preparation 
The membrane was cut into the desired length and soaked in distilled water. Then, it was 
boiled for 15 min in 10 mM sodium hydrogen carbonate solution, and another 15 min in 10 
mM EDTA (this latter treatment was repeated with a fresh solution). Finally, the membrane 
was rinsed with deionised water and was stored, at 4 ºC, in 20 mM Tris-HCl, pH 7.5. Before 
use, it was rinsed with deionised water and then with 50 mM K2HPO4/KH2PO4 buffer, pH 
7.0, containing 2.5 mM EDTA. 
 
• Inactivation of papain and dialysis 
Papain was inactivated by the compound 3.1b. The inhibitor (100 µL of a stock solution 
580 µM) was added to a medium containing activated papain (600 µL of a stock solution 1 
mg/mL) and 1.3 mL of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA. 
When the enzymatic activity was assessed in the presence of BAPA, an inactivation degree of 
ca. 80% was found, after 2 h of incubation. The sample was also assayed for papain 
concentration using the Bradford Reagent (see below), allowing the expression of enzymatic 
activity as AU/s/µg papain. This value was used for comparison purposes with the dialysed 
sample. 
The enzyme-inhibitor mixture was then dialysed at 4 ºC over a period of 24 h, against 0.8 
L of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA and 2 mM DTT. 
Aliquots of 200 µL were removed at 5, 19 and 24 h of dialysis and assayed for enzymatic 
activity in the presence of BAPA, and for papain concentration using the Bradford Reagent. 
A blank mixture, replacing the inhibitor solution by DMSO, was dialysed and assayed in 
parallel. 
Both experiments (with and without the inhibitor) were run in duplicate. 
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• Determination of papain concentration 
The papain concentration was assessed using the Bradford Reagent (Bio-Rad).176  This 
product contains the dye Coomassie Brilliant Blue G-250, phosphoric acid and MeOH. The 
method is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465 to 595 nm when it binds to protein. The dye-
protein complex is relatively stable (absorbance may be recorded from 5 min to 1 h after 
complex formation).177  
The supplier of Bradford Reagent indicates a microassay procedure (for protein 
concentrations ≤ 25 µg/mL), which was used as follows: 200 µL of Bradford Reagent were 
added to a quartz cuvette with 50 µL of the papain solution and 750 µL of 50 mM 
K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA. Mixing was performed by 
inverting the cuvette several times. The A595 was read after 5 min against a blank solution with 
200 µL of Bradford Reagent and 800 µL of 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, 
containing 2.5 mM EDTA. 
By working in this way, dialysed-papain concentration in the cuvette is estimated in ca. 15 
µg/mL. Because this protein concentration is within the range indicated by the supplier, 
obedience to Lambert-Beer’s law should be expected. Nevertheless, it was thought that 
departure might occur due to the presence of the bound inhibitor. The law’s validity was 
therefore investigated by performing the experiment in Figure AI.9. In addition, Figure AI.10 
also shows equal spectra for the dye-papain complex in the presence and absence of 
compound 3.1b, excluding any interference from the inhibitor at 595 nm. 
The protein content in the aliquots from incubation medium, during dialysis, was always 
superior to 80%. This percentage was calculated comparatively to the protein content 
determined before the dialysis. 
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Figure AI.9 Dependence of the absorption at 595 nm on the amount of papain inactivated by 3.1b. The 
assay was performed by adding 10, 20, 50 and 75 µL of a papain-inhibitor incubation mixture (after inactivation) 
into a quartz cuvette with 50 mM K2HPO4/KH2PO4 buffer, pH 7.0, containing 2.5 mM EDTA (790, 780, 750 and 
725 µL, respectively) and 200 µL of Bradford Reagent. Points are experimental and line is from linear regression 
analysis of the data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AI.10 Visible spectra depicting the dye-papain complex in the presence and absence of the 
inhibitor 3.1b. 
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AI.4.6 Procedures for bovine spleen cathepsin B 
 
Cathepsin B inhibition assay. Cathepsin B (10 units/2 mL) was activated during 15 min 
in 20 mM sodium acetate buffer, pH 5.0, containing 1.0 mM EDTA and 30 mM DTT. 
Reactions were started by addition of the inhibitor stock solution in DMSO (50 µL) to the 
incubation solution containing cathepsin B (20 µL of the stock solution 10 units/2 mL) and 
930 µL of 20 mM sodium acetate buffer, pH 5.0, containing only 1.0 mM EDTA. At various 
time intervals, cathepsin B activity was assayed by taking a 100 µL aliquot of the incubation 
solution and adding it to a quartz cuvette containing 100 µL of the Cbz-S-Lys-ONp stock 
solution (0.8 mM in DMSO) and 800 µL of 20 mM sodium acetate buffer, pH 5.0, containing 
1.0 mM EDTA and 2.0 mM DTT. Enzymatic activity was monitored at 326 nm, over a period 
of 3 min, against a blank of 20 mM sodium acetate buffer, pH 5.0, containing 1.0 mM EDTA 
and 2.0 mM DTT. 
A blank incubation mixture, replacing the inhibitor solution by DMSO, was run and 
assayed in parallel. 
 
 
Determination of Km. Experiments for determination of Km were carried out as described 
above, except that the inhibitor solution in the incubation mixture was replaced by DMSO (50 
µL). Substrate final concentrations in the cuvette ranged from 5.0 to 80 µM. When the 
concentrations were 5 and 10 µM, the hydrolysis was complete after approximately 1 min and 
the rate, v, was calculated from the data obtained in the initial 30 s of the reaction. 
Each concentration was assayed at least two times. 
 
 
AI.4.7 Inhibition assay for porcine pancreatic elastase 
 
The inhibitor (50 µL of a stock solution in DMSO) was mixed with 750 µL of 0.1 M 
Hepes buffer, previously adjusted to pH 7.2, and 200 µL of a stock solution of enzyme (50 
µM in 0.1 M Hepes buffer, pH 7.2). Aliquots (100 µL) were withdrawn at different time 
intervals and transferred to a quartz cuvette containing 5 µL of the Suc-Ala-Ala-Ala-4-
nitroanilide stock solution (12.5 mM in DMSO) and 895 µL of 0.1 M Hepes buffer. 
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Proteolytic activity was measured by following the release of p-nitroaniline for 50 s at 390 nm 
against a blank of 0.1 M Hepes buffer. 
 
 
AI.4.8 Determination of kobs, k2, KI and kinact 
 
The enzymatic activity, v, expressed as AU/s, was determined from the slopes of the plots 
of absorbance versus reaction time (see Figure AI.11 for a typical example). 
When performing an inhibitor assay, the activity v found immediately after the addition of 
the inhibitor was referred to as v0 and it was usually similar to the one showed by the blank 
assay. The ratio v/v0 was referred to as RA (residual activity). 
Pseudo first-order inactivation rate constants, kobs, were determined from plots of lnRA 
versus incubation time. 
In the case of hyperbolic dependences, KI and kinact values were determined by computer-
fit (Sigma Plot® software) using least squares nonlinear regression analysis to Equation 3.3 
(Section 3.3.1). 
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Figure AI.11 Series of progression curves for the papain-catalysed hydrolysis of BAPA, at different times 
of the enzyme-inhibitor incubation. The experiment was carried out at pH 7.0 at 25 ºC, using as inhibitor the 
naphthoquinone derivative 3.6 in a 50 µM concentration. 
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APPENDIX II. Pseudo first-order rate constants for the cysteine-
catalised decomposition of vinyl sultams, vinyl sulfonamide and 
naphthoquinones 
 
 
Table AII.1 Pseudo first-order rate constants, kobs, for the reaction of vinyl sultams 2.67a, 2.67b, 2.68a and 
2.69b with cysteine at pH 6.9, at 25 ºC and ionic strength 0.5 M. 
 
2.67a 
[cys] (mM) kobs (10−4 s−1) 
1.31 1.86 ± 0.01 
1.97 2.11 ± 0.15 
2.32 2.37 ± 0.06 
3.02 3.50 ± 0.03 
  
kcat 0.11 M−1 s−1  
2.67b 
[cys] (mM) kobs (10−4 s−1) 
1.48 1.89 ± 0.09 
1.94 2.57 ± 0.02 
2.36 2.77 ± 0.13 
  
  
kcat 0.12 M−1 s−1  
 
2.68a 
[cys] (mM) kobs (10−4 s−1) 
0.85 1.70 ± 0.23 
1.60 2.34 ± 0.18 
2.46 3.76 ± 0.12 
3.88 5.21 ± 0.11 
  
kcat 0.13 M−1 s−1  
 
2.69b 
[cys] (mM) kobs (10−4 s−1) 
0.85 1.57 ± 0.25 
1.60 2.40 ± 0.27 
2.46 3.63 ± 0.30 
3.88 5.75 ± 0.13 
  
kcat 0.14 M−1 s−1  
 
 
 
 
Table AII.2 Pseudo first-order rate constants, kobs, for the reaction of vinyl sulfonamide 2.84a with cysteine 
at pH 6.9, at 25 ºC and ionic strength 0.5 M. 
 
[cys] (mM) kobs (10−4 s−1) 
1.79 2.24 ± 0.08 
2.30 2.57 ± 0.08 
3.08 3.24 ± 0.06 
3.62 5.02 ± 0.05 
  
kcat 0.13 M−1 s−1 
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Table AII.3 Pseudo first-order rate constants, kobs, for the reaction of naphthoquinones 3.1a, 3.1b, 3.1c, 3.5, 
3.8, 3.13 and 3.11 with cysteine at pH 7.1, at 25 ºC and ionic strength 0.5 M. For 3.11, the rates were 
measured at three additional pH values: 7.9, 8.0 and 8.8. 
 
3.1a 
[cys] (mM) kobs (10−3 s−1) 
0.44 0.58 ± 0.06 
0.90 1.72 ± 0.16 
1.93 2.82 ± 0.01 
3.19 5.83 ± 0.30 
  
kcat 1.78 M−1 s−1  
3.1b 
[cys] (mM) kobs (10−4 s−1) 
0.97 0.48 ± 0.07 
1.95 0.58 ± 0.01 
2.84 0.86 ± 0.06 
4.89 2.20 ± 0.10 
  
kcat 0.04 M−1 s−1  
 
 
3.1c 
[cys] (mM) kobs (10−5 s−1) 
1.86 3.68 ± 0.08 
3.34 5.10 ± 0.01 
3.75 7.32 ± 0.09 
4.84 8.25 ± 0.48 
  
kcat 0.02 M−1 s−1  
 
 
3.5 
[cys] (mM) kobs (10−3 s−1) 
0.71 0.55 ± 0.03 
1.13 1.05 ± 0.04 
1.93 1.47 ± 0.04 
2.58 2.33 ± 0.01 
  
kcat 0.87 M−1 s−1  
 
3.8 
[cys] (mM) kobs (10−2 s−1) 
0.06 0.94 ± 0.02 
0.17 1.37 ± 0.08 
2.01 2.17 ± 0.34 
3.33 2.60 ± 0.21 
5.41 2.82 ± 0.16 
   
 
3.13 
[cys] (mM) kobs (10−2 s−1) 
0.44 0.37 ± 0.01 
1.90 1.37 ± 0.01 
3.42 2.62 ± 0.01 
4.37 3.56 ± 0.07 
  
kcat 7.98 M−1 s−1  
 
 
3.11 (pH 7.1) 
[cys] (mM) kobs (10−2 s−1) 
0.44 0.36 ± 0.04 
1.92 1.38 ± 0.00 
2.92 2.19 ± 0.07 
4.78 3.24 ± 0.13 
  
kcat 6.84 M−1 s−1  
 
 
3.11 (pH 7.9) 
[cys] (mM) kobs (10−1 s−1) 
2.77 0.82 ± 0.06 
3.92 1.05 ± 0.06 
  
 
 
kcat 27.2 M−1 s−1  
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3.11 (pH 8.0) 
[cys] (mM) kobs (10−2 s−1) 
0.37 1.46 ± 0.02 
1.13 3.96 ± 0.12 
1.64 5.57 ± 0.10 
  
kcat 33.6 M−1 s−1  
3.11 (pH 8.8) 
[cys] (mM) kobs (10−1 s−1) 
0.37 0.37 ± 0.04 
1.80 1.78 ± 0.01 
  
  
kcat 98.7 M−1 s−1  
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APPENDIX III. Spectral scanning for the reaction of a 
naphthoquinone with cysteine 
 
 
 
Reaction time (min)  0  108  216  396  648  756  828  900  1152
 
Figure AIII.1 UV-visible spectra depicting the reaction, at 25 ºC, of 3.1b (50 µM) with cysteine ca. 5 mM 
in 50 mM K2HPO4/KH2PO4 buffer, pH 7.14, containing KCl to maintain ionic strength at 0.5 M. Spectrum 
of 3.1b in buffer lacking cysteine is in magenta and is overlapped with the first spectrum of the reaction. No 
isosbestic point could be detected. At 277.3 nm (wavelength used to monitor the kinetic reaction), the 
absorbance increased until a plateau region had been reached (ca. 756 min). Subsequently, there was a decrease 
in the absorption at this wavelength (reaction time ≥ 828 min). 
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APPENDIX IV. Kinetic equation for the reaction of 1,4-
naphthoquinone with cysteine 
 
In Section 3.2.2, the kinetic data for the reaction of naphthoquinone 3.8 with cysteine 
were computer-fitted to Equation 3.1. 
 
[ ]( ) [ ]( )[ ] [ ]{ }taacys tcysobs cys/H/1
cys
++= + KKK
k
k                                                                                              (3.1) 
 
As mentioned, in deriving this kinetic expression, it was assumed that reaction of 3.8, NQ, 
with cysteine thiolate, cys−, involves initial and reversible formation of an adduct, cys-NQ, 
which decomposes into the final product, cysNQ. This situation can be described by the 
following equation, 
 
cys− + NQ
Kcys cys-NQ cysNQ
kcys
                                                                                     (AIV.1) 
 
Equation 3.1 was solved in the following manner. From Equation AIV.1, 
 
[ ]
[ ][ ]NQ cys
NQ-cys
 cys =K                                                                                                                           (AIV.2) 
 
and considering that the total naphthoquinone concentration, [NQ]t, and that of the unreacted 
naphthoquinone, [NQ], are related by 
 
[NQ] = [NQ]t − [cys-NQ]                                                                                                              (AIV.3) 
 
then, [NQ] from Equation AIV.2 may be substituted to give 
 
[ ] [ ][ ][ ] cys1
NQ cys
NQcys
 cys
t cys
K
K
+=−                                                                                                         (AIV.4) 
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On the other hand, the rate, v, of formation of the product, cysNQ, is given by 
 
v = kcys[cys-NQ]                                                                                                                             (AIV.5) 
 
where kcys is a first-order rate constant. Thus, [cys-NQ] from Equation AIV.4 may be 
substituted to give 
 
[ ][ ]
[ ] cys1
NQ cys
 cys
t cys cys
K
Kk
v +=                                                                                                                  (AIV.6) 
 
Taking into account that 
 
v = kobs[NQ]t                                                                                                                                  (AIV.7) 
 
then, substitution of v from Equation AIV.6 gives Equation AIV.8, after division of the 
nominator and denominator by Kcys 
 
[ ]
[ ] cys/1
 cys
 cys
 cys
obs += K
k
k                                                                                                                     (AIV.8) 
 
 
Considering that 
 
 
H
+
cys
Ka cys−+                                                                                                                    (AIV.9) 
 
 
From Equation AIV.9, 
 
[ ][ ]
[ ]cys
H cys
a
+
=K                                                                                                                            (AIV.10) 
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[ ][ ] [ ]t
a cys
a
t cys
obs
cysH
cys
++
= +
KK
K
k
k
and considering that the total cysteine concentration, [cys]t, and that of the undissociated 
cysteine, [cys], are related by 
 
[cys] = [cys]t − [cys−]                                                                                                                 (AIV.11) 
 
Then, [cys] from Equation AIV.10 may be substituted to give 
 
[ ] [ ][ ]++= Hcys cys a t aKK                                                                                                                         (AIV.12) 
 
Substitution of [cys−] from Equation AIV.8 gives Equation 3.1, after division of the 
nominator and denominator by KaKcys 
 
 
                                                                                                                       (3.1) 
 
 
 
with 
 
 
[ ]
α=
+ + 1H
a
 a
K
K                                                                                                                             (AIV.13) 
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APPENDIX V. Data for the graphical representation in Figure 
3.11 
 
Table AV.1 LUMO energies and Hammett σp constants for naphthoquinones. 
 
O
O
R1
R2
R3
R4  
Compound R1 R2 R3 R4 ELUMO/Hartree σpa 
3.1b GlyOEt H H H −0.1097 −0.68 
3.1c NHMe H H H −0.1070 −0.84 
3.5 OEt H H H −0.1114 −0.24 
3.6 Br H H H −0.1320 0.22 
3.8 H H H H −0.1245 0 
3.9 Cl Cl H H −0.1370 0.46 
3.11 Me H H H −0.1193 −0.17 
a The σp values were obtained from Perrin et al.178  
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APPENDIX VI. Pseudo first-order rate constants for papain- and 
cathepsin B-catalised decomposition of quinones 
 
 
Table AVI.1 Pseudo first-order rate constants, kobs, for inactivation of the papain by quinones 3.1b-d, 3.2a-
c, 3.3a,b, 3.5, 3.6, 3.9, 3.11, 3.13, 3.20, 3.21 and 3.22, at pH 7.0 at 25 ºC. 
 
3.1b 
[3.1b] (µM) kobs (10−4 s−1) 
2.90 0.52 ± 0.01 
5.80 1.13 ± 0.10 
15.0 2.41 ± 0.48 
29.0 2.73 ± 0.45 
58.0 2.63 ± 0.13  
3.1c 
[3.1c] (mM) kobs (10−4 s−1) 
0.15 1.00  
0.30 2.04 ± 0.20 
0.45 3.32 ± 0.02 
0.62 4.63 ± 0.52  
 
3.1d 
[3.1d] (µM) kobs (10−4 s−1) 
26.0 0.30 
40.0 0.43 ± 0.05 
52.0 0.55 
75.0 0.80 
104.0 0.98 
156.0 1.22  
 
3.2a 
[3.2a] (µM) kobs (10−5 s−1) 
9.30 1.83 
23.3 6.06 ± 1.34 
34.9 6.92 ± 1.30 
46.5 8.83 ± 0.47  
 
3.2b 
[3.2b] (µM) kobs (10−3 s−1) 
26.0 0.29 ± 0.03 
53.0 0.52 ± 0.04 
160.0 0.82 ± 0.02 
340.0 1.06 ± 0.02 
530.0 1.14 ± 0.03  
 
3.2c 
[3.2c] (µM) kobs (10−4 s−1) 
60.0 0.69 ± 0.08 
120.0 1.19 ± 0.22 
180.0 2.02 ± 0.45 
270.0 2.76 ± 0.18  
 
3.3a 
[3.3a] (µM) kobs (10−5 s−1) 
61.0 4.09 ± 0.58  
 
3.3b 
[3.3b] (µM) kobs (10−4 s−1) 
50 2.00 ± 0.24 
150 4.97 
300 7.93 ± 1.17 
400 8.83 
500 8.81 ± 0.84  
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3.5 
[3.5] (µM) kobs (10−3 s−1) 
23.3 0.16 
58.2 0.37 ± 0.02 
117.0 0.80 ± 0.05 
300.0 0.98 ± 0.02 
450 1.03 ± 0.07  
3.6 
[3.6] (µM) kobs (10−3 s−1) 
25.0 0.71 ± 0.13 
33.0 0.66 ± 0.04 
50.0 0.85 ± 0.07 
75.0 1.26 ± 0.11 
100.0 1.30 ± 0.12 
125.0 1.44 ± 0.18  
 
3.9 
[3.9] (µM) kobs (10−3 s−1) 
75.0 0.28 ± 0.03 
150.0 0.86 
175.0 1.15 ± 0.09 
200.0 1.18  
 
3.11 
[3.11] (µM) kobs (10−3 s−1) 
100.0 0.63 ± 0.08 
150.0 0.92 ± 0.17 
200.0 1.06 ± 0.01 
250.0 1.17 ± 0.11 
300.0 1.58 ± 0.08  
 
3.13 
[3.13] (µM) kobs (10−3 s−1) 
75.0 0.69 ± 0.10 
100.0 0.63 ± 0.08 
125.0 1.02 ± 0.08 
150.0 1.12 ± 0.11 
200.0 1.98 ± 0.40  
 
3.20 
[3.20] (µM) kobs (10−3 s−1) 
30.1 0.59 ± 0.02 
60.2 0.87 ± 0.13 
75.0 0.92 
90.0 1.44 
120.0 1.81  
 
3.21 
[3.21] (µM) kobs (10−3 s−1) 
24.0 0.50 ± 0.04 
48.0 0.91 
72.0 1.04 
96.0 1.08 ± 0.04  
 
3.22 
[3.22] (mM) kobs (10−3 s−1) 
0.52 0.21 ± 0.01 
0.98 0.43 ± 0.33  
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Table AVI.2 Pseudo first-order rate constants, kobs, for inactivation of bovine spleen cathepsin B by 
quinones 3.1b, 3.2b, 3.5 and 3.6 at pH 5.0 at 25 ºC. 
 
3.1b 
[3.1b] (µM) kobs (10−4 s−1) 
5.80 0.35 
15.0 0.49 ± 0.08 
29.0 0.83 
58.0 0.90 
116.0 1.05 ± 0.05 
290.0 1.02 ± 0.09  
3.2b 
[3.2b] (µM) kobs (10−4 s−1) 
26.5 0.75 
53.0 1.18 ± 0.15 
106.0 1.70 
160.0 1.74 ± 0.20  
 
3.5 
[3.5] (mM) kobs (10−4 s−1) 
0.06 0.45 
0.30 1.09 ± 0.13 
0.45 1.62 
0.80 2.05 ± 0.16 
1.20 2.63 ± 0.19  
 
3.6 
[3.6] (µM) kobs (10−4 s−1) 
25.0 0.58  
50.0 2.98 ± 1.10 
75.0 4.34 ± 0.62 
125.0 6.68 ± 0.12  
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